Citation Report
List of articles citing

Multiplex genome engineering using CRISPR/Cas systems

DOI: 10.1126/science.1231143
Science, 2013, 339, 819-23.

#	Paper	IF	Citations
2194	Democratizing CRISPR? Stories, practices, and politics of science and governance on the agricultural gene editing frontier. **2020**, 8,		
2193	Corrigendum. **1970**, 185, D66-D66		
2192	Phospholipase Cdelta3 regulates RhoA/Rho kinase signaling and neurite outgrowth. **2011**, 286, 8459-8471		30
2191	Low cholesterol triggers membrane microdomain-dependent CD44 shedding and suppresses tumor cell migration. **2011**, 286, 1999-2007		116
2190	Swimming into prominence: the zebrafish as a valuable tool for studying human myopathies and muscular dystrophies. **2013**, 280, 4187-97		50
2189	CRISPR-Cas systems target a diverse collection of invasive mobile genetic elements in human microbiomes. **2013**, 14, R40		45
2188	High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity. **2013**, 31, 839-43		1078
2187	Meeting report: genetics and genome engineering. **2013**, 35, 411-413		
2186	Tackling neurodegenerative diseases: animal models of Alzheimer's disease and Parkinson's disease. **2013**, 35, 425-440		9
2185	A rapid assay to quantify the cleavage efficiency of custom-designed nucleases in planta. **2013**, 82, 207-21		10
2184	DNA targeting specificity of RNA-guided Cas9 nucleases. **2013**, 31, 827-32		3056
2183	Optical control of mammalian endogenous transcription and epigenetic states. **2013**, 500, 472-476		635
2182	From genetics of inflammatory bowel disease towards mechanistic insights. **2013**, 34, 371-8		67
2181	CRISPR-Cas. **2013**, 43, 158-165		2
2180	CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. **2013**, 31, 833-8		1341
2179	The transience of transient overexpression. **2013**, 10, 715-21		140
2178	Inactivation of hepatitis B virus replication in cultured cells and in vivo with engineered transcription activator-like effector nucleases. **2013**, 21, 1889-97		155

2177	TAL effectors: highly adaptable phytobacterial virulence factors and readily engineered DNA-targeting proteins. **2013**, 23, 390-8	99
2176	CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. **2013**, 154, 442-51	2255
2175	Multiplex and homologous recombination-mediated genome editing in Arabidopsis and Nicotiana benthamiana using guide RNA and Cas9. **2013**, 31, 688-91	1001
2174	Targeted mutagenesis in the model plant Nicotiana benthamiana using Cas9 RNA-guided endonuclease. **2013**, 31, 691-3	742
2173	Targeted genome modification of crop plants using a CRISPR-Cas system. **2013**, 31, 686-8	1266
2172	Heritable gene targeting in the mouse and rat using a CRISPR-Cas system. **2013**, 31, 681-3	505
2171	Simultaneous generation and germline transmission of multiple gene mutations in rat using CRISPR-Cas systems. **2013**, 31, 684-6	339
2170	Engineering subtle targeted mutations into the mouse genome. **2013**, 51, 605-18	26
2169	RNA-guided gene activation by CRISPR-Cas9-based transcription factors. **2013**, 10, 973-6	861
2168	CRISPR RNA-guided activation of endogenous human genes. **2013**, 10, 977-9	789
2167	Retroviruses facilitate the rapid evolution of the mammalian placenta. **2013**, 35, 853-61	59
2166	The potential of stem cell research for the treatment of neuronal damage in glaucoma. **2013**, 353, 311-25	14
2165	Genome engineering of Drosophila with the CRISPR RNA-guided Cas9 nuclease. **2013**, 194, 1029-35	692
2164	One-step generation of mice carrying reporter and conditional alleles by CRISPR/Cas-mediated genome engineering. **2013**, 154, 1370-9	1194
2163	Highly efficient targeted mutagenesis of Drosophila with the CRISPR/Cas9 system. **2013**, 4, 220-8	598
2162	Efficient genome editing in plants using a CRISPR/Cas system. **2013**, 23, 1229-32	677
2161	Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. **2013**, 154, 1380-9	2348
2160	Efficient isolation of specific genomic regions and identification of associated proteins by engineered DNA-binding molecule-mediated chromatin immunoprecipitation (enChIP) using CRISPR. **2013**, 439, 132-6	145

2159	Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system. **2013**, 23, 1163-71	546
2158	Engineering the Caenorhabditis elegans genome using Cas9-triggered homologous recombination. **2013**, 10, 1028-34	605
2157	Cardiac regenerative medicine 2.0. **2013**, 31, 209-11	3
2156	A nanobody-based system using fluorescent proteins as scaffolds for cell-specific gene manipulation. **2013**, 154, 928-39	87
2155	Current approaches for efficient genetic editing in human pluripotent stem cells. **2013**, 8, 461-467	
2154	Promise and issues of genetically modified crops. **2013**, 16, 255-60	43
2153	Exploiting CRISPR/Cas: interference mechanisms and applications. **2013**, 14, 14518-31	24
2152	Highly efficient genome modifications mediated by CRISPR/Cas9 in Drosophila. **2013**, 195, 289-91	261
2151	Tunable and multifunctional eukaryotic transcription factors based on CRISPR/Cas. **2013**, 2, 604-13	259
2150	Tuning cell cycle of insect cells for enhanced protein production. **2013**, 168, 55-61	7
2149	Analysis of SOX2-expressing cell populations derived from human pluripotent stem cells. **2013**, 1, 464-78	28
2148	Generation of mutant mice by pronuclear injection of circular plasmid expressing Cas9 and single guided RNA. **2013**, 3, 3355	298
2147	Genomic impact of CRISPR immunization against bacteriophages. **2013**, 41, 1383-91	41
2146	Advances in genetic modification of pluripotent stem cells. **2013**, 31, 994-1001	22
2145	UP-TORR: online tool for accurate and Up-to-Date annotation of RNAi Reagents. **2013**, 195, 37-45	35
2144	Generalized bacterial genome editing using mobile group II introns and Cre-lox. **2013**, 9, 685	63
2143	CRISPR interference (CRISPRi) for sequence-specific control of gene expression. **2013**, 8, 2180-96	677
2142	Pancreas-specific Cre driver lines and considerations for their prudent use. **2013**, 18, 9-20	123

2141	Genome engineering using the CRISPR-Cas9 system. **2013**, 8, 2281-2308		6243
2140	Studying immunity to zoonotic diseases in the natural host - keeping it real. **2013**, 13, 851-61		67
2139	Molecular biology. New tool for genome surgery. *Science*, **2013**, 339, 768-70	33.3	37
2138	Generation of targeted mouse mutants by embryo microinjection of TALEN mRNA. **2013**, 8, 2355-79		50
2137	Exciting prospects for precise engineering of Caenorhabditis elegans genomes with CRISPR/Cas9. **2013**, 195, 635-42		52
2136	High-resolution network biology: connecting sequence with function. **2013**, 14, 865-79		65
2135	CRISPR/Cas-induced double-strand breaks boost the frequency of gene replacements for humanizing the mouse Cnr2 gene. **2013**, 441, 815-9		18
2134	Type I interferon imposes a TSG101/ISG15 checkpoint at the Golgi for glycoprotein trafficking during influenza virus infection. **2013**, 14, 510-21		32
2133	RNA-guided genome editing in plants using a CRISPR-Cas system. **2013**, 6, 1975-83		492
2132	Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus. **2013**, 3, 2510		371
2131	RNA-dependent DNA endonuclease Cas9 of the CRISPR system: Holy Grail of genome editing?. **2013**, 21, 562-7		53
2130	Repurposing CRISPR/Cas9 for in situ functional assays. **2013**, 27, 2602-14		102
2129	Application of the CRISPR-Cas system for efficient genome engineering in plants. **2013**, 6, 2008-11		382
2128	A ruler protein in a complex for antiviral defense determines the length of small interfering CRISPR RNAs. **2013**, 288, 27888-97		91
2127	Beyond GWASs: illuminating the dark road from association to function. **2013**, 93, 779-97		515
2126	Accelerated homologous recombination and subsequent genome modification in Drosophila. **2013**, 140, 4818-25		133
2125	RNA-guided nucleases: a new era for engineering the genomes of model and nonmodel organisms. **2013**, 195, 303-8		14
2124	A variant CRISPR-Cas9 system adds versatility to genome engineering. **2013**, 110, 15514-5		29

2123	Repair of strand breaks by homologous recombination. **2013**, 5, a012740	543
2122	Efficient CRISPR/Cas9 genome editing with low off-target effects in zebrafish. **2013**, 140, 4982-7	334
2121	Expanding horizons: ciliary proteins reach beyond cilia. **2013**, 47, 353-76	64
2120	Efficient multiplex biallelic zebrafish genome editing using a CRISPR nuclease system. **2013**, 110, 13904-9	879
2119	Seamless genome editing in human pluripotent stem cells using custom endonuclease-based gene targeting and the piggyBac transposon. **2013**, 8, 2061-78	64
2118	Dynamic gene expression for metabolic engineering of mammalian cells in culture. **2013**, 20, 212-20	35
2117	Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. **2013**, 13, 653-8	917
2116	Correction of a genetic disease in mouse via use of CRISPR-Cas9. **2013**, 13, 659-62	433
2115	Dynamic imaging of genomic loci in living human cells by an optimized CRISPR/Cas system. **2013**, 155, 1479-91	1306
2114	Connecting signaling pathways underlying communication to ASD vulnerability. **2013**, 113, 97-133	8
2113	Plant genome editing made easy: targeted mutagenesis in model and crop plants using the CRISPR/Cas system. **2013**, 9, 39	431
2112	Demonstration of CRISPR/Cas9/sgRNA-mediated targeted gene modification in Arabidopsis, tobacco, sorghum and rice. **2013**, 41, e188	828
2111	Getting a grip on genetic modification in brown algae. **2013**, 49, 816-8	1
2110	Genome engineering in Saccharomyces cerevisiae using CRISPR-Cas systems. **2013**, 41, 4336-43	1094
2109	A simple strategy for heritable chromosomal deletions in zebrafish via the combinatorial action of targeting nucleases. **2013**, 14, R69	22
2108	A modified TALEN-based system for robust generation of knock-out human pluripotent stem cell lines and disease models. **2013**, 14, 773	27
2107	Quantifying transcription factor kinetics: at work or at play?. **2013**, 48, 492-514	77
2106	Staying on target with CRISPR-Cas. **2013**, 31, 807-9	50

2105	Mutants of Cre recombinase with improved accuracy. **2013**, 4, 2509		28
2104	Male-sterile maize plants produced by targeted mutagenesis of the cytochrome P450-like gene (MS26) using a re-designed I-CreI homing endonuclease. **2013**, 76, 888-99		92
2103	Heritable custom genomic modifications in Caenorhabditis elegans via a CRISPR-Cas9 system. **2013**, 195, 1181-5		104
2102	Cell intrinsic immunity spreads to bystander cells via the intercellular transfer of cGAMP. **2013**, 503, 530-4		357
2101	Orthogonal Cas9 proteins for RNA-guided gene regulation and editing. **2013**, 10, 1116-21		615
2100	Cas9 as a versatile tool for engineering biology. **2013**, 10, 957-63		897
2099	Sox proteins: regulators of cell fate specification and differentiation. **2013**, 140, 4129-44		351
2098	Precise and heritable genome editing in evolutionarily diverse nematodes using TALENs and CRISPR/Cas9 to engineer insertions and deletions. **2013**, 195, 331-48		136
2097	Progress in genomics according to bingo: 2013 edition. **2013**, 14, 143		1
2096	LULL(ed) into complacency: a perspective on licenses and stem cell translational science. **2013**, 4, 98		5
2095	The humankind genome: from genetic diversity to the origin of human diseases. **2013**, 56, 705-16		17
2094	RNA-guided human genome engineering via Cas9. *Science*, **2013**, 339, 823-6	33.3	6363
2093	Technology: a CRISPR genome-editing tool. **2013**, 14, 80		33
2092	Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. **2013**, 31, 230-2		1369
2091	A library of TAL effector nucleases spanning the human genome. **2013**, 31, 251-8		289
2090	RNA-guided editing of bacterial genomes using CRISPR-Cas systems. **2013**, 31, 233-9		1636
2089	Efficient genome editing in zebrafish using a CRISPR-Cas system. **2013**, 31, 227-9		2094
2088	Effects of genetic variation on the E. coli host-circuit interface. **2013**, 4, 231-7		56

2087	Genetic marking of sex using a W chromosome-linked transgene. **2013**, 43, 1079-86	12
2086	Transgene-free genome editing in Caenorhabditis elegans using CRISPR-Cas. **2013**, 195, 1167-71	82
2085	Highly improved gene targeting by germline-specific Cas9 expression in Drosophila. **2013**, 195, 715-21	359
2084	Structure of an RNA silencing complex of the CRISPR-Cas immune system. **2013**, 52, 146-52	100
2083	Modeling human disease with pluripotent stem cells: from genome association to function. **2013**, 12, 656-68	149
2082	Progress in the genetics of polygenic brain disorders: significant new challenges for neurobiology. **2013**, 80, 578-87	63
2081	RNA guides genome engineering. **2013**, 31, 208-9	60
2080	Biotechnology: Rewriting a genome. **2013**, 495, 50-1	121
2079	CRISPR-Cas systems and RNA-guided interference. **2013**, 4, 267-78	126
2078	Dogma derailed: the many influences of RNA on the genome. **2013**, 49, 783-94	129
2077	Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. **2013**, 152, 1173-83	2988
2076	A CRISPR view of genome sequences. **2013**, 11, 226	7
2075	Genome-scale engineering for systems and synthetic biology. **2013**, 9, 641	231
2074	RNA-programmed genome editing in human cells. **2013**, 2, e00471	1443
2073	crRNA and tracrRNA guide Cas9-mediated DNA interference in Streptococcus thermophilus. **2013**, 10, 841-51	150
2072	RNA-guided genome editing la carte. **2013**, 23, 733-4	14
2071	A crisper look at genome editing: RNA-guided genome modification. **2013**, 21, 720-2	18
2070	TALEN-based gene correction for epidermolysis bullosa. **2013**, 21, 1151-9	202

2069	Site-directed nucleases: a paradigm shift in predictable, knowledge-based plant breeding. **2013**, 31, 375-83	114
2068	Genome editing with RNA-guided Cas9 nuclease in zebrafish embryos. **2013**, 23, 465-72	592
2067	Enhanced efficiency of human pluripotent stem cell genome editing through replacing TALENs with CRISPRs. **2013**, 12, 393-4	391
2066	Transcription activator-like effector nucleases (TALENs): a highly efficient and versatile tool for genome editing. **2013**, 110, 1811-21	167
2065	Scaling up the systematic hunt for mammalian genetic interactions. **2013**, 10, 397-9	3
2064	Evidence for the widespread distribution of CRISPR-Cas system in the Phylum Cyanobacteria. **2013**, 10, 687-93	61
2063	Generation of gene-modified mice via Cas9/RNA-mediated gene targeting. **2013**, 23, 720-3	430
2062	One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. **2013**, 153, 910-8	2571
2061	Epigenomic strategies at the interface of genetic and environmental risk factors for autism. **2013**, 58, 396-401	61
2060	CRISPR model building. **2013**, 6, 455-455	
2059	Emerging tools for synthetic genome design. **2013**, 35, 359-70	15
2058	Genome engineering at the dawn of the golden age. **2013**, 14, 135-58	94
2057	Processing-independent CRISPR RNAs limit natural transformation in Neisseria meningitidis. **2013**, 50, 488-503	206
2056	High-resolution transcriptome maps reveal strain-specific regulatory features of multiple Campylobacter jejuni isolates. **2013**, 9, e1003495	201
2055	Genetic approaches to neural circuits in the mouse. **2013**, 36, 183-215	146
2054	A CRISPR way to engineer the human genome. **2013**, 14, 107	30
2053	High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. **2013**, 31, 822-6	2178
2052	Potential directions for chicken immunology research. **2013**, 41, 463-8	9

2051	Remodeling neurodegeneration: somatic cell reprogramming-based models of adult neurological disorders. **2013**, 78, 957-69	51
2050	CRISPR-Cas and restriction-modification systems are compatible and increase phage resistance. **2013**, 4, 2087	137
2049	Heritable genome editing in C. elegans via a CRISPR-Cas9 system. **2013**, 10, 741-3	669
2048	Recent advances in the heterologous expression of microbial natural product biosynthetic pathways. **2013**, 30, 1121-38	156
2047	ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. **2013**, 31, 397-405	2526
2046	Bacterial sRNAs: regulation in stress. **2013**, 303, 217-29	82
2045	TALEN or Cas9 - rapid, efficient and specific choices for genome modifications. **2013**, 40, 281-9	120
2044	RNA-guided genome editing for target gene mutations in wheat. **2013**, 3, 2233-8	263
2043	Optimized gene editing technology for Drosophila melanogaster using germ line-specific Cas9. **2013**, 110, 19012-7	258
2042	Toward pluripotency by reprogramming: mechanisms and application. **2013**, 4, 820-32	16
2041	Flowing through the CRISPR-CAScade: Will genome editing boost cell therapies?. **2013**, 1, 3	2
2040	Heritable gene knockout in Caenorhabditis elegans by direct injection of Cas9-sgRNA ribonucleoproteins. **2013**, 195, 1177-80	199
2039	Targeted heritable mutation and gene conversion by Cas9-CRISPR in Caenorhabditis elegans. **2013**, 195, 1173-6	80
2038	Comparing zinc finger nucleases and transcription activator-like effector nucleases for gene targeting in Drosophila. **2013**, 3, 1717-25	52
2037	Targeted mutagenesis tools for modelling psychiatric disorders. **2013**, 354, 9-25	12
2036	Genome editing of human pluripotent stem cells to generate human cellular disease models. **2013**, 6, 896-904	94
2035	Evolutionary dynamics of the prokaryotic adaptive immunity system CRISPR-Cas in an explicit ecological context. **2013**, 195, 3834-44	68
2034	Generation of an ICF syndrome model by efficient genome editing of human induced pluripotent stem cells using the CRISPR system. **2013**, 14, 19774-81	84

2033	In silico abstraction of zinc finger nuclease cleavage profiles reveals an expanded landscape of off-target sites. **2013**, 41, e181	43
2032	Newer gene editing technologies toward HIV gene therapy. **2013**, 5, 2748-66	63
2031	Electron microscopy studies of Type III CRISPR machines in Sulfolobus solfataricus. **2013**, 41, 1427-30	1
2030	Are we there yet? Navigating roadblocks to induced pluripotent stem cell therapy translation. **2013**, 8, 389-91	1
2029	A guide RNA sequence design platform for the CRISPR/Cas9 system for model organism genomes. **2013**, 2013, 270805	55
2028	Programmable DNA cleavage in vitro by Cas9. **2013**, 41, 1401-6	20
2027	Inner-outer beauty: DNA-binding surface tags as cellular barcodes. **2013**, 10, 399-401	1
2026	What makes a model system great?. **2013**, 2, e26287	2
2025	A perspective on micro-evo-devo: progress and potential. **2013**, 195, 625-34	40
2024	Targeted mutagenesis of Arabidopsis thaliana using engineered TAL effector nucleases. **2013**, 3, 1697-705	102
2023	A CRISPR CASe for high-throughput silencing. **2013**, 4, 193	31
2022	Efficient nonmeiotic allele introgression in livestock using custom endonucleases. **2013**, 110, 16526-31	216
2021	Beyond the antigen receptor: editing the genome of T-cells for cancer adoptive cellular therapies. **2013**, 4, 221	31
2020	New Method of Genome Editing Derived From CRISPR/Cas9. **2013**, 40, 691	
2019	Expanded activity of dimer nucleases by combining ZFN and TALEN for genome editing. **2013**, 3, 2376	20
2018	Programmable repression and activation of bacterial gene expression using an engineered CRISPR-Cas system. **2013**, 41, 7429-37	713
2017	Zinc fingers, TAL effectors, or Cas9-based DNA binding proteins: what's best for targeting desired genome loci?. **2013**, 6, 1384-7	34
2016	Agammaglobulinemia: causative mutations and their implications for novel therapies. **2013**, 9, 1205-21	23

2015	A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. **2013**, 9, 696	69
2014	Efficient genome engineering in human pluripotent stem cells using Cas9 from Neisseria meningitidis. **2013**, 110, 15644-9	508
2013	Biallelic genome modification in F(0) Xenopus tropicalis embryos using the CRISPR/Cas system. **2013**, 51, 827-34	146
2012	Double-strand DNA end-binding and sliding of the toroidal CRISPR-associated protein Csn2. **2013**, 41, 6347-59	37
2011	CRISPR/Cas9-mediated genome engineering and the promise of designer flies on demand. **2013**, 7, 249-55	68
2010	Genomic editing opens new avenues for zebrafish as a model for neurodegeneration. **2013**, 127, 461-70	46
2009	One-step assembly and targeted integration of multigene constructs assisted by the I-SceI meganuclease in Saccharomyces cerevisiae. **2013**, 13, 769-81	42
2008	Optimization of scarless human stem cell genome editing. **2013**, 41, 9049-61	302
2007	CRISPR/Cas9 systems targeting β-globin and CCR5 genes have substantial off-target activity. **2013**, 41, 9584-92	456
2006	CRISPR-Cas: evolution of an RNA-based adaptive immunity system in prokaryotes. **2013**, 10, 679-86	127
2005	Efficient generation of large-scale genome-modified mice using gRNA and CAS9 endonuclease. **2013**, 41, e187	175
2004	Notable advances 2013. **2013**, 19, 1564-1565	
2003	Crisper results for CRISPR. **2013**, 6, 950-950	
2002	Sculpting genomes with a hammer and chisel. **2013**, 10, 839-40	3
2001	Efficient genome editing in Caenorhabditis elegans by CRISPR-targeted homologous recombination. **2013**, 41, e193	105
2000	Heritable gene-targeting with gRNA/Cas9 in rats. **2013**, 23, 1322-5	48
1999	Transcription activator like effector (TALE)-directed piggyBac transposition in human cells. **2013**, 41, 9197-207	55
1998	Special focus CRISPR-Cas. **2013**, 10, 655-8	6

1997	Recent advances in developing nucleic acid-based HBV therapy. **2013**, 8, 1489-504	6
1996	US regulation misses some GM crops. **2013**, 500, 389-90	30
1995	Automated design of bacterial genome sequences. **2013**, 7, 108	1
1994	Genome engineering with TAL-effector nucleases and alternative modular nuclease technologies. **2013**, 13, 291-303	30
1993	From Agrobacterium to viral vectors: genome modification of plant cells by rare cutting restriction enzymes. **2013**, 57, 639-50	7
1992	Directed genome engineering for genome optimization. **2013**, 57, 621-7	14
1991	Heritable and precise zebrafish genome editing using a CRISPR-Cas system. **2013**, 8, e68708	270
1990	Direct cloning of isogenic murine DNA in yeast and relevance of isogenicity for targeting in embryonic stem cells. **2013**, 8, e74207	2
1989	Rapid assembly of customized TALENs into multiple delivery systems. **2013**, 8, e80281	13
1988	(Non-)translational medicine: targeting bacterial RNA. **2013**, 4, 230	6
1987	Modeling High-Grade Serous Carcinoma: How Converging Insights into Pathogenesis and Genetics are Driving Better Experimental Platforms. **2013**, 3, 217	30
1986	Efficient gene knockout in goats using CRISPR/Cas9 system. **2014**, 9, e106718	156
1985	To nick or not to nick: comparison of I-SceI single- and double-strand break-induced recombination in yeast and human cells. **2014**, 9, e88840	21
1984	Heritable multiplex genetic engineering in rats using CRISPR/Cas9. **2014**, 9, e89413	77
1983	CRISPR/Cas-mediated targeted mutagenesis in Daphnia magna. **2014**, 9, e98363	70
1982	sgRNAcas9: a software package for designing CRISPR sgRNA and evaluating potential off-target cleavage sites. **2014**, 9, e100448	218
1981	HomeRun Vector Assembly System: a flexible and standardized cloning system for assembly of multi-modular DNA constructs. **2014**, 9, e100948	10
1980	CRISPR/Cas9-mediated gene knock-down in post-mitotic neurons. **2014**, 9, e105584	75

1979	Optimization of genome engineering approaches with the CRISPR/Cas9 system. **2014**, 9, e105779	86
1978	Heat-stable molecule derived from Streptococcus cristatus induces APOBEC3 expression and inhibits HIV-1 replication. **2014**, 9, e106078	7
1977	CRISPRseek: a bioconductor package to identify target-specific guide RNAs for CRISPR-Cas9 genome-editing systems. **2014**, 9, e108424	123
1976	Protospacer adjacent motif (PAM)-distal sequences engage CRISPR Cas9 DNA target cleavage. **2014**, 9, e109213	73
1975	Improved genome editing in human cell lines using the CRISPR method. **2014**, 9, e109752	33
1974	Efficient gene targeting in golden Syrian hamsters by the CRISPR/Cas9 system. **2014**, 9, e109755	58
1973	Antibody-free magnetic cell sorting of genetically modified primary human CD4+ T cells by one-step streptavidin affinity purification. **2014**, 9, e111437	16
1972	Evaluation of sgRNA target sites for CRISPR-mediated repression of TP53. **2014**, 9, e113232	38
1971	TALEN/CRISPR-mediated eGFP knock-in add-on at the OCT4 locus does not impact differentiation of human embryonic stem cells towards endoderm. **2014**, 9, e114275	20
1970	CRISPR reveals a distal super-enhancer required for Sox2 expression in mouse embryonic stem cells. **2014**, 9, e114485	118
1969	High-throughput genome editing and phenotyping facilitated by high resolution melting curve analysis. **2014**, 9, e114632	87
1968	[The revolution of the CRISPR is underway]. **2014**, 30, 1066-9	1
1967	Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery. **2014**, 3, e04766	744
1966	Developments in the tools and methodologies of synthetic biology. **2014**, 2, 60	63
1965	Concerning RNA-guided gene drives for the alteration of wild populations. **2014**, 3,	525
1964	Death by a thousand cuts: the challenges and diverse landscape of lignocellulosic hydrolysate inhibitors. **2014**, 5, 90	62
1963	The Use of Patient-Specific Induced Pluripotent Stem Cells (iPSCs) to Identify Osteoclast Defects in Rare Genetic Bone Disorders. **2014**, 3, 1490-510	6
1962	Molecular biology approaches in bioadhesion research. **2014**, 5, 983-93	12

1961	Safety assessment and detection methods of genetically modified organisms. **2014**, 6, 27-32	1
1960	Viral hybrid-vectors for delivery of autonomous replicons. **2014**, 14, 10-23	11
1959	Gene therapeutic approaches to inhibit hepatitis B virus replication. **2015**, 7, 150-64	11
1958	Progress and Problems with Viral Vectors for Delivery of Talens. **2014**, 08,	7
1957	Inactivation of an integrated antibiotic resistance gene in mammalian cells to re-enable antibiotic selection. **2014**, 56, 198-201	2
1956	Germ Cell, Stem Cell, and Genomic Modification in Birds. **2014**, 04,	3
1955	HIV Excision Utilizing CRISPR/Cas9 Technology: Attacking the Proviral Quasispecies in Reservoirs to Achieve a Cure. **2014**, 1,	32
1954	Induced Pluripotent Stem Cells for the Treatment of Hemophilia A. **2014**, 05,	1
1953	One-step generation of phenotype-expressing triple-knockout mice with heritable mutated alleles by the CRISPR/Cas9 system. **2014**, 60, 324-7	23
1952	Gene Therapy for Primary Immune Deficiencies. **2014**, 1043-1058	
1951	. **2014**,	4
1950	CasFinder: Flexible algorithm for identifying specific Cas9 targets in genomes. **2014**,	41
1949	DNA Plasmids for Non-viral Gene Therapy of Cancer. **2014**, 39-59	1
1948	Are genes switched on when they kiss?. **2014**, 5, 103-12	6
1947	Visualization of specific DNA sequences in living mouse embryonic stem cells with a programmable fluorescent CRISPR/Cas system. **2014**, 5, 163-72	117
1946	Perspective: Revealing molecular secrets. **2014**, 508, S20	7
1945	Constraint and opportunity in genome innovation. **2014**, 11, 186-96	4
1944	Reprogramming homing endonuclease specificity through computational design and directed evolution. **2014**, 42, 2564-76	24

1943	Approaches for establishing the function of regulatory genetic variants involved in disease. **2014**, 6, 92	31
1942	Redesign of extensive protein-DNA interfaces of meganucleases using iterative cycles of in vitro compartmentalization. **2014**, 111, 4061-6	42
1941	Direct activation of human and mouse Oct4 genes using engineered TALE and Cas9 transcription factors. **2014**, 42, 4375-90	124
1940	MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens. **2014**, 15, 554	821
1939	A CRISPR/Cas9 toolkit for multiplex genome editing in plants. **2014**, 14, 327	669
1938	Structural maintenance of chromosomes flexible hinge domain containing 1 (SMCHD1) promotes non-homologous end joining and inhibits homologous recombination repair upon DNA damage. **2014**, 289, 34024-32	10
1937	PTIP associates with Artemis to dictate DNA repair pathway choice. **2014**, 28, 2693-8	85
1936	Efficient and heritable gene targeting in tilapia by CRISPR/Cas9. **2014**, 197, 591-9	147
1935	A synthetic lethal screen identifies FAT1 as an antagonist of caspase-8 in extrinsic apoptosis. **2014**, 33, 181-97	32
1934	Alternative splicing at GYNNGY 5' splice sites: more noise, less regulation. **2014**, 42, 13969-80	15
1933	Allele-specific genome editing and correction of disease-associated phenotypes in rats using the CRISPR-Cas platform. **2014**, 5, 4240	140
1932	Synthetic Gene Circuits. **2014**, 1-56	5
1931	Dissecting the mechanism of histone deacetylase inhibitors to enhance the activity of zinc finger nucleases delivered by integrase-defective lentiviral vectors. **2014**, 25, 599-608	14
1930	Substitutions of two amino acids in the nucleotide-binding site domain of a resistance protein enhance the hypersensitive response and enlarge the PM3F resistance spectrum in wheat. **2014**, 27, 265-76	59
1929	Synthetic Biology and Therapies for Infectious Diseases. **2014**, 109-180	
1928	COSMID: A Web-based Tool for Identifying and Validating CRISPR/Cas Off-target Sites. **2014**, 3, e214	219
1927	The CRISPR/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates In Vivo. **2014**, 3, e186	274
1926	Cell death-inducing DFFA-like effector b is required for hepatitis C virus entry into hepatocytes. **2014**, 88, 8433-44	29

1925	The hypoxic tumor microenvironment: driving the tumorigenesis of non-small-cell lung cancer. **2014**, 10, 2659-74	32
1924	Efficient engineering of a bacteriophage genome using the type I-E CRISPR-Cas system. **2014**, 11, 42-4	94
1923	3.4 Rational Approaches for Transgene Expression: Targeted Integration and Episomal Maintenance. **2014**, 173-215	2
1922	The PPFIA1-PP2A protein complex promotes trafficking of Kif7 to the ciliary tip and Hedgehog signaling. **2014**, 7, ra117	34
1921	Integrating animal models and in vitro tissue models to elucidate the role of desmosomal proteins in diseases. **2014**, 21, 55-63	5
1920	The emerging nexus of active DNA demethylation and mitochondrial oxidative metabolism in post-mitotic neurons. **2014**, 15, 22604-25	9
1919	SSFinder: high throughput CRISPR-Cas target sites prediction tool. **2014**, 2014, 742482	35
1918	High-efficiency targeted editing of large viral genomes by RNA-guided nucleases. **2014**, 10, e1004090	105
1917	Emerging gene editing strategies for Duchenne muscular dystrophy targeting stem cells. **2014**, 5, 148	15
1916	Efficient CRISPR/Cas9 plasmids for rapid and versatile genome editing in Drosophila. **2014**, 4, 2279-82	72
1915	Addgene: making materials sharing "science as usual". **2014**, 12, e1001991	13
1914	Use of genetically modified mesenchymal stem cells to treat neurodegenerative diseases. **2014**, 15, 1719-45	56
1913	Aptamer-guided gene targeting in yeast and human cells. **2014**, 42, e61	16
1912	Wild-type macrophages reverse disease in heme oxygenase 1-deficient mice. **2014**, 124, 1522-30	35
1911	Genomic dissection of the seed. **2014**, 5, 464	23
1910	Structure and Function of CRISPR-Cas System. **2014**, 54, 247-252	
1909	Multiplex genomic structure variation mediated by TALEN and ssODN. **2014**, 15, 41	23
1908	Serine integrase chimeras with activity in E. coli and HeLa cells. **2014**, 3, 895-903	9

1907	The I-TevI nuclease and linker domains contribute to the specificity of monomeric TALENs. **2014**, 4, 1155-65	17
1906	An evaluation of high-throughput approaches to QTL mapping in Saccharomyces cerevisiae. **2014**, 196, 853-65	56
1905	CRISPR-mediated genomic deletion of Sox2 in the axolotl shows a requirement in spinal cord neural stem cell amplification during tail regeneration. **2014**, 3, 444-59	92
1904	Chemical modifications of artificial restriction DNA cutter (ARCUT) to promote its in vivo and in vitro applications. **2014**, 5, e1112457	4
1903	TALEN-mediated single-base-pair editing identification of an intergenic mutation upstream of BUB1B as causative of PCS (MVA) syndrome. **2014**, 111, 1461-6	43
1902	High-efficiency genome editing via 2A-coupled co-expression of fluorescent proteins and zinc finger nucleases or CRISPR/Cas9 nickase pairs. **2014**, 42, e84	59
1901	Simultaneous gene editing by injection of mRNAs encoding transcription activator-like effector nucleases into mouse zygotes. **2014**, 34, 1649-58	23
1900	Spatial control of the GEN1 Holliday junction resolvase ensures genome stability. **2014**, 5, 4844	61
1899	Counting Molecules Within Cells. **2014**, 1, 1-74	3
1898	3' end formation of pre-mRNA and phosphorylation of Ser2 on the RNA polymerase II CTD are reciprocally coupled in human cells. **2014**, 28, 342-56	95
1897	Role of epigenetics in expression of recombinant proteins from mammalian cells. **2014**, 2, 403-419	11
1896	Functionally distinct ERAP1 allotype combinations distinguish individuals with Ankylosing Spondylitis. **2014**, 111, 17594-9	76
1895	Targeted gene therapy and cell reprogramming in Fanconi anemia. **2014**, 6, 835-48	54
1894	Next-generation models of human cardiogenesis via genome editing. **2014**, 4, a013920	3
1893	Large chromosomal deletions and heritable small genetic changes induced by CRISPR/Cas9 in rice. **2014**, 42, 10903-14	413
1892	Performance of the Cas9 nickase system in Drosophila melanogaster. **2014**, 4, 1955-62	30
1891	CRISPR-Cas: an efficient tool for genome engineering of virulent bacteriophages. **2014**, 42, 9504-13	98
1890	CRISPR/Cas9 systems have off-target activity with insertions or deletions between target DNA and guide RNA sequences. **2014**, 42, 7473-85	428

1889	Highly specific and efficient CRISPR/Cas9-catalyzed homology-directed repair in Drosophila. **2014**, 196, 961-71	512
1888	Conditional knockout mouse models of cancer. **2014**, 2014, 1217-33	18
1887	Next Generation Plant Biotechnology. **2014**, 77-100	3
1886	Modularized CRISPR/dCas9 effector toolkit for target-specific gene regulation. **2014**, 3, 986-9	23
1885	Multistage regulator based on tandem promoters and CRISPR/Cas. **2014**, 3, 1007-10	1
1884	TALEN-mediated somatic mutagenesis in murine models of cancer. **2014**, 74, 5311-21	22
1883	Rapid target gene validation in complex cancer mouse models using re-derived embryonic stem cells. **2014**, 6, 212-25	71
1882	Zebrafish: a model vertebrate suitable for the analysis of human genetic disorders. **2014**, 54, 8-11	32
1881	Measuring error rates in genomic perturbation screens: gold standards for human functional genomics. **2014**, 10, 733	203
1880	Translating human genetics into mouse: the impact of ultra-rapid in vivo genome editing. **2014**, 56, 34-45	28
1879	Targeted mutagenesis using CRISPR/Cas system in medaka. **2014**, 3, 362-71	129
1878	Comparison of TALE designer transcription factors and the CRISPR/dCas9 in regulation of gene expression by targeting enhancers. **2014**, 42, e155	135
1877	An atlas of soybean small RNAs identifies phased siRNAs from hundreds of coding genes. **2014**, 26, 4584-601	114
1876	Making designer mutants in model organisms. **2014**, 141, 4042-54	90
1875	Mutagenesis and phenotyping resources in zebrafish for studying development and human disease. **2014**, 13, 82-94	33
1874	RNA-guided genome editing of mammalian cells. **2014**, 1114, 269-77	35
1873	Progress and prospects for engineered T cell therapies. **2014**, 166, 818-29	13
1872	DNA replicons for plant genome engineering. **2014**, 26, 151-63	359

1871	The potential for manipulating RNA with pentatricopeptide repeat proteins. **2014**, 78, 772-82	50
1870	Enhancing stem cell survival in an ischemic heart by CRISPR-dCas9-based gene regulation. **2014**, 83, 702-5	7
1869	Common marmoset as a new model animal for neuroscience research and genome editing technology. **2014**, 56, 53-62	137
1868	Versatile strategy for isolating transcription activator-like effector nuclease-mediated knockout mutants in Caenorhabditis elegans. **2014**, 56, 78-85	12
1867	Exploiting the unique regenerative capacity of the liver to underpin cell and gene therapy strategies for genetic and acquired liver disease. **2014**, 56, 141-52	3
1866	Tracking context-specific transcription factors regulating hox activity. **2014**, 243, 16-23	8
1865	Genome editing. The new frontier of genome engineering with CRISPR-Cas9. *Science*, **2014**, 346, 1258096	33.3 3479
1864	Creating cancer translocations in human cells using Cas9 DSBs and nCas9 paired nicks. **2014**, 546, 251-71	13
1863	Mouse Genetics. **2014**,	2
1862	Targeted and genome-wide sequencing reveal single nucleotide variations impacting specificity of Cas9 in human stem cells. **2014**, 5, 5507	106
1861	Missing genetic risk in neural tube defects: can exome sequencing yield an insight?. **2014**, 100, 642-6	10
1860	Tagging endogenous loci for live-cell fluorescence imaging and molecule counting using ZFNs, TALENs, and Cas9. **2014**, 546, 139-60	27
1859	Genome engineering in human cells. **2014**, 546, 93-118	10
1858	Nuclease-mediated genome editing: At the front-line of functional genomics technology. **2014**, 56, 2-13	48
1857	Cas9-based genome editing in Drosophila. **2014**, 546, 415-39	28
1856	Cas9-based genome editing in Arabidopsis and tobacco. **2014**, 546, 459-72	34
1855	Simple and rapid in vivo generation of chromosomal rearrangements using CRISPR/Cas9 technology. **2014**, 9, 1219-27	149
1854	Cas9-based genome editing in zebrafish. **2014**, 546, 377-413	36

1853	Enhanced specificity and efficiency of the CRISPR/Cas9 system with optimized sgRNA parameters in Drosophila. **2014**, 9, 1151-62	208
1852	Determining the specificities of TALENs, Cas9, and other genome-editing enzymes. **2014**, 546, 47-78	54
1851	Targeted genome editing in human cells using CRISPR/Cas nucleases and truncated guide RNAs. **2014**, 546, 21-45	33
1850	In vitro enzymology of Cas9. **2014**, 546, 1-20	66
1849	Research Highlights. **2014**, 32, 340-340	
1848	Targeted inversion and reversion of the blood coagulation factor 8 gene in human iPS cells using TALENs. **2014**, 111, 9253-8	113
1847	Expanding the zinc-finger recombinase repertoire: directed evolution and mutational analysis of serine recombinase specificity determinants. **2014**, 42, 4755-66	18
1846	Adapting CRISPR/Cas9 for functional genomics screens. **2014**, 546, 193-213	16
1845	Human finger-prick induced pluripotent stem cells facilitate the development of stem cell banking. **2014**, 3, 586-98	36
1844	Efficient chromosomal gene modification with CRISPR/cas9 and PCR-based homologous recombination donors in cultured Drosophila cells. **2014**, 42, e89	88
1843	A co-CRISPR strategy for efficient genome editing in Caenorhabditis elegans. **2014**, 197, 1069-80	181
1842	CRISPR-mediated targeted mRNA degradation in the archaeon Sulfolobus solfataricus. **2014**, 42, 5280-8	81
1841	Multi-input CRISPR/Cas genetic circuits that interface host regulatory networks. **2014**, 10, 763	166
1840	Hypomyelinating leukodystrophies: translational research progress and prospects. **2014**, 76, 5-19	111
1839	Genome editing using artificial site-specific nucleases in zebrafish. **2014**, 56, 26-33	45
1838	Database for exchangeable gene trap clones: pathway and gene ontology analysis of exchangeable gene trap clone mouse lines. **2014**, 56, 161-74	12
1837	A CRISPR/Cas9-based system for reprogramming cell lineage specification. **2014**, 3, 940-7	147
1836	Can genome engineering be used to target cancer-associated enhancers?. **2014**, 6, 493-501	7

1835	Gene regulatory elements of the cardiac conduction system. **2014**, 13, 28-38	5
1834	A high-throughput screening strategy for detecting CRISPR-Cas9 induced mutations using next-generation sequencing. **2014**, 15, 1002	71
1833	Zymomonas mobilis: a novel platform for future biorefineries. **2014**, 7, 101	129
1832	Functional genetics for all: engineered nucleases, CRISPR and the gene editing revolution. **2014**, 5, 43	69
1831	Strategies for gene disruption in Drosophila. **2014**, 4, 63	15
1830	Generation of multi-gene knockout rabbits using the Cas9/gRNA system. **2014**, 3, 12	69
1829	TALENs mediate efficient and heritable mutation of endogenous genes in the marine annelid Platynereis dumerilii. **2014**, 197, 77-89	42
1828	The p160/steroid receptor coactivator family: potent arbiters of uterine physiology and dysfunction. **2014**, 91, 122	21
1827	IgH class switching exploits a general property of two DNA breaks to be joined in cis over long chromosomal distances. **2014**, 111, 2644-9	30
1826	Zebrafish as an innovative model for neuroendocrine tumors. **2014**, 21, R67-83	30
1825	RNA interference screening to detect targetable molecules in hematopoietic stem cells. **2014**, 21, 283-8	3
1824	Engineered zinc-finger transcription factors activate OCT4 (POU5F1), ´SOX2, ´KLF4, ´c-MYC (MYC) and miR302/367. **2014**, 42, 6158-67	19
1823	Non-coding RNAs as potent tools for crop improvement. **2014**, 1, 186-189	4
1822	Fast and efficient Drosophila melanogaster gene knock-ins using MiMIC transposons. **2014**, 4, 2381-7	13
1821	Dynamic regulation of FGF23 by Fam20C phosphorylation, GalNAc-T3 glycosylation, and furin proteolysis. **2014**, 111, 5520-5	208
1820	Design of Vectors for Optimizing Transgene Expression. **2014**, 489-511	2
1819	Genome engineering using the CRISPR/Cas system. **2014**, 4, 69	7
1818	An RNF168 fragment defective for focal accumulation at DNA damage is proficient for inhibition of homologous recombination in BRCA1 deficient cells. **2014**, 42, 7720-33	21

1817	MicroRNA in teleost fish. **2014**, 6, 1911-37	128
1816	Generation of genomic deletions in mammalian cell lines via CRISPR/Cas9. **2015**, e52118	75
1815	Gene Editing. **2014**, 229-248	2
1814	Novel fluorescent genome editing reporters for monitoring DNA repair pathway utilization at endonuclease-induced breaks. **2014**, 42, e4	45
1813	Specific inhibition of diverse pathogens in human cells by synthetic microRNA-like oligonucleotides inferred from RNAi screens. **2014**, 111, 4548-53	52
1812	Expanding the catalog of cas genes with metagenomes. **2014**, 42, 2448-59	17
1811	Advances in genome editing technology and its promising application in evolutionary and ecological studies. **2014**, 3, 24	32
1810	Drug repurposing screen identifies lestaurtinib amplifies the ability of the poly (ADP-ribose) polymerase 1 inhibitor AG14361 to kill breast cancer associated gene-1 mutant and wild type breast cancer cells. **2014**, 16, R67	13
1809	Editing livestock genomes with site-specific nucleases. **2013**, 26, 74-82	15
1808	TSpred: a web server for the rational design of temperature-sensitive mutants. **2014**, 42, W277-84	6
1807	MegaTevs: single-chain dual nucleases for efficient gene disruption. **2014**, 42, 8816-29	14
1806	Easy quantitative assessment of genome editing by sequence trace decomposition. **2014**, 42, e168	1102
1805	Gene therapy briefs. **2014**, 25, 482-5	
1804	Stem cells for investigation and treatment of inherited retinal disease. **2014**, 23, R9-R16	54
1803	An efficient antiviral strategy for targeting hepatitis B virus genome using transcription activator-like effector nucleases. **2014**, 22, 303-311	116
1802	Generation of knockout mice using engineered nucleases. **2014**, 69, 85-93	22
1801	Plant genome engineering in full bloom. **2014**, 19, 284-7	71
1800	A simple TALEN-based protocol for efficient genome-editing in Drosophila. **2014**, 69, 32-7	11

1799	EFCAB7 and IQCE regulate hedgehog signaling by tethering the EVC-EVC2 complex to the base of primary cilia. **2014**, 28, 483-96	52
1798	Efficient generation of genome-modified mice via offset-nicking by CRISPR/Cas system. **2014**, 445, 791-4	56
1797	Regulation of TET protein stability by calpains. **2014**, 6, 278-84	68
1796	Engineering nucleases for gene targeting: safety and regulatory considerations. **2014**, 31, 18-27	69
1795	Generation of germ cells in vitro in the era of induced pluripotent stem cells. **2014**, 81, 2-19	24
1794	Genome editing and animal models. **2014**, 59, 1-6	6
1793	Molecular mechanisms of CRISPR-mediated microbial immunity. **2014**, 71, 449-65	75
1792	PIGN mutations cause congenital anomalies, developmental delay, hypotonia, epilepsy, and progressive cerebellar atrophy. **2014**, 15, 85-92	50
1791	Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. **2014**, 32, 551-3	694
1790	Crystal structure of Cas9 in complex with guide RNA and target DNA. **2014**, 156, 935-49	1131
1789	Gene Correction. **2014**,	
1788	CRISPR-Cas-mediated targeted genome editing in human cells. **2014**, 1114, 245-67	43
1787	Dual sgRNAs facilitate CRISPR/Cas9-mediated mouse genome targeting. **2014**, 281, 1717-25	97
1786	Genome engineering with targetable nucleases. **2014**, 83, 409-39	392
1785	Gene editing at CRISPR speed. **2014**, 32, 309-12	29
1784	Generation of human endometrial knockout cell lines with the CRISPR/Cas9 system confirms the prostaglandin F2□synthase activity of aldo-ketoreductase 1B1. **2014**, 20, 650-63	5
1783	High-throughput screening of a CRISPR/Cas9 library for functional genomics in human cells. **2014**, 509, 487-91	512
1782	A TALEN-based strategy for efficient bi-allelic miRNA ablation in human cells. **2014**, 20, 948-55	14

1781	Engineering the Caenorhabditis elegans genome with CRISPR/Cas9. **2014**, 68, 381-8		38
1780	Engineering Xenopus embryos for phenotypic drug discovery screening. **2014**, 69-70, 225-46		47
1779	Application of TALEs, CRISPR/Cas and sRNAs as trans-acting regulators in prokaryotes. **2014**, 29, 46-54		29
1778	Cas9 in close-up. **2014**, 32, 338-40		5
1777	E-CRISP: fast CRISPR target site identification. **2014**, 11, 122-3		526
1776	Isolation of single-base genome-edited human iPS cells without antibiotic selection. **2014**, 11, 291-3		175
1775	Feasibility for a large scale mouse mutagenesis by injecting CRISPR/Cas plasmid into zygotes. **2014**, 56, 122-9		67
1774	Opportunities in plant synthetic biology. **2014**, 65, 1921-6		15
1773	Precision genetic modifications: a new era in molecular biology and crop improvement. **2014**, 239, 921-39		41
1772	CRISPR-based technologies: prokaryotic defense weapons repurposed. **2014**, 30, 111-8		79
1771	An efficient TALEN mutagenesis system in rice. **2014**, 69, 2-8		20
1770	Structures of Cas9 endonucleases reveal RNA-mediated conformational activation. *Science*, **2014**, 343, 1247997	33.3	701
1769	CRISPR-Cas systems for editing, regulating and targeting genomes. **2014**, 32, 347-55		2182
1768	A guide to genome engineering with programmable nucleases. **2014**, 15, 321-34		853
1767	The noncoding RNA revolution-trashing old rules to forge new ones. **2014**, 157, 77-94		1466
1766	Nanomedicine: tiny particles and machines give huge gains. **2014**, 42, 243-59		21
1765	Disruption of long-range gene regulation in human genetic disease: a kaleidoscope of general principles, diverse mechanisms and unique phenotypic consequences. **2014**, 133, 815-45		25
1764	Biotechnological applications of mobile group II introns and their reverse transcriptases: gene targeting, RNA-seq, and non-coding RNA analysis. **2014**, 5, 2		55

1763	CRISPR/Cas9 for genome editing: progress, implications and challenges. **2014**, 23, R40-6		355
1762	CRISPR-Cas system: a powerful tool for genome engineering. **2014**, 85, 209-18		38
1761	Multiple copies of a linear donor fragment released in situ from a vector improve the efficiency of zinc-finger nuclease-mediated genome editing. **2014**, 21, 282-8		5
1760	Genetic Modification in Human Pluripotent Stem Cells by Homologous Recombination and CRISPR/Cas9 System. **2016**, 1307, 173-90		20
1759	Designer microbes for biosynthesis. **2014**, 29, 55-61		19
1758	From dead leaf, to new life: TAL effectors as tools for synthetic biology. **2014**, 78, 753-71		40
1757	Illuminating DNA replication during Drosophila development using TALE-lights. **2014**, 24, R144-5		28
1756	Evolution of transcription factor binding in metazoans - mechanisms and functional implications. **2014**, 15, 221-33		143
1755	Laying a solid foundation for Manhattan--'setting the functional basis for the post-GWAS era'. **2014**, 30, 140-9		68
1754	SunnyTALEN: a second-generation TALEN system for human genome editing. **2014**, 111, 683-91		20
1753	Efficient genome modification by CRISPR-Cas9 nickase with minimal off-target effects. **2014**, 11, 399-402		575
1752	Function-based identification of mammalian enhancers using site-specific integration. **2014**, 11, 566-71		59
1751	Cut site selection by the two nuclease domains of the Cas9 RNA-guided endonuclease. **2014**, 289, 13284-94		64
1750	Cell-penetrating peptides: A tool for effective delivery in gene-targeted therapies. **2014**, 66, 182-194		55
1749	TALEN-mediated gene mutagenesis in rhesus and cynomolgus monkeys. **2014**, 14, 323-328		155
1748	Role of mouse and human autophagy proteins in IFN-□nduced cell-autonomous responses against Toxoplasma gondii. **2014**, 192, 3328-35		84
1747	Common genetic variants modulate pathogen-sensing responses in human dendritic cells. *Science*, **2014**, 343, 1246980	33.3	309
1746	TALEN-induced gene knock out in Drosophila. **2014**, 56, 86-91		14

1745	A versatile framework for microbial engineering using synthetic non-coding RNAs. **2014**, 12, 341-54	90
1744	The chondrocytic journey in endochondral bone growth and skeletal dysplasia. **2014**, 102, 52-73	50
1743	Elements and machinery of non-coding RNAs: toward their taxonomy. **2014**, 15, 489-507	63
1742	Exploiting CRISPR/Cas systems for biotechnology. **2014**, 36, 34-8	48
1741	Genome-wide binding of the CRISPR endonuclease Cas9 in mammalian cells. **2014**, 32, 670-6	666
1740	Targeted genomic rearrangements using CRISPR/Cas technology. **2014**, 5, 3728	203
1739	Fusion of catalytically inactive Cas9 to FokI nuclease improves the specificity of genome modification. **2014**, 32, 577-582	624
1738	CRISPR-Cas systems: Prokaryotes upgrade to adaptive immunity. **2014**, 54, 234-44	470
1737	Modeling human neurological disorders with induced pluripotent stem cells. **2014**, 129, 388-99	77
1736	Natural selection and infectious disease in human populations. **2014**, 15, 379-93	255
1735	The dynamic architectural and epigenetic nuclear landscape: developing the genomic almanac of biology and disease. **2014**, 229, 711-27	11
1734	The rise of regulatory RNA. **2014**, 15, 423-37	897
1733	Cancer cell lines for drug discovery and development. **2014**, 74, 2377-84	234
1732	Global microRNA depletion suppresses tumor angiogenesis. **2014**, 28, 1054-67	52
1731	Multigeneration analysis reveals the inheritance, specificity, and patterns of CRISPR/Cas-induced gene modifications in Arabidopsis. **2014**, 111, 4632-7	511
1730	MLL3 is a haploinsufficient 7q tumor suppressor in acute myeloid leukemia. **2014**, 25, 652-65	206
1729	Bacterial genome instability. **2014**, 78, 1-39	239
1728	Methods for targeted mutagenesis in zebrafish using TALENs. **2014**, 69, 76-84	21

1727	Biochemical systems approaches for the analysis of histone modification readout. **2014**, 1839, 657-68		17
1726	Pol III Promoters to Express Small RNAs: Delineation of Transcription Initiation. **2014**, 3, e161		66
1725	Identification of a splicing variant that regulates type 2 diabetes risk factor CDKAL1 level by a coding-independent mechanism in human. **2014**, 23, 4639-50		36
1724	Gibberellin acts positively then negatively to control onset of flower formation in Arabidopsis. *Science*, **2014**, 344, 638-41	33.3	158
1723	Fungal extrolites as a new source for therapeutic compounds and as building blocks for applications in synthetic biology. **2014**, 169, 652-65		19
1722	Genome-wide analysis reveals characteristics of off-target sites bound by the Cas9 endonuclease. **2014**, 32, 677-83		553
1721	Multiplexed and programmable regulation of gene networks with an integrated RNA and CRISPR/Cas toolkit in human cells. **2014**, 54, 698-710		345
1720	Functional interpretation of non-coding sequence variation: concepts and challenges. **2014**, 36, 191-9		38
1719	Both CRISPR/Cas-based nucleases and nickases can be used efficiently for genome engineering in Arabidopsis thaliana. **2014**, 79, 348-59		475
1718	Fine-mapping natural alleles: quantitative complementation to the rescue. **2014**, 23, 2377-82		28
1717	Efficient simultaneous excision of multiple selectable marker cassettes using I-SceI-induced double-strand DNA breaks in Saccharomyces cerevisiae. **2014**, 14, 741-54		24
1716	The CRISPR/Cas9 system produces specific and homozygous targeted gene editing in rice in one generation. **2014**, 12, 797-807		540
1715	CEP290 gene transfer rescues Leber congenital amaurosis cellular phenotype. **2014**, 21, 662-72		100
1714	Genome-scale neurogenetics: methodology and meaning. **2014**, 17, 756-63		74
1713	Self-processing of ribozyme-flanked RNAs into guide RNAs in vitro and in vivo for CRISPR-mediated genome editing. **2014**, 56, 343-9		357
1712	Endonucleases: new tools to edit the mouse genome. **2014**, 1842, 1942-1950		48
1711	The three major types of CRISPR-Cas systems function independently in CRISPR RNA biogenesis in Streptococcus thermophilus. **2014**, 93, 98-112		60
1710	Programmable removal of bacterial strains by use of genome-targeting CRISPR-Cas systems. **2014**, 5, e00928-13		236

1709	Classification and evolution of type II CRISPR-Cas systems. **2014**, 42, 6091-105		288
1708	Cas-OFFinder: a fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleases. **2014**, 30, 1473-5		1015
1707	CRISPR/Cas9-mediated targeted mutagenesis in the liverwort Marchantia polymorpha L. **2014**, 55, 475-81		179
1706	Lignin bioengineering. **2014**, 26, 189-98		115
1705	RNA events. Cas9 targeting and the CRISPR revolution. *Science*, **2014**, 344, 707-8	33.3	62
1704	Mechanisms of epigenetic memory and addiction. **2014**, 33, 1091-103		39
1703	DNA assembly for plant biology: techniques and tools. **2014**, 19, 14-9		36
1702	Translation: screening for novel therapeutics with disease-relevant cell types derived from human stem cell models. **2014**, 75, 952-60		29
1701	Identification of LRRC8 heteromers as an essential component of the volume-regulated anion channel VRAC. *Science*, **2014**, 344, 634-8	33.3	364
1700	CRISPR/Cas technology: a revolutionary approach for genome engineering. **2014**, 57, 639-40		19
1699	Accelerating genome editing in CHO cells using CRISPR Cas9 and CRISPy, a web-based target finding tool. **2014**, 111, 1604-16		137
1698	Unlocking the treasure trove: from genes to schizophrenia biology. **2014**, 40, 492-6		13
1697	Multiple genome modifications by the CRISPR/Cas9 system in zebrafish. **2014**, 19, 555-64		85
1696	Oligonucleotide-based targeted gene editing in C. elegans via the CRISPR/Cas9 system. **2014**, 24, 247-50		70
1695	One gene, many neuropsychiatric disorders: lessons from Mendelian diseases. **2014**, 17, 773-81		92
1694	Revitalizing psychiatric therapeutics. **2014**, 39, 220-9		61
1693	Genome-scale CRISPR-Cas9 knockout screening in human cells. *Science*, **2014**, 343, 84-87	33.3	3080
1692	Targeted mutagenesis in Zea mays using TALENs and the CRISPR/Cas system. **2014**, 41, 63-8		435

1691	Cas9 effector-mediated regulation of transcription and differentiation in human pluripotent stem cells. **2014**, 141, 219-23		210
1690	TALE: a tale of genome editing. **2014**, 114, 25-32		25
1689	Human pluripotent stem cell models of autism spectrum disorder: emerging frontiers, opportunities, and challenges towards neuronal networks in a dish. **2014**, 231, 1089-104		16
1688	Diversity, evolution, and therapeutic applications of small RNAs in prokaryotic and eukaryotic immune systems. **2014**, 11, 113-34		16
1687	CRISPRs: molecular signatures used for pathogen subtyping. **2014**, 80, 430-9		101
1686	Synthetic nucleases for genome engineering in plants: prospects for a bright future. **2014**, 78, 727-41		181
1685	Direct in vivo RNAi screen unveils myosin IIa as a tumor suppressor of squamous cell carcinomas. *Science*, **2014**, 343, 309-13	33.3	185
1684	Targeted genome engineering techniques in Drosophila. **2014**, 68, 29-37		55
1683	Planting the seed: target recognition of short guide RNAs. **2014**, 22, 74-83		53
1682	One-step generation of different immunodeficient mice with multiple gene modifications by CRISPR/Cas9 mediated genome engineering. **2014**, 46, 49-55		98
1681	Next generation approaches to study virus entry and infection. **2014**, 4, 8-14		14
1680	Improving CRISPR-Cas nuclease specificity using truncated guide RNAs. **2014**, 32, 279-284		1371
1679	Single-step generation of gene knockout-rescue system in pluripotent stem cells by promoter insertion with CRISPR/Cas9. **2014**, 444, 158-63		11
1678	Genotyping with CRISPR-Cas-derived RNA-guided endonucleases. **2014**, 5, 3157		100
1677	DNA interrogation by the CRISPR RNA-guided endonuclease Cas9. **2014**, 507, 62-7		1171
1676	Generation of gene-modified cynomolgus monkey via Cas9/RNA-mediated gene targeting in one-cell embryos. **2014**, 156, 836-43		764
1675	Development-inspired reprogramming of the mammalian central nervous system. *Science*, **2014**, 343, 1239882	33.3	69
1674	Genome-wide prediction of highly specific guide RNA spacers for CRISPR-Cas9-mediated genome editing in model plants and major crops. **2014**, 7, 923-6		211

1673	Lactobacillus buchneri genotyping on the basis of clustered regularly interspaced short palindromic repeat (CRISPR) locus diversity. **2014**, 80, 994-1001		41
1672	Fundamentals of vitamin D hormone-regulated gene expression. **2014**, 144 Pt A, 5-11		86
1671	Epigenetics and the regulation of stress vulnerability and resilience. **2014**, 264, 157-70		129
1670	Genetic screens in human cells using the CRISPR-Cas9 system. *Science*, **2014**, 343, 80-4	33.3	1874
1669	Distal enhancers: new insights into heart development and disease. **2014**, 24, 294-302		32
1668	Visualizing epigenetics: current advances and advantages in HDAC PET imaging techniques. **2014**, 264, 186-97		32
1667	2013: Signaling breakthroughs of the year. **2014**, 7, eg1		0
1666	CasOT: a genome-wide Cas9/gRNA off-target searching tool. **2014**, 30, 1180-1182		232
1665	Cas9-based tools for targeted genome editing and transcriptional control. **2014**, 80, 1544-52		50
1664	Genome-wide recessive genetic screening in mammalian cells with a lentiviral CRISPR-guide RNA library. **2014**, 32, 267-73		734
1663	Efficient RNA/Cas9-mediated genome editing in Xenopus tropicalis. **2014**, 141, 707-14		125
1662	Synthetic biology in mammalian cells: next generation research tools and therapeutics. **2014**, 15, 95-107		206
1661	Targeted genome modification technologies and their applications in crop improvements. **2014**, 33, 575-83		114
1660	Ecological Genomics. **2014**,		8
1659	Highly efficient CRISPR/Cas9-mediated knock-in in zebrafish by homology-independent DNA repair. **2014**, 24, 142-53		436
1658	Genetically engineered humanized mouse models for preclinical antibody studies. **2014**, 28, 171-80		12
1657	Highly efficient gene knockout in mice and zebrafish with RNA-guided endonucleases. **2014**, 24, 125-31		215
1656	The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. *Science*, **2014**, 343, 305-9	33.3	876

1655	Megabase-scale deletion using CRISPR/Cas9 to generate a fully haploid human cell line. **2014**, 24, 2059-65		173
1654	High-resolution transcript profiling of the atypical biotrophic interaction between Theobroma cacao and the fungal pathogen Moniliophthora perniciosa. **2014**, 26, 4245-69		83
1653	Innate immunity. A Spaetzle-like role for nerve growth factor □in vertebrate immunity to Staphylococcus aureus. *Science*, **2014**, 346, 641-646	33.3	55
1652	A cell-intrinsic role for TLR2-MYD88 in intestinal and breast epithelia and oncogenesis. **2014**, 16, 1238-48		85
1651	Resources for functional genomics studies in Drosophila melanogaster. **2014**, 197, 1-18		53
1650	Genetic and genomic tools for the marine annelid Platynereis dumerilii. **2014**, 197, 19-31		48
1649	Peeking into a cool future: genome editing to delete PCSK9 and control hypercholesterolemia in a single shot. **2014**, 115, 472-4		2
1648	Gene therapy for the nervous system: challenges and new strategies. **2014**, 11, 817-39		58
1647	Chemical biology. A bump-and-hole approach to engineer controlled selectivity of BET bromodomain chemical probes. *Science*, **2014**, 346, 638-641	33.3	108
1646	Perspectives of green microalgal research for biofuels. **2014**, 145-146, 15-25		1
1645	Efficient ablation of genes in human hematopoietic stem and effector cells using CRISPR/Cas9. **2014**, 15, 643-52		324
1644	Genome editing for human gene therapy. **2014**, 546, 273-95		14
1643	Genome editing in human stem cells. **2014**, 546, 119-38		70
1642	RNA-mediated regulation in Gram-positive pathogens: an overview punctuated with examples from the group A Streptococcus. **2014**, 94, 9-20		17
1641	Efficient search, mapping, and optimization of multi-protein genetic systems in diverse bacteria. **2014**, 10, 731		164
1640	CRISPR/Cas9-mediated conversion of eGFP- into Gal4-transgenic lines in zebrafish. **2014**, 9, 2823-40		46
1639	The role of chromatin and epigenetics in the polyphenisms of ant castes. **2014**, 13, 235-45		29
1638	Guidelines for genetic studies in single patients: lessons from primary immunodeficiencies. **2014**, 211, 2137-49		158

1637	Use of the CRISPR/Cas9 system to produce genetically engineered pigs from in vitro-derived oocytes and embryos. **2014**, 91, 78		213
1636	Progress and challenges in the development of a cell-based therapy for hemophilia A. **2014**, 12, 1954-65		21
1635	High-efficiency genome editing and allele replacement in prototrophic and wild strains of Saccharomyces. **2014**, 198, 859-66		20
1634	Guide RNA functional modules direct Cas9 activity and orthogonality. **2014**, 56, 333-339		174
1633	The intraflagellar transport protein IFT27 promotes BBSome exit from cilia through the GTPase ARL6/BBS3. **2014**, 31, 265-278		145
1632	Phylogeny of Cas9 determines functional exchangeability of dual-RNA and Cas9 among orthologous type II CRISPR-Cas systems. **2014**, 42, 2577-90		251
1631	CRISPR in the liver. **2014**, 7, 447-447		
1630	Multiplex CRISPR/Cas9-based genome engineering from a single lentiviral vector. **2014**, 42, e147		232
1629	Target specificity of the CRISPR-Cas9 system. **2014**, 2, 59-70		184
1628	Beyond the bolus: transgenic tools for investigating the neurophysiology of learning and memory. **2014**, 21, 506-18		5
1627	The contribution of natural selection to present-day susceptibility to chronic inflammatory and autoimmune disease. **2014**, 31, 66-78		50
1626	Mutagenesis and homologous recombination in Drosophila cell lines using CRISPR/Cas9. **2014**, 3, 42-9		83
1625	Efficient in vivo deletion of a large imprinted lncRNA by CRISPR/Cas9. **2014**, 11, 829-35		121
1624	TALEN knockout of the PSIP1 gene in human cells: analyses of HIV-1 replication and allosteric integrase inhibitor mechanism. **2014**, 88, 9704-17		59
1623	Selective VPS34 inhibitor blocks autophagy and uncovers a role for NCOA4 in ferritin degradation and iron homeostasis in vivo. **2014**, 16, 1069-79		370
1622	In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system. **2014** , 516, 423-7		407
1621	Oncogene regulation. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element. *Science*, **2014**, 346, 1373-7	33.3	484
1620	IFT27 links the BBSome to IFT for maintenance of the ciliary signaling compartment. **2014**, 31, 279-290		171

1619	Genome editing using Cas9 nickases. **2014**, 546, 161-74	53
1618	Mouse Genome Editing Using the CRISPR/Cas System. **2014**, 83, 15.7.1-27	65
1617	Selection of chromosomal DNA libraries using a multiplex CRISPR system in Saccharomyces cerevisiae. **2014**,	1
1616	Multiplex engineering of industrial yeast genomes using CRISPRm. **2014**, 546, 473-89	62
1615	The iCRISPR platform for rapid genome editing in human pluripotent stem cells. **2014**, 546, 215-50	52
1614	Protein engineering of Cas9 for enhanced function. **2014**, 546, 491-511	17
1613	Assaying break and nick-induced homologous recombination in mammalian cells using the DR-GFP reporter and Cas9 nucleases. **2014**, 546, 175-91	18
1612	CRISPR/Cas9-based genome editing in mice by single plasmid injection. **2014**, 546, 319-36	45
1611	Tissue-specific genome editing in Ciona embryos by CRISPR/Cas9. **2014**, 141, 4115-20	90
1610	Clipping of predetermined fragments from the human genome by S1 nuclease-PNA combinations. **2014**, 50, 8674-6	9
1609	Efficient knockout of transplanted green fluorescent protein gene in medaka using TALENs. **2014**, 16, 674-83	10
1608	Creating class I MHC-null pigs using guide RNA and the Cas9 endonuclease. **2014**, 193, 5751-7	103
1607	The solute carrier SLC35F2 enables YM155-mediated DNA damage toxicity. **2014**, 10, 768-773	125
1606	CRISPR/Cas9 mediated generation of stable chondrocyte cell lines with targeted gene knockouts; analysis of an aggrecan knockout cell line. **2014**, 69, 118-25	18
1605	Characterization of genomic deletion efficiency mediated by clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 nuclease system in mammalian cells. **2014**, 289, 21312-24	236
1604	A piggyBac route to transgenic honeybees. **2014**, 111, 8708-9	8
1603	Genome engineering: the next genomic revolution. **2014**, 11, 1009-11	22
1602	Engineered red blood cells as carriers for systemic delivery of a wide array of functional probes. **2014**, 111, 10131-6	124

1601	RNA-guided endonuclease provides a therapeutic strategy to cure latent herpesviridae infection. **2014**, 111, 13157-62	156
1600	Nascent RNA interaction keeps PRC2 activity poised and in check. **2014**, 28, 1983-8	133
1599	Cellular reprogramming by transcription factor engineering. **2014**, 28, 1-9	6
1598	Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins. **2014**, 24, 1012-9	1085
1597	A gene regulatory network controls the binary fate decision of rod and bipolar cells in the vertebrate retina. **2014**, 30, 513-27	115
1596	The potential role of SRY in epigenetic gene regulation during brain sexual differentiation in mammals. **2014**, 86, 135-65	22
1595	Specific and heritable gene editing in Arabidopsis. **2014**, 111, 4357-8	25
1594	Adeno-associated virus vectors as therapeutic and investigational tools in the cardiovascular system. **2014**, 114, 1827-46	84
1593	Biopharmaceutical protein production bySaccharomyces cerevisiae: current state and future prospects. **2014**, 2, 167-182	27
1592	The extended pluripotency protein interactome and its links to reprogramming. **2014**, 28, 16-24	17
1591	MicroRNA-mediated surveillance of phosphate transporters on the move. **2014**, 19, 647-55	53
1590	Synthetic biology and therapeutic strategies for the degenerating brain: Synthetic biology approaches can transform classical cell and gene therapies, to provide new cures for neurodegenerative diseases. **2014**, 36, 979-90	16
1589	Wolbachia endosymbionts and human disease control. **2014**, 195, 88-95	76
1588	Efficient editing of malaria parasite genome using the CRISPR/Cas9 system. **2014**, 5, e01414-14	85
1587	PyBamView: a browser-based application for viewing short read alignments. **2014**, 30, 3405-7	3
1586	Genome editing in rice and wheat using the CRISPR/Cas system. **2014**, 9, 2395-410	455
1585	First evidence of comparative responses of Toll-like receptor 22 (TLR22) to relatively resistant and susceptible Indian farmed carps to Argulus siamensis infection. **2014**, 47, 25-35	33
1584	Generation of cell-based systems to visualize chromosome damage and translocations in living cells. **2014**, 9, 2476-92	15

1583	Generation and Use of Transgenic Mice in Drug Discovery. **2014**, 131-148	2
1582	The genome editing toolbox: a spectrum of approaches for targeted modification. **2014**, 30, 87-94	28
1581	Bacteriophage-based synthetic biology for the study of infectious diseases. **2014**, 19, 59-69	48
1580	Structural basis of PAM-dependent target DNA recognition by the Cas9 endonuclease. **2014**, 513, 569-73	783
1579	Dissecting mammalian immunity through mutation. **2014**, 92, 392-9	8
1578	One-step generation of knockout pigs by zygote injection of CRISPR/Cas system. **2014**, 24, 372-5	331
1577	Pluripotent stem cells as a platform for cardiac arrhythmia drug screening. **2014**, 16, 334	7
1576	Analysis of the arabidopsis REM gene family predicts functions during flower development. **2014**, 114, 1507-15	25
1575	RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection. **2014**, 111, 11461-6	386
1574	Seamless gene correction of □-thalassemia mutations in patient-specific iPSCs using CRISPR/Cas9 and piggyBac. **2014**, 24, 1526-33	302
1573	Conditional targeting of Ispd using paired Cas9 nickase and a single DNA template in mice. **2014**, 4, 637-42	34
1572	From transplantation to transgenics: mouse models of developmental hematopoiesis. **2014**, 42, 707-16	9
1571	Polo-like kinase 1 licenses CENP-A deposition at centromeres. **2014**, 158, 397-411	96
1570	The emerging roles of deubiquitylating enzymes (DUBs) in the TGF□and BMP pathways. **2014**, 26, 2186-92	26
1569	Genomics of Plant-Associated Fungi and Oomycetes: Dicot Pathogens. **2014**,	7
1568	Targeted gene knockout in chickens mediated by TALENs. **2014**, 111, 12716-21	113
1567	Efficient, complete deletion of synaptic proteins using CRISPR. **2014**, 83, 1051-7	87
1566	Conditional knockouts generated by engineered CRISPR-Cas9 endonuclease reveal the roles of coronin in C. elegans neural development. **2014**, 30, 625-36	116

1565	New mechanistic and therapeutic targets for pediatric heart failure: report from a National Heart, Lung, and Blood Institute working group. **2014**, 130, 79-86		41
1564	Simultaneous editing of three homoeoalleles in hexaploid bread wheat confers heritable resistance to powdery mildew. **2014**, 32, 947-51		1161
1563	Gene disruption by cell-penetrating peptide-mediated delivery of Cas9 protein and guide RNA. **2014**, 24, 1020-7		442
1562	Harnessing CRISPR-Cas9 immunity for genetic engineering. **2014**, 19, 114-119		52
1561	The pancreatic □cell: recent insights from human genetics. **2014**, 25, 425-34		23
1560	RNA guided genome editing in mouse germ-line stem cells. **2014**, 41, 409-11		1
1559	CRISPR-mediated direct mutation of cancer genes in the mouse liver. **2014**, 514, 380-4		521
1558	Zebrafish: a new vertebrate model for visualizing myelination in vivo. **2014**, 261, 278-80		
1557	Generating genetically modified mice using CRISPR/Cas-mediated genome engineering. **2014**, 9, 1956-68		352
1556	The new CRISPR-Cas system: RNA-guided genome engineering to efficiently produce any desired genetic alteration in animals. **2014**, 23, 707-16		51
1555	Inactivation of the human papillomavirus E6 or E7 gene in cervical carcinoma cells by using a bacterial CRISPR/Cas RNA-guided endonuclease. **2014**, 88, 11965-72		193
1554	How chemistry supports cell biology: the chemical toolbox at your service. **2014**, 24, 751-60		25
1553	Expansion of the CRISPR-Cas9 genome targeting space through the use of H1 promoter-expressed guide RNAs. **2014**, 5, 4516		52
1552	Efficient CRISPR-Cas9-mediated genome editing in Plasmodium falciparum. **2014**, 11, 915-8		162
1551	The mitochondrial translocator protein, TSPO, inhibits HIV-1 envelope glycoprotein biosynthesis via the endoplasmic reticulum-associated protein degradation pathway. **2014**, 88, 3474-84		32
1550	Prevention of muscular dystrophy in mice by CRISPR/Cas9-mediated editing of germline DNA. *Science*, **2014**, 345, 1184-1188	33.3	493
1549	Improving the specificity and efficacy of CRISPR/CAS9 and gRNA through target specific DNA reporter. **2014**, 189, 1-8		12
1548	Chromosomal translocations in human cells are generated by canonical nonhomologous end-joining. **2014**, 55, 829-842		221

1547	Construction of a quadruple auxotrophic mutant of an industrial polyploid saccharomyces cerevisiae strain by using RNA-guided Cas9 nuclease. **2014**, 80, 7694-701	90
1546	OutKnocker: a web tool for rapid and simple genotyping of designer nuclease edited cell lines. **2014**, 24, 1719-23	83
1545	Low incidence of off-target mutations in individual CRISPR-Cas9 and TALEN targeted human stem cell clones detected by whole-genome sequencing. **2014**, 15, 27-30	394
1544	Efficient gene editing in adult mouse livers via adenoviral delivery of CRISPR/Cas9. **2014**, 588, 3954-8	80
1543	Efficient homologous recombination-mediated genome engineering in zebrafish using TALE nucleases. **2014**, 141, 3807-18	93
1542	Toward a genetic dissection of cortical circuits in the mouse. **2014**, 83, 1284-302	82
1541	Primate-specific endogenous retrovirus-driven transcription defines naive-like stem cells. **2014**, 516, 405-9	272
1540	Improving the efficiency for generation of genome-edited zebrafish by labeling primordial germ cells. **2014**, 55, 329-34	11
1539	Genome modification by CRISPR/Cas9. **2014**, 281, 5186-93	86
1538	A single blastocyst assay optimized for detecting CRISPR/Cas9 system-induced indel mutations in mice. **2014**, 14, 69	53
1537	Exploiting Issatchenkia orientalis SD108 for succinic acid production. **2014**, 13, 121	46
1536	Glucocorticoid receptor binds half sites as a monomer and regulates specific target genes. **2014**, 15, 418	86
1535	Regulation of transcription by long noncoding RNAs. **2014**, 48, 433-55	318
1534	A bistable genetic switch based on designable DNA-binding domains. **2014**, 5, 5007	53
1533	Rational design of highly active sgRNAs for CRISPR-Cas9-mediated gene inactivation. **2014**, 32, 1262-7	1000
1532	Genomics and Genome Engineering in Xenopus. **2014**, 383-402	1
1531	Beyond genome sequencing: lineage tracking with barcodes to study the dynamics of evolution, infection, and cancer. **2014**, 104, 417-30	52
1530	Impact of RNA-guided technologies for target identification and deconvolution. **2014**, 19, 1327-37	18

1529	CRISPR/Cas-mediated genome editing in the rat via direct injection of one-cell embryos. **2014**, 9, 2493-512		148
1528	Genomic editing tools to model human diseases with isogenic pluripotent stem cells. **2014**, 23, 2673-86		42
1527	Analysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases. **2014**, 24, 132-41		966
1526	The G□□Src signaling pathway regulates TNF-induced necroptosis via control of necrosome translocation. **2014**, 24, 417-32		21
1525	CRISPR-Cas9 knockin mice for genome editing and cancer modeling. **2014**, 159, 440-55		1089
1524	Selective and strain-specific NFAT4 activation by the Toxoplasma gondii polymorphic dense granule protein GRA6. **2014**, 211, 2013-32		76
1523	Saturation editing of genomic regions by multiplex homology-directed repair. **2014**, 513, 120-3		223
1522	A simplified and efficient germline-specific CRISPR/Cas9 system for Drosophila genomic engineering. **2014**, 8, 52-7		81
1521	How the ribosome hands the A-site tRNA to the P site during EF-G-catalyzed translocation. *Science*, **2014**, 345, 1188-91	33.3	120
1520	DNA repair mechanisms and their biological roles in the malaria parasite Plasmodium falciparum. **2014**, 78, 469-86		65
1519	Evolutionary engineering by genome shuffling. **2014**, 98, 3877-87		55
1518	Transposon based activation tagging in diploid strawberry and monoploid derivatives of potato. **2014**, 33, 1203-16		8
1517	Simple generation of albino C57BL/6J mice with G291T mutation in the tyrosinase gene by the CRISPR/Cas9 system. **2014**, 25, 327-34		78
1516	Biotechnology. Regulating gene drives. *Science*, **2014**, 345, 626-8	33.3	232
1515	Homing endonucleases from mobile group I introns: discovery to genome engineering. **2014**, 5, 7		86
1514	Transcriptional and epigenetic regulation of PPAR□expression during adipogenesis. **2014**, 4, 29		140
1513	Gene targeting using the Agrobacterium tumefaciens-mediated CRISPR-Cas system in rice. **2014**, 7, 5		153
1512	Advances in fluorescence labeling strategies for dynamic cellular imaging. **2014**, 10, 512-23		336

1511	Gene Targeting by Homologous Recombination. **2014**,	1
1510	Deciphering memory function with optogenetics. **2014**, 122, 341-90	15
1509	CRISPR/Cas9 and TALEN-mediated knock-in approaches in zebrafish. **2014**, 69, 142-50	130
1508	CRISPR/Cas9-Directed Genome Editing of Cultured Cells. **2014**, 107, 31.1.1-17	51
1507	Genome editing assessment using CRISPR Genome Analyzer (CRISPR-GA). **2014**, 30, 2968-70	107
1506	Genome wide functional genetics in haploid cells. **2014**, 588, 2415-21	16
1505	First CRISPR-Cas patent opens race to stake out intellectual property. **2014**, 32, 599-601	11
1504	Engineering synthetic TALE and CRISPR/Cas9 transcription factors for regulating gene expression. **2014**, 69, 188-97	27
1503	Current advances in polymer-based nanotheranostics for cancer treatment and diagnosis. **2014**, 6, 21859-73	159
1502	BuD, a helix-loop-helix DNA-binding domain for genome modification. **2014**, 70, 2042-52	19
1501	Non-viral vectors for gene-based therapy. **2014**, 15, 541-55	2032
1500	TALEN-mediated gene mutations in monkeys. **2014**, 30, 379-380	2
1499	Homologous recombination in human embryonic stem cells using CRISPR/Cas9 nickase and a long DNA donor template. **2014**, 5, 258-60	59
1498	Opening the genetic toolbox of niche model organisms with high throughput techniques: novel proteins in regeneration as a case study. **2014**, 36, 407-18	5
1497	Zinc finger nuclease-mediated knockout of AHR or ARNT in human breast cancer cells abolishes basal and ligand-dependent regulation of CYP1B1 and differentially affects estrogen receptor □ transactivation. **2014**, 138, 89-103	19
1496	A cut above the rest: targeted genome editing technologies in human pluripotent stem cells. **2014**, 289, 4594-9	100
1495	Biallelic targeting of expressed genes in mouse embryonic stem cells using the Cas9 system. **2014**, 69, 171-178	20
1494	Somatic mosaicism and allele complexity induced by CRISPR/Cas9 RNA injections in mouse zygotes. **2014**, 393, 3-9	218

1493	Using targeted chromatin regulators to engineer combinatorial and spatial transcriptional regulation. **2014**, 158, 110-20	93
1492	The future of drug discovery: enabling technologies for enhancing lead characterization and profiling therapeutic potential. **2014**, 9, 847-58	9
1491	Whole-genome sequencing analysis reveals high specificity of CRISPR/Cas9 and TALEN-based genome editing in human iPSCs. **2014**, 15, 12-3	274
1490	Using RNAi screening technologies to interrogate the extrinsic apoptosis pathway. **2014**, 544, 129-60	2
1489	Genome engineering via TALENs and CRISPR/Cas9 systems: challenges and perspectives. **2014**, 12, 1006-14	86
1488	A CRISPR view of development. **2014**, 28, 1859-72	174
1487	The genome landscape of the african green monkey kidney-derived vero cell line. **2014**, 21, 673-83	130
1486	Role of stem cells in large animal genetic engineering in the TALENs-CRISPR era. **2013**, 26, 65-73	10
1485	A defined zebrafish line for high-throughput genetics and genomics: NHGRI-1. **2014**, 198, 167-70	65
1484	CRISPR/Cas9-mediated genome engineering: an adeno-associated viral (AAV) vector toolbox. **2014**, 9, 1402-12	186
1483	Xcc-facilitated agroinfiltration of citrus leaves: a tool for rapid functional analysis of transgenes in citrus leaves. **2014**, 33, 1993-2001	55
1482	Surrogate reporter-based enrichment of cells containing RNA-guided Cas9 nuclease-induced mutations. **2014**, 5, 3378	92
1481	CRISPR-Cas9-assisted recombineering in Lactobacillus reuteri. **2014**, 42, e131	253
1480	Targeted gene integration using the combination of a sequence-specific DNA-binding protein and phiC31 integrase. **2014**, 186, 139-47	2
1479	Engineering large viral DNA genomes using the CRISPR-Cas9 system. **2014**, 58, 513-22	61
1478	Whole genome sequencing reveals a novel CRISPR system in industrial Clostridium acetobutylicum. **2014**, 41, 1677-85	7
1477	Cancer mouse models: past, present and future. **2014**, 27, 54-60	37
1476	Genetic modification and screening in rat using haploid embryonic stem cells. **2014**, 14, 404-14	71

1475	A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia. **2014**, 157, 369-381	419
1474	Genetic Engineering. **2014**, 1-79	1
1473	CHOPCHOP: a CRISPR/Cas9 and TALEN web tool for genome editing. **2014**, 42, W401-7	707
1472	Hairy root transformation using Agrobacterium rhizogenes as a tool for exploring cell type-specific gene expression and function using tomato as a model. **2014**, 166, 455-69	219
1471	Synthetic zinc finger proteins: the advent of targeted gene regulation and genome modification technologies. **2014**, 47, 2309-18	85
1470	Engineering human tumour-associated chromosomal translocations with the RNA-guided CRISPR-Cas9 system. **2014**, 5, 3964	167
1469	Genetic diagnosis of autism spectrum disorders: the opportunity and challenge in the genomics era. **2014**, 51, 249-62	31
1468	The sheep genome illuminates biology of the rumen and lipid metabolism. *Science*, **2014**, 344, 1168-1173	33.3 294
1467	Genome editing in the human malaria parasite Plasmodium falciparum using the CRISPR-Cas9 system. **2014**, 32, 819-21	423
1466	Applications of TALENs and CRISPR/Cas9 in human cells and their potentials for gene therapy. **2014** , 56, 681-8	33
1465	Disrupting the male germ line to find infertility and contraception targets. **2014**, 75, 101-8	11
1464	Sandwiched zinc-finger nucleases demonstrating higher homologous recombination rates than conventional zinc-finger nucleases in mammalian cells. **2014**, 24, 813-6	1
1463	Highly efficient multiplex targeted mutagenesis and genomic structure variation in Bombyx mori cells using CRISPR/Cas9. **2014**, 49, 35-42	69
1462	A highly effective TALEN-mediated approach for targeted gene disruption in Xenopus tropicalis and zebrafish. **2014**, 69, 58-66	43
1461	Generation of targeted mouse mutants by embryo microinjection of TALENs. **2014**, 69, 94-101	14
1460	CRISPR/Cas9 mediated genome engineering in Drosophila. **2014**, 69, 128-36	88
1459	CRISPR/Cas9 and genome editing in Drosophila. **2014**, 41, 7-19	144
1458	Quantifying genome-editing outcomes at endogenous loci with SMRT sequencing. **2014**, 7, 293-305	94

1457	Approaches to in vitro tissue regeneration with application for human disease modeling and drug development. **2014**, 19, 754-62	33
1456	Efficient gene targeting in zebrafish mediated by a zebrafish-codon-optimized cas9 and evaluation of off-targeting effect. **2014**, 41, 43-6	60
1455	Toward establishing an efficient and versatile gene targeting system in higher plants. **2014**, 3, 2-6	10
1454	Genetic studies of Crohn's disease: past, present and future. **2014**, 28, 373-86	73
1453	MicroRNA target identification: lessons from hypoxamiRs. **2014**, 21, 1249-68	12
1452	Expression QTL-based analyses reveal candidate causal genes and loci across five tumor types. **2014**, 23, 5294-302	61
1451	Chromatin features and the epigenetic regulation of pluripotency states in ESCs. **2014**, 141, 2376-90	67
1450	The combinational use of CRISPR/Cas9-based gene editing and targeted toxin technology enables efficient biallelic knockout of the □1,3-galactosyltransferase gene in porcine embryonic fibroblasts. **2014**, 21, 291-300	37
1449	Seamless modification of wild-type induced pluripotent stem cells to the natural CCR5□32 mutation confers resistance to HIV infection. **2014**, 111, 9591-6	241
1448	Precision genome editing: a small revolution for glycobiology. **2014**, 24, 663-80	45
1447	Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing. **2014**, 115, 488-92	345
1446	An integrative analysis of colon cancer identifies an essential function for PRPF6 in tumor growth. **2014**, 28, 1068-84	65
1445	Stem cells on the brain: modeling neurodevelopmental and neurodegenerative diseases using human induced pluripotent stem cells. **2014**, 28, 5-29	43
1444	Enhancing the specificity of recombinase-mediated genome engineering through dimer interface redesign. **2014**, 136, 5047-56	24
1443	The emerging age of cell-free synthetic biology. **2014**, 588, 2755-61	71
1442	An iCRISPR platform for rapid, multiplexable, and inducible genome editing in human pluripotent stem cells. **2014**, 15, 215-226	331
1441	Development and applications of CRISPR-Cas9 for genome engineering. **2014**, 157, 1262-1278	3595
1440	DrugTargetSeqR: a genomics- and CRISPR-Cas9-based method to analyze drug targets. **2014**, 10, 626-8	84

1439	Caspase-mediated cleavage of phospholipid flippase for apoptotic phosphatidylserine exposure. *Science*, **2014**, 344, 1164-8	33.3	323
1438	Programmable design of functional ribonucleoprotein complexes. **2014**, 9, 2045-51		5
1437	Heritable/conditional genome editing in C. elegans using a CRISPR-Cas9 feeding system. **2014**, 24, 886-9		34
1436	MicroRNAs in normal and psoriatic skin. **2014**, 46, 113-22		27
1435	RNA interference of plant MAPK cascades for functional studies. **2014**, 1171, 91-103		2
1434	The architecture of gene expression: integrating dispersed cis-regulatory modules into coherent regulatory domains. **2014**, 27, 74-82		40
1433	Promising future for the transgenic rat in transplantation research. **2014**, 28, 155-62		10
1432	Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing. **2014**, 32, 941-6		342
1431	Rapid and efficient assembly of transcription activator-like effector genes by USER cloning. **2014**, 41, 339-47		5
1430	Toward product attribute control: developments from genome sequencing. **2014**, 30, 40-4		9
1429	[Scientific review on novel genome editing techniques]. **2014**, 55, 231-46		
1428	Gene Inactivation Strategies: An Update. **2014**,		
1427	Synthetic RNAs for Gene Regulation: Design Principles and Computational Tools. **2014**, 2, 65		23
1426	Precise gene deletion and replacement using the CRISPR/Cas9 system in human cells. **2014**, 57, 115-24		108
1425	Targeted genome editing tools for disease modeling and gene therapy. **2014**, 14, 2-9		42
1424	Expanding the genetic editing tool kit: ZFNs, TALENs, and CRISPR-Cas9. **2014**, 124, 4154-61		252
1423	Mouse genome engineering using designer nucleases. **2014**,		10
1422	Selection of chromosomal DNA libraries using a multiplex CRISPR system. **2014**, 3,		224

1421	Efficient CRISPR/Cas9-mediated gene editing in Arabidopsis thaliana and inheritance of modified genes in the T2 and T3 generations. **2014**, 9, e99225	122
1420	One-step generation of myostatin gene knockout sheep via the CRISPR/Cas9 system. **2014**, 1, 2	48
1419	Functions and Applications of RNA-Guided CRISPR-Cas Immune Systems. **2014**, 1-24	
1418	Precision genome engineering in lactic acid bacteria. **2014**, 13 Suppl 1, S10	48
1417	Genetic rearrangements of variable di-residue (RVD)-containing repeat arrays in a baculoviral TALEN system. **2014**, 1, 14050	13
1416	New horizons in genome engineering of Drosophila melanogaster. **2014**, 89, 3-8	17
1415	Asymmetric parental genome engineering by Cas9 during mouse meiotic exit. **2014**, 4, 7621	39
1414	Induced pluripotent stem cells: Landscape for studying and treating hereditary hearing loss. **2014**, 9, 151-155	4
1413	A novel two-step genome editing strategy with CRISPR-Cas9 provides new insights into telomerase action and TERT gene expression. **2015**, 16, 231	58
1412	Pop in, pop out: a novel gene-targeting strategy for use with CRISPR-Cas9. **2015**, 16, 244	5
1411	The Sigma-2 Receptor and Progesterone Receptor Membrane Component 1 are Different Binding Sites Derived From Independent Genes. **2015**, 2, 1806-13	71
1410	Congenital Myasthenic Syndrome Type 19 Is Caused by Mutations in COL13A1, Encoding the Atypical Non-fibrillar Collagen Type XIII α1 Chain. **2015**, 97, 878-85	51
1409	Genome engineering of isogenic human ES cells to model autism disorders. **2015**, 43, e65	12
1408	Genome editing for crop improvement: Challenges and opportunities. **2015**, 6, 183-205	113
1407	Epigenome-modifying tools in asthma. **2015**, 7, 1017-32	39
1406	Tailor-made CRISPR/Cas system for highly efficient targeted gene replacement in the rice blast fungus. **2015**, 112, 2543-9	120
1405	Connecting genotypes, phenotypes and fitness: harnessing the power of CRISPR/Cas9 genome editing. **2015**, 24, 3810-22	38
1404	Genomics as the key to unlocking the polyploid potential of wheat. **2015**, 208, 1008-22	84

1403	CRISPR/Cas9-mediated genome engineering of CHO cell factories: Application and perspectives. **2015**, 10, 979-94	82
1402	Disruption of MeCP2 attenuates circadian rhythm in CRISPR/Cas9-based Rett syndrome model mouse. **2015**, 20, 992-1005	28
1401	Bacteriophages of Lactic Acid Bacteria and Biotechnological Tools. **2015**, 100-119	1
1400	Gene Targeting in Neuroendocrinology. **2015**, 5, 1645-76	15
1399	[Application and potential of genome engineering by artificial enzymes]. **2015**, 135, 405-14	
1398	Positive Regulation of Interleukin-2 Expression by a Pseudokinase, Tribbles 1, in Activated T Cells. **2015**, 38, 1126-33	6
1397	Genome editing of CXCR4 by CRISPR/cas9 confers cells resistant to HIV-1 infection. **2015**, 5, 15577	139
1396	Generation of artificial drooping leaf mutants by CRISPR-Cas9 technology in rice. **2016**, 90, 231-5	14
1395	TALEN- and CRISPR/Cas9-Mediated Gene Editing in Human Pluripotent Stem Cells Using Lipid-Based Transfection. **2015**, 34, 5B.3.1-5B.3.25	21
1394	A marker-free system for highly efficient construction of vaccinia virus vectors using CRISPR Cas9. **2015**, 2, 15035	39
1393	CRISPR/Cas9 nickase-mediated disruption of hepatitis B virus open reading frame S and X. **2015**, 5, 13734	79
1392	Large genomic fragment deletion and functional gene cassette knock-in via Cas9 protein mediated genome editing in one-cell rodent embryos. **2015**, 5, 17517	72
1391	Nanobody-targeted E3-ubiquitin ligase complex degrades nuclear proteins. **2015**, 5, 14269	54
1390	Peri-implantation lethality in mice carrying megabase-scale deletion on 5qc3.3 is caused by Exoc1 null mutation. **2015**, 5, 13632	17
1389	Homology-directed repair in rodent zygotes using Cas9 and TALEN engineered proteins. **2015**, 5, 14410	56
1388	Efficient genome editing in filamentous fungus Trichoderma reesei using the CRISPR/Cas9 system. **2015**, 1, 15007	267
1387	A geminivirus-based guide RNA delivery system for CRISPR/Cas9 mediated plant genome editing. **2015**, 5, 14926	135
1386	Efficient CRISPR/Cas9-mediated biallelic gene disruption and site-specific knockin after rapid selection of highly active sgRNAs in pigs. **2015**, 5, 13348	52

1385 DIY Guide to Creating GMO Sapiens. **2015**, 137-162

1384 ST3Gal-4 is the primary sialyltransferase regulating the synthesis of E-, P-, and L-selectin ligands on human myeloid leukocytes. **2015**, 125, 687-96 54

1383 The lethal response to Cdk1 inhibition depends on sister chromatid alignment errors generated by KIF4 and isoform 1 of PRC1. **2015**, 5, 14798 18

1382 Direct production of XY(DMY-) sex reversal female medaka (Oryzias latipes) by embryo microinjection of TALENs. **2015**, 5, 14057 15

1381 Synthesis of an arrayed sgRNA library targeting the human genome. **2015**, 5, 14987 34

1380 Single-step generation of rabbits carrying a targeted allele of the tyrosinase gene using CRISPR/Cas9. **2015**, 64, 31-7 56

1379 Knockout crickets for the study of learning and memory: Dopamine receptor Dop1 mediates aversive but not appetitive reinforcement in crickets. **2015**, 5, 15885 59

1378 The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol. **2015**, 2015, 59 2

1377 Highly efficient CRISPR/Cas9-mediated transgene knockin at the H11 locus in pigs. **2015**, 5, 14253 81

1376 Phosphoproteomic screening identifies Rab GTPases as novel downstream targets of PINK1. **2015**, 34, 2840-61 127

1375 Computational Prediction of miRNA Genes from Small RNA Sequencing Data. **2015**, 3, 7 33

1374 Derivation of cardiac progenitor cells from embryonic stem cells. **2015**, 52047 4

1373 Detailed phenotypic and molecular analyses of genetically modified mice generated by CRISPR-Cas9-mediated editing. **2015**, 10, e0116484 33

1372 Assembly and validation of versatile transcription activator-like effector libraries. **2014**, 4, 4857 7

1371 CRISPR/gRNA-directed synergistic activation mediator (SAM) induces specific, persistent and robust reactivation of the HIV-1 latent reservoirs. **2015**, 5, 16277 94

1370 Double strand break repair by capture of retrotransposon sequences and reverse-transcribed spliced mRNA sequences in mouse zygotes. **2015**, 5, 12281 29

1369 Preliminary Characterization of a Leptin Receptor Knockout Rat Created by CRISPR/Cas9 System. **2015**, 5, 15942 24

1368 Subcloning plus insertion (SPI)--a novel recombineering method for the rapid construction of gene targeting vectors. **2015**, e52155 2

1367	Construction of a gene knockout CHO cell line using a simple gene targeting method. **2015**, 9, P2	3
1366	Rapidly generating knockout mice from H19-Igf2 engineered androgenetic haploid embryonic stem cells. **2015**, 1, 15031	8
1365	Pathogenicity of Bovine Neonatal Pancytopenia-associated vaccine-induced alloantibodies correlates with Major Histocompatibility Complex class I expression. **2015**, 5, 12748	8
1364	Resequencing of the common marmoset genome improves genome assemblies and gene-coding sequence analysis. **2015**, 5, 16894	28
1363	Transient Low-Temperature Effects on Propidium Iodide Uptake in Lance Array Nanoinjected HeLa Cells. **2015**, 6,	
1362	Integrating transcriptional and protein interaction networks to prioritize condition-specific master regulators. **2015**, 9, 80	18
1361	Quantitative evaluation of the immunodeficiency of a mouse strain by tumor engraftments. **2015**, 8, 59	35
1360	Rewriting the blueprint of life by synthetic genomics and genome engineering. **2015**, 16, 125	18
1359	Selection of a hepatitis C virus with altered entry factor requirements reveals a genetic interaction between the E1 glycoprotein and claudins. **2015**, 62, 1059-69	33
1358	Covalent Modification of a Cysteine Residue in the XPB Subunit of the General Transcription Factor TFIIH Through Single Epoxide Cleavage of the Transcription Inhibitor Triptolide. **2015**, 127, 1879-1883	3
1357	The African Turquoise Killifish: A Model for Exploring Vertebrate Aging and Diseases in the Fast Lane. **2015**, 80, 275-9	20
1356	Fifty Years After Huxley: The Roadmap of Reproductive Medicine Revisited and Updated: The 2015 SRI-Pardi Distinguished Scientist Plenary Lecture of the Society for Reproductive Investigation. **2015**, 22, 1330-5	
1355	A protocol for the identification and validation of novel genetic causes of kidney disease. **2015**, 16, 152	6
1354	Single amino acid substitution (G42E) in the receptor binding domain of mouse mammary tumour virus envelope protein facilitates infection of non-murine cells in a transferrin receptor 1-independent manner. **2015**, 12, 43	14
1353	The utility of transposon mutagenesis for cancer studies in the era of genome editing. **2015**, 16, 229	20
1352	Making sense of GWAS: using epigenomics and genome engineering to understand the functional relevance of SNPs in non-coding regions of the human genome. **2015**, 8, 57	187
1351	CRISPR-Cas: From the Bacterial Adaptive Immune System to a Versatile Tool for Genome Engineering. **2015**, 54, 13508-14	17
1350	Developments in our understanding of the genetic basis of birth defects. **2015**, 103, 680-91	22

1349	Cdk8 deletion in the Apc(Min) murine tumour model represses EZH2 activity and accelerates tumourigenesis. **2015**, 237, 508-19	39
1348	[Pluripotent stem cells as a source for T cell research and clinical application]. **2015**, 38, 101-8	
1347	Crystal Structure of Cas9. **2015**, 57, 96-103	
1346	Epithelial DLD-1 Cells with Disrupted E-cadherin Gene Retain the Ability to Form Cell Junctions and Apico-basal Polarity. **2015**, 40, 79-94	3
1345	Arabidopsis PLC2 is involved in auxin-modulated reproductive development. **2015**, 84, 504-15	32
1344	Target-specific variants of Flp recombinase mediate genome engineering reactions in mammalian cells. **2015**, 282, 3323-33	9
1343	CRISPR-Cas: von einem bakteriellen adaptiven Immunsystem zu einem vielseitigen Werkzeug f die Gentechnik. **2015**, 127, 13710-13716	4
1342	Self-assembled DNA nanoclews for the efficient delivery of CRISPR-Cas9 for genome editing. **2015**, 54, 12029-33	393
1341	CrisprGE: a central hub of CRISPR/Cas-based genome editing. **2015**, 2015, bav055	25
1340	Generation of Foxo3-targeted Mice by Injection of mRNAs Encoding Transcription Activator-like Effector Nucleases (TALENs) into Zygotes. **2015**, 50, 474-83	2
1339	Integrated cell and process engineering for improved transient production of a "difficult-to-express" fusion protein by CHO cells. **2015**, 112, 2527-42	45
1338	Functional knockout of FUT8 in Chinese hamster ovary cells using CRISPR/Cas9 to produce a defucosylated antibody. **2015**, 15, 660-666	25
1337	Self-Assembled DNA Nanoclews for the Efficient Delivery of CRISPRCas9 for Genome Editing. **2015**, 127, 12197-12201	67
1336	Highly efficient heritable plant genome engineering using Cas9 orthologues from Streptococcus thermophilus and Staphylococcus aureus. **2015**, 84, 1295-305	177
1335	Atherosclerosis: cell biology and lipoproteins-focus on CD40 signaling, PCSK9, and novel animal models. **2015**, 26, 245-6	2
1334	. **2015**,	9
1333	CRISPR/Cas9 Genome Editing System in Drosophila. **2015**, s1,	1
1332	Synthetic Biology and Intellectual Property Rights. **2015**,	1

1331	Next Generation Sequencing: The Current Challenge is the Translation into Clinics. **2015**, 02,	
1330	New Techniques for the Study of Neural Tube Defects. **2016**, 4,	5
1329	The Use of Innovative Tools to Reproduce Human Cancer Translocations: Lessons from the CRISPR/Cas System. **2015**, 3, 273-278	
1328	From Gene Targeting to Genome Editing: Transgenic animals applications and beyond. **2015**, 87, 1323-48	32
1327	Gene therapy for hemophilia. **2015**, 20, 556-603	40
1326	Twenty years of modelling NPM-ALK-induced lymphomagenesis. **2015**, 7, 236-47	3
1325	CRISPR-Cas9 Human Genome Editing: Challenges, Ethical Concerns and Implications. **2015**, 06,	3
1324	Online High-throughput Mutagenesis Designer Using Scoring Matrix of Sequence-specific Endonucleases. **2015**, 12, 35-48	11
1323	Multiplexed CRISPR/Cas9 genome editing increases the efficacy of homologous-dependent repair of donor sequences in mammalian cells. **2015**, 111,	
1322	ASXL1 mutation correction by CRISPR/Cas9 restores gene function in leukemia cells and increases survival in mouse xenografts. **2015**, 6, 44061-71	46
1321	Application of CRISPR/cas9-Directed Homologous Recombination to the Generation of Human Tumor Cells with Conditional Knockout of an X-Linked MicroRNA Locus. **2015**, 04,	
1320	[Application of Cas9/CRISPR to the study of synaptic function]. **2015**, 31, 137-8	0
1319	Study on Technology Development Status of Genetically Modified Soybean Based on Patent Analysis. **2015**, 8, 603-611	1
1318	Modeling Viral Infectious Diseases and Development of Antiviral Therapies Using Human Induced Pluripotent Stem Cell-Derived Systems. **2015**, 7, 3835-56	23
1317	Affinity proteomics to study endogenous protein complexes: pointers, pitfalls, preferences and perspectives. **2015**, 58, 103-19	39
1316	Application of genomics-assisted breeding for generation of climate resilient crops: progress and prospects. **2015**, 6, 563	161
1315	Chromatin Dynamics in the Regulation of CFTR Expression. **2015**, 6, 543-58	18
1314	Direct Injection of CRISPR/Cas9-Related mRNA into Cytoplasm of Parthenogenetically Activated Porcine Oocytes Causes Frequent Mosaicism for Indel Mutations. **2015**, 16, 17838-56	46

1313 Single-Base Pair Genome Editing in Human Cells by Using Site-Specific Endonucleases. **2015**, 16, 21128-37 8

1312 Genome Editing Using Mammalian Haploid Cells. **2015**, 16, 23604-14 11

1311 Application of CRISPR/Cas9 Technology to HBV. **2015**, 16, 26077-86 25

1310 Induced Pluripotency and Gene Editing in Disease Modelling: Perspectives and Challenges. **2015**, 16, 28614-34 17

1309 Efficacy of the porcine species in biomedical research. **2015**, 6, 293 84

1308 A new age in functional genomics using CRISPR/Cas9 in arrayed library screening. **2015**, 6, 300 69

1307 Deciphering Human Cell-Autonomous Anti-HSV-1 Immunity in the Central Nervous System. **2015**, 6, 208 15

1306 Novel Genome-Editing Tools to Model and Correct Primary Immunodeficiencies. **2015**, 6, 250 27

1305 Roles of octopamine and dopamine in appetitive and aversive memory acquisition studied in olfactory conditioning of maxillary palpi extension response in crickets. **2015**, 9, 230 21

1304 [The CRISPR system can correct or modify the expression of genes responsible for hereditary diseases]. **2015**, 31, 1014-22 3

1303 CRISPR-Cas9: A Revolutionary Tool for Cancer Modelling. **2015**, 16, 22151-68 17

1302 CRISPR/Cas9-Mediated Rapid Generation of Multiple Mouse Lines Identified Ccdc63 as Essential for Spermiogenesis. **2015**, 16, 24732-50 34

1301 Quantification of cellular NEMO content and its impact on NF-Β activation by genotoxic stress. **2015**, 10, e0116374 3

1300 A rapid molecular approach for chromosomal phasing. **2015**, 10, e0118270 39

1299 A high excision potential of TALENs for integrated DNA of HIV-based lentiviral vector. **2015**, 10, e0120047 44

1298 Large genomic fragment deletions and insertions in mouse using CRISPR/Cas9. **2015**, 10, e0120396 94

1297 CCTop: An Intuitive, Flexible and Reliable CRISPR/Cas9 Target Prediction Tool. **2015**, 10, e0124633 493

1296 Highly efficient CRISPR/HDR-mediated knock-in for mouse embryonic stem cells and zygotes. **2015**, 59, 201-2, 204, 206-8 59

1295	Generation of α1,3-galactosyltransferase and cytidine monophospho-N-acetylneuraminic acid hydroxylase gene double-knockout pigs. **2015**, 61, 449-57	32
1294	A CRISPR-Cas9 System for Genetic Engineering of Filamentous Fungi. **2015**, 10, e0133085	350
1293	Efficient Generation of Myostatin Knock-Out Sheep Using CRISPR/Cas9 Technology and Microinjection into Zygotes. **2015**, 10, e0136690	170
1292	Opening a New Era in Neural Circuit Research. **2015**, 53, 673-680	0
1291	Nmf9 Encodes a Highly Conserved Protein Important to Neurological Function in Mice and Flies. **2015**, 11, e1005344	4
1290	A Tandem Duplicate of Anti-Müllerian Hormone with a Missense SNP on the Y Chromosome Is Essential for Male Sex Determination in Nile Tilapia, Oreochromis niloticus. **2015**, 11, e1005678	210
1289	Efficient Multiple Genome Modifications Induced by the crRNAs, tracrRNA and Cas9 Protein Complex in Zebrafish. **2015**, 10, e0128319	62
1288	CRISPR/Cas9n-Mediated Deletion of the Snail 1Gene (SNAI1) Reveals Its Role in Regulating Cell Morphology, Cell-Cell Interactions, and Gene Expression in Ovarian Cancer (RMG-1) Cells. **2015**, 10, e0132260	16
1287	Occurrence and Diversity of CRISPR-Cas Systems in the Genus Bifidobacterium. **2015**, 10, e0133661	53
1286	An Integrated System for Precise Genome Modification in Escherichia coli. **2015**, 10, e0136963	22
1285	Redesigning Recombinase Specificity for Safe Harbor Sites in the Human Genome. **2015**, 10, e0139123	10
1284	Single-Cell Expression Profiling Reveals a Dynamic State of Cardiac Precursor Cells in the Early Mouse Embryo. **2015**, 10, e0140831	23
1283	Inhibition of HIV-1 Viral Infection by an Engineered CRISPR Csy4 RNA Endoribonuclease. **2015**, 10, e0141335	3
1282	Generation and Inheritance of Targeted Mutations in Potato (Solanum tuberosum L.) Using the CRISPR/Cas System. **2015**, 10, e0144591	148
1281	CRISPR/Cas system: Novel roles for Evolution and Survival of Bacterial Pathogens and Application for Genome Editing. **2015**, 26, 14-21	
1280	The Expression of a Novel Mitochondrially-Encoded Gene in Gonadic Precursors May Drive Paternal Inheritance of Mitochondria. **2015**, 10, e0137468	22
1279	Development of a targeted flip-in system in avian DT40 cells. **2015**, 10, e0122006	12
1278	Targeting Non-Coding RNAs in Plants with the CRISPR-Cas Technology is a Challenge yet Worth Accepting. **2015**, 6, 1001	31

1277 Obesity genetics in mouse and human: back and forth, and back again. **2015**, 3, e856 83

1276 A molecular toolbox for genetic manipulation of zebrafish. **2015**, 151 22

1275 Animal Models of Diet-induced Hypercholesterolemia. **2015**, 4

1274 CRISPR/CAS9-Mediated Genome Editing of miRNA-155 Inhibits Proinflammatory Cytokine Production by RAW264.7 Cells. **2015**, 2015, 326042 36

1273 Animal Models of Human Pathology 2014. **2015**, 2015, 721348

1272 Efficient Mitochondrial Genome Editing by CRISPR/Cas9. **2015**, 2015, 305716 107

1271 Integrative Analysis of CRISPR/Cas9 Target Sites in the Human HBB Gene. **2015**, 2015, 514709 10

1270 Zebrafish Craniofacial Development: A Window into Early Patterning. **2015**, 115, 235-69 76

1269 CRISPR/Cas9 nuclease cleavage combined with Gibson assembly for seamless cloning. **2015**, 58, 161-70 48

1268 Cancer-associated TERT promoter mutations abrogate telomerase silencing. **2015**, 4, 153

1267 Ferritinophagy via NCOA4 is required for erythropoiesis and is regulated by iron dependent HERC2-mediated proteolysis. **2015**, 4, 195

1266 The prenyltransferase UBIAD1 is the target of geranylgeraniol in degradation of HMG CoA reductase. **2015**, 4, 52

1265 Rethinking Patentable Subject Matter and Related Issues. **2015**,

1264 The CRISPR revolution and its impact on cancer research. **2015**, 145, w14230 10

1263 . **2015**, 5

1262 The therapeutic potential of genome editing for -thalassemia. **2015**, 4, 7

1261 In vivo Gene Correction of Cystic Fibrosis. **2015**, 1

1260 Genome-wide specificity of DNA binding, gene regulation, and chromatin remodeling by TALE- and CRISPR/Cas9-based transcriptional activators. **2015**, 25, 1158-69 99

1259	MiR-2 family targets awd and fng to regulate wing morphogenesis in Bombyx mori. **2015**, 12, 742-8		36
1258	Activity and specificity of TRV-mediated gene editing in plants. **2015**, 10, e1044191		48
1257	Site-specific integration in CHO cells mediated by CRISPR/Cas9 and homology-directed DNA repair pathway. **2015**, 5, 8572		127
1256	DUBs, the regulation of cell identity and disease. **2015**, 465, 1-26		50
1255	Core Concept: CRISPR gene editing. **2015**, 112, 6245-6		12
1254	Targeted genome editing in primate embryos. **2015**, 25, 767-8		27
1253	An Inducible Caspase-9 Suicide Gene to Improve the Safety of Therapy Using Human Induced Pluripotent Stem Cells. **2015**, 23, 1475-85		64
1252	Applications of the CRISPR-Cas9 system in cancer biology. **2015**, 15, 387-95		260
1251	Expanding the Biologist's Toolkit with CRISPR-Cas9. **2015**, 58, 568-74		311
1250	Targeted Gene Mutation in Plants. **2015**, 253-272		4
1249	Somatic Genome Manipulation. **2015**,		1
1248	Targeted DNA degradation using a CRISPR device stably carried in the host genome. **2015**, 6, 6989		83
1247	BK Channels Alleviate Lysosomal Storage Diseases by Providing Positive Feedback Regulation of Lysosomal Ca2+ Release. **2015**, 33, 427-41		73
1246	Building biological foundries for next-generation synthetic biology. **2015**, 58, 658-65		16
1245	Repetitive elements regulate circular RNA biogenesis. **2015**, 5, 1-7		36
1244	Rapid and precise engineering of the Caenorhabditis elegans genome with lethal mutation co-conversion and inactivation of NHEJ repair. **2015**, 199, 363-77		130
1243	SEX DETERMINATION. A male-determining factor in the mosquito Aedes aegypti. *Science*, **2015**, 348, 1268-70	33.3	193
1242	Choosing the Right Tool for the Job: RNAi, TALEN, or CRISPR. **2015**, 58, 575-85		269

1241 Repairing organs: lessons from intestine and liver. **2015**, 31, 344-51 23

1240 CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus. **2015**, 5, 10833 205

1239 Evolution of an epigenetic gene ensemble within the genus Anopheles. **2015**, 7, 901-15 6

1238 miRNAs and lncRNAs in reproductive development. **2015**, 238, 46-52 27

1237 Challenges in CRISPR/CAS9 Delivery: Potential Roles of Nonviral Vectors. **2015**, 26, 452-62 133

1236 Advances in New Technology for Targeted Modification of Plant Genomes. **2015**, 5

1235 MYC Drives Pten/Trp53-Deficient Proliferation and Metastasis due to IL6 Secretion and AKT Suppression via PHLPP2. **2015**, 5, 636-51 52

1234 Optimization of methods for the genetic modification of human T cells. **2015**, 93, 896-908 20

1233 Generation of Isogenic Human iPS Cell Line Precisely Corrected by Genome Editing Using the CRISPR/Cas9 System. **2015**, 11, 774-87 53

1232 Application of Mouse Genetics to Human Disease: Generation and Analysis of Mouse Models. **2015**, 63-75

1231 Techniques Analyzing Chromatin Modifications at Specific Single Loci. **2015**, 79-100

1230 Identification of miR-2400 gene as a novel regulator in skeletal muscle satellite cells proliferation by targeting MYOG gene. **2015**, 463, 624-31 15

1229 Generation of B cell-deficient pigs by highly efficient CRISPR/Cas9-mediated gene targeting. **2015**, 42, 437-44 36

1228 Developing CRISPR Technology in Major Crop Plants. **2015**, 145-159 2

1227 Lung Stem Cells in the Epithelium and Vasculature. **2015**,

1226 Engineered Nucleases Lead to Genome Editing Revolution in Rats. **2015**, 183-195

1225 Somatic Cell Nuclear Transfer and the Creation of Transgenic Large Animal Models. **2015**, 123-143 1

1224 T-Cell Costimulation and Its Applications in Diseases. **2015**, 255-292 3

1223	Measuring and Reducing Off-Target Activities of Programmable Nucleases Including CRISPR-Cas9. **2015**, 38, 475-81	144
1222	In Vitro Reconstitution and Crystallization of Cas9 Endonuclease Bound to a Guide RNA and a DNA Target. **2015**, 558, 515-537	19
1221	Assembling the Streptococcus thermophilus clustered regularly interspaced short palindromic repeats (CRISPR) array for multiplex DNA targeting. **2015**, 478, 131-3	9
1220	A Toolkit of CRISPR-Based Genome Editing Systems in Drosophila. **2015**, 42, 141-9	32
1219	DSDecode: A Web-Based Tool for Decoding of Sequencing Chromatograms for Genotyping of Targeted Mutations. **2015**, 8, 1431-3	130
1218	Molecular signatures of vaccine adjuvants. **2015**, 33, 5302-7	50
1217	Exceptional opportunities in medical science: a view from the National Institutes of Health. **2015**, 313, 131-2	46
1216	Enhancer-associated RNAs as therapeutic targets. **2015**, 15, 723-34	19
1215	Visualization of mouse induced pluripotent stem cells for evaluation of tracheal regeneration. **2015** , 135, 395-401	3
1214	The short and long of noncoding sequences in the control of vascular cell phenotypes. **2015**, 72, 3457-88	25
1213	The mTORC1/4E-BP pathway coordinates hemoglobin production with L-leucine availability. **2015**, 8, ra34	39
1212	CRISPR-Cas9-mediated genome editing and guide RNA design. **2015**, 26, 501-10	41
1211	Rapid and highly efficient mammalian cell engineering via Cas9 protein transfection. **2015**, 208, 44-53	433
1210	PIK3R1 negatively regulates the epithelial-mesenchymal transition and stem-like phenotype of renal cancer cells through the AKT/GSK3/CTNNB1 signaling pathway. **2015**, 5, 8997	46
1209	Sequence determinants of improved CRISPR sgRNA design. **2015**, 25, 1147-57	335
1208	Bionanotechnology and the future of glioma. **2015**, 6, S45-58	18
1207	Engineering Sequence-Specific DNA Binding Proteins for Antiviral Gene Editing. **2015**, 63-94	4
1206	Gene Therapy for Chronic Hepatitis B Virus Infection. **2015**, 151-189	

1205	A Perspective on the Future of High-Throughput RNAi Screening: Will CRISPR Cut Out the Competition or Can RNAi Help Guide the Way?. **2015**, 20, 1040-51	27
1204	CRISPR/Cas9-mediated reporter knock-in in mouse haploid embryonic stem cells. **2015**, 5, 10710	25
1203	Functional analysis of Bombyx Wnt1 during embryogenesis using the CRISPR/Cas9 system. **2015**, 79, 73-9	50
1202	Removal of redundant contigs from de novo RNA-Seq assemblies via homology search improves accurate detection of differentially expressed genes. **2015**, 16, 1031	20
1201	Personalized medicine for cystic fibrosis: establishing human model systems. **2015**, 50 Suppl 40, S14-23	31
1200	Evaluation of human and non-human primate antibody binding to pig cells lacking GGTA1/CMAH/β4GalNT2 genes. **2015**, 22, 194-202	221
1199	Lampreys as Diverse Model Organisms in the Genomics Era. **2015**, 65, 1046-1056	39
1198	The omics era of Fusarium graminearum: opportunities and challenges. **2015**, 207, 1-3	11
1197	What history tells us XXXIX. CRISPR-Cas: From a prokaryotic immune system to a universal genome editing tool. **2015**, 40, 829-32	11
1196	Specific induction of endogenous viral restriction factors using CRISPR/Cas-derived transcriptional activators. **2015**, 112, E7249-56	33
1195	Computational and molecular tools for scalable rAAV-mediated genome editing. **2015**, 43, e30	5
1194	CrEdit: CRISPR mediated multi-loci gene integration in Saccharomyces cerevisiae. **2015**, 14, 97	105
1193	OCT4 activity during conversion of human intermediately reprogrammed stem cells to iPSCs through mesenchymal-epithelial transition. **2016**, 143, 15-23	15
1192	FGF2 mediates hepatic progenitor cell formation during human pluripotent stem cell differentiation by inducing the WNT antagonist NKD1. **2015**, 29, 2463-74	26
1191	A molecular ruler regulates cytoskeletal remodelling by the Rho kinases. **2015**, 6, 10029	36
1190	Stepping toward therapeutic CRISPR. **2015**, 112, 15536-7	7
1189	Covalent Modification of Bacteriophage T4 DNA Inhibits CRISPR-Cas9. **2015**, 6, e00648	58
1188	CCR5 Disruption in Induced Pluripotent Stem Cells Using CRISPR/Cas9 Provides Selective Resistance of Immune Cells to CCR5-tropic HIV-1 Virus. **2015**, 4, e268	94

1187	Rapid characterization of CRISPR-Cas9 protospacer adjacent motif sequence elements. **2015**, 16, 253	126
1186	Gene-modified embryonic stem cell test to characterize chemical risks. **2015**, 22, 18252-9	
1185	CRISPR/Cas9 system as an innovative genetic engineering tool: Enhancements in sequence specificity and delivery methods. **2015**, 1856, 234-43	15
1184	High-Efficiency Genome Editing in Arabidopsis Using YAO Promoter-Driven CRISPR/Cas9 System. **2015**, 8, 1820-3	217
1183	Memory and Combinatorial Logic Based on DNA Inversions: Dynamics and Evolutionary Stability. **2015**, 4, 1361-72	32
1182	CRISPR/Cas9-mediated genome engineering of the ferret. **2015**, 25, 1372-5	30
1181	Safeguarding CRISPR-Cas9 gene drives in yeast. **2015**, 33, 1250-1255	231
1180	WU-CRISPR: characteristics of functional guide RNAs for the CRISPR/Cas9 system. **2015**, 16, 218	182
1179	Induction of targeted, heritable mutations in barley and Brassica oleracea using RNA-guided Cas9 nuclease. **2015**, 16, 258	335
1178	Advanced technologies for genetically manipulating the silkworm Bombyx mori, a model Lepidopteran insect. **2015**, 282,	21
1177	Nuclear domain 'knock-in' screen for the evaluation and identification of small molecule enhancers of CRISPR-based genome editing. **2015**, 43, 9379-92	172
1176	Redesign of the monomer-monomer interface of Cre recombinase yields an obligate heterotetrameric complex. **2015**, 43, 9076-85	12
1175	A generic strategy for CRISPR-Cas9-mediated gene tagging. **2015**, 6, 10237	132
1174	Research: Biology's big hit. **2015**, 528, S4-5	2
1173	Aging Stem Cells Lose the Capability to Distribute Damaged Proteins Asymmetrically. **2015**, 18, 581-4	3
1172	Pharmacological inhibition of DNA-PK stimulates Cas9-mediated genome editing. **2015**, 7, 93	141
1171	Resources for the design of CRISPR gene editing experiments. **2015**, 16, 260	78
1170	Optimizing sgRNA structure to improve CRISPR-Cas9 knockout efficiency. **2015**, 16, 280	202

1169	VEGF Signaling: Methods and Protocols. Preface. **2015**, 1332, v-vi		3
1168	Hoxb6 can interfere with somitogenesis in the posterior embryo through a mechanism independent of its rib-promoting activity. **2016**, 143, 437-48		10
1167	Mutant-Based Reverse Genetics for Functional Genomics of Non-model Crops. **2015**, 473-487		1
1166	Microbial CRISPR□as System: From Bacterial Immunity to Next-Generation Antimicrobials. **2015**, 217-234		
1165	The CENP-L-N Complex Forms a Critical Node in an Integrated Meshwork of Interactions at the Centromere-Kinetochore Interface. **2015**, 60, 886-98		108
1164	Advances in genetics and genomics: use and limitations in achieving malaria elimination goals. **2015**, 109, 123-41		4
1163	Microbial Factories. **2015**,		1
1162	Towards a new era in medicine: therapeutic genome editing. **2015**, 16, 286		42
1161	A localized nucleolar DNA damage response facilitates recruitment of the homology-directed repair machinery independent of cell cycle stage. **2015**, 29, 1151-63		132
1160	Genome Editing and Its Applications in Model Organisms. **2015**, 13, 336-44		38
1159	A Simple CRISPR/Cas9 System for Multiplex Genome Editing in Rice. **2015**, 42, 703-6		86
1158	Stem cell reprogramming: basic implications and future perspective for movement disorders. **2015**, 30, 301-12		5
1157	Current and future delivery systems for engineered nucleases: ZFN, TALEN and RGEN. **2015**, 205, 120-7		76
1156	Genetic Transformation Systems in Fungi, Volume 1. **2015**,		1
1155	CRISPR-Cas9 genome editing of a single regulatory element nearly abolishes target gene expression in mice--brief report. **2015**, 35, 312-5		39
1154	Stem cells. m6A mRNA methylation facilitates resolution of naïve pluripotency toward differentiation. *Science*, **2015**, 347, 1002-6	33.3	904
1153	Metabolism. Differential regulation of mTORC1 by leucine and glutamine. *Science*, **2015**, 347, 194-8	33.3	442
1152	Fanconi anemia gene editing by the CRISPR/Cas9 system. **2015**, 26, 114-26		76

1151	Non-integrating gamma-retroviral vectors as a versatile tool for transient zinc-finger nuclease delivery. **2014**, 4, 4656	19
1150	Non-genetic engineering of cells for drug delivery and cell-based therapy. **2015**, 91, 125-40	157
1149	Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease. **2015**, 476, 196-205	168
1148	Harnessing the clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated Cas9 system to disrupt the hepatitis B virus. **2015**, 22, 404-12	173
1147	Digenome-seq: genome-wide profiling of CRISPR-Cas9 off-target effects in human cells. **2015**, 12, 237-43, 1 p following 243	652
1146	Activin/Nodal signalling in stem cells. **2015**, 142, 607-19	107
1145	Functional genomic screening approaches in mechanistic toxicology and potential future applications of CRISPR-Cas9. **2015**, 764, 31-42	14
1144	CRISPR-engineered mosaicism rapidly reveals that loss of Kcnj13 function in mice mimics human disease phenotypes. **2015**, 5, 8366	64
1143	Markerless chromosomal gene deletion in Clostridium beijerinckii using CRISPR/Cas9 system. **2015**, 200, 1-5	131
1142	Therapeutic genome editing: prospects and challenges. **2015**, 21, 121-31	809
1141	Personalized therapeutic strategies for patients with retinitis pigmentosa. **2015**, 15, 391-402	38
1140	Directed evolution combined with synthetic biology strategies expedite semi-rational engineering of genes and genomes. **2015**, 6, 136-40	15
1139	A recently evolved isoform of the transcription factor BES1 promotes brassinosteroid signaling and development in Arabidopsis thaliana. **2015**, 27, 361-74	63
1138	Suppression of pervasive noncoding transcription in embryonic stem cells by esBAF. **2015**, 29, 362-78	52
1137	Inducible in vivo genome editing with CRISPR-Cas9. **2015**, 33, 390-394	355
1136	Multiplex CRISPR/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy. **2015**, 6, 6244	307
1135	Multigene editing in the Escherichia coli genome via the CRISPR-Cas9 system. **2015**, 81, 2506-14	560
1134	Gene targeting and editing in crop plants: a new era of precision opportunities. **2015**, 35, 1	47

1133	A practical guide to induced pluripotent stem cell research using patient samples. **2015**, 95, 4-13	45
1132	Dissecting the roles of TRBP and PACT in double-stranded RNA recognition and processing of noncoding RNAs. **2015**, 6, 271-89	28
1131	Molecular scissors and their application in genetically modified farm animals. **2015**, 24, 381-96	47
1130	Multiplex metabolic pathway engineering using CRISPR/Cas9 in Saccharomyces cerevisiae. **2015**, 28, 213-222	292
1129	From trans to cis: transcriptional regulatory networks in neocortical development. **2015**, 31, 77-87	36
1128	Path from schizophrenia genomics to biology: gene regulation and perturbation in neurons derived from induced pluripotent stem cells and genome editing. **2015**, 31, 113-27	7
1127	New insights into mechanisms that regulate DNA methylation patterning. **2015**, 218, 14-20	36
1126	Real-time resolution of point mutations that cause phenovariance in mice. **2015**, 112, E440-9	51
1125	USP30 and parkin homeostatically regulate atypical ubiquitin chains on mitochondria. **2015**, 17, 160-9	186
1124	Covalent modification of a cysteine residue in the XPB subunit of the general transcription factor TFIIH through single epoxide cleavage of the transcription inhibitor triptolide. **2015**, 54, 1859-63	49
1123	A split-Cas9 architecture for inducible genome editing and transcription modulation. **2015**, 33, 139-42	467
1122	Coordinated regulatory variation associated with gestational hyperglycaemia regulates expression of the novel hexokinase HKDC1. **2015**, 6, 6069	62
1121	Emerging critical roles of Fe-S clusters in DNA replication and repair. **2015**, 1853, 1253-71	137
1120	Small molecules enhance CRISPR genome editing in pluripotent stem cells. **2015**, 16, 142-7	303
1119	Developmental control of polycomb subunit composition by GATA factors mediates a switch to non-canonical functions. **2015**, 57, 304-316	95
1118	Loss-of-function variants of SETD5 cause intellectual disability and the core phenotype of microdeletion 3p25.3 syndrome. **2015**, 23, 753-60	55
1117	An alternative retinoic acid-responsive Stra6 promoter regulated in response to retinol deficiency. **2015**, 290, 4356-66	18
1116	A robust TALENs system for highly efficient mammalian genome editing. **2014**, 4, 3632	16

1115	Creation of fragrant rice by targeted knockout of the OsBADH2 gene using TALEN technology. **2015**, 13, 791-800	204
1114	Exogenous enzymes upgrade transgenesis and genetic engineering of farm animals. **2015**, 72, 1907-29	25
1113	CRISPR/Cas9: The Leading Edge of Genome Editing Technology. **2015**, 25-41	6
1112	Efficient generation of genetically distinct pigs in a single pregnancy using multiplexed single-guide RNA and carbohydrate selection. **2015**, 22, 20-31	105
1111	Highly efficient targeted mutagenesis in one-cell mouse embryos mediated by the TALEN and CRISPR/Cas systems. **2014**, 4, 5705	50
1110	The impact of CRISPR-Cas9 on target identification and validation. **2015**, 20, 450-7	49
1109	The roles of CRISPR-Cas systems in adaptive immunity and beyond. **2015**, 32, 36-41	132
1108	CRISPR: a new method for genetic engineering - a prokaryotic immune component may potentially open a new era of gene silencing. **2015**, 22, 3-5	4
1107	SCFTIR1/AFB-based auxin perception: mechanism and role in plant growth and development. **2015**, 27, 9-19	259
1106	Concise review: modeling multiple sclerosis with stem cell biological platforms: toward functional validation of cellular and molecular phenotypes in inflammation-induced neurodegeneration. **2015**, 4, 252-60	17
1105	Genomic profiling of DNA methyltransferases reveals a role for DNMT3B in genic methylation. **2015**, 520, 243-7	421
1104	Gene and cell therapy for pancreatic cancer. **2015**, 15, 505-16	14
1103	Mouse genome engineering via CRISPR-Cas9 for study of immune function. **2015**, 42, 18-27	60
1102	Strategies for cloning and manipulating natural and synthetic chromosomes. **2015**, 23, 57-68	18
1101	Targeted Genome Editing Using Site-Specific Nucleases. **2015**,	6
1100	Stem cells as tools for studying the genetics of inherited retinal degenerations. **2014**, 5, a017160	10
1099	Efficient CRISPR-rAAV engineering of endogenous genes to study protein function by allele-specific RNAi. **2015**, 43, e45	23
1098	On the road to synthetic life: the minimal cell and genome-scale engineering. **2016**, 36, 416-23	26

1097	Unbiased detection of off-target cleavage by CRISPR-Cas9 and TALENs using integrase-defective lentiviral vectors. **2015**, 33, 175-8	321
1096	Mathematically guided approaches to distinguish models of periodic patterning. **2015**, 142, 409-19	57
1095	The CRISPR/Cas system inhibited the pro-oncogenic effects of alternatively spliced fibronectin extra domain A via editing the genome in salivary adenoid cystic carcinoma cells. **2015**, 21, 608-18	13
1094	CRISPR-Cas9: a new and promising player in gene therapy. **2015**, 52, 289-96	115
1093	Multicolor CRISPR labeling of chromosomal loci in human cells. **2015**, 112, 3002-7	276
1092	Genome editing strategies: potential tools for eradicating HIV-1/AIDS. **2015**, 21, 310-21	33
1091	Precise in-frame integration of exogenous DNA mediated by CRISPR/Cas9 system in zebrafish. **2015**, 5, 8841	167
1090	High-throughput screens in mammalian cells using the CRISPR-Cas9 system. **2015**, 282, 2089-96	42
1089	The Potential of AAV-Mediated Gene Targeting for Gene and Cell Therapy Applications. **2015**, 1, 16-22	6
1088	Efficiently editing the vaccinia virus genome by using the CRISPR-Cas9 system. **2015**, 89, 5176-9	67
1087	Law, history and lessons in the CRISPR patent conflict. **2015**, 33, 256-7	36
1086	A CRISPR/Cas9 vector system for tissue-specific gene disruption in zebrafish. **2015**, 32, 756-64	251
1085	Curing genetic mutations for the next generation: CRISPR/Cas9-mediated gene correction in mouse spermatogonial stem cells. **2015**, 60, 400-402	1
1084	PINK1 kinase catalytic activity is regulated by phosphorylation on serines 228 and 402. **2015**, 290, 2798-811	72
1083	Boosting CRISPR/Cas9 multiplex editing capability with the endogenous tRNA-processing system. **2015**, 112, 3570-5	728
1082	Site-directed mutagenesis in Arabidopsis thaliana using dividing tissue-targeted RGEN of the CRISPR/Cas system to generate heritable null alleles. **2015**, 241, 271-84	121
1081	Prospects for genetically modified non-human primate models, including the common marmoset. **2015**, 93, 110-5	63
1080	Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids. **2015**, 21, 256-62	669

1079	The structural biology of CRISPR-Cas systems. **2015**, 30, 100-111	100
1078	Dual-reporter surrogate systems for efficient enrichment of genetically modified cells. **2015**, 72, 2763-72	30
1077	Contemplating 3-Hydroxypropionic Acid Biosynthesis in Klebsiella pneumoniae. **2015**, 55, 131-9	3
1076	Spinal cord injury induced neuropathic pain: Molecular targets and therapeutic approaches. **2015**, 30, 645-58	11
1075	Use of the CRISPR/Cas9 system as an intracellular defense against HIV-1 infection in human cells. **2015**, 6, 6413	234
1074	Bacterial CRISPR/Cas DNA endonucleases: A revolutionary technology that could dramatically impact viral research and treatment. **2015**, 479-480, 213-20	44
1073	Genetic screens and functional genomics using CRISPR/Cas9 technology. **2015**, 282, 1383-93	56
1072	Manipulating Endogenous Genes. **2015**, 273-293	1
1071	One-step high-efficiency CRISPR/Cas9-mediated genome editing in Streptomyces. **2015**, 47, 231-43	193
1070	Genome-wide CRISPR screen in a mouse model of tumor growth and metastasis. **2015**, 160, 1246-60	544
1069	Dual sgRNA-directed gene knockout using CRISPR/Cas9 technology in Caenorhabditis elegans. **2014**, 4, 7581	80
1068	Improved cell-penetrating zinc-finger nuclease proteins for precision genome engineering. **2015**, 4, e232	41
1067	Genome-wide CIITA-binding profile identifies sequence preferences that dictate function versus recruitment. **2015**, 43, 3128-42	20
1066	A Dual-reporter system for real-time monitoring and high-throughput CRISPR/Cas9 library screening of the hepatitis C virus. **2015**, 5, 8865	39
1065	Genome Engineering for Therapeutic Applications. **2015**, 27-43	2
1064	A versatile reporter system for CRISPR-mediated chromosomal rearrangements. **2015**, 16, 111	45
1063	Biological Roles of Hydroxysteroid (11-Beta) Dehydrogenase 1 (HSD11B1), HSD11B2, and Glucocorticoid Receptor (NR3C1) in Sheep Conceptus Elongation. **2015**, 93, 38	22
1062	Adenovirus-Mediated Somatic Genome Editing of Pten by CRISPR/Cas9 in Mouse Liver in Spite of Cas9-Specific Immune Responses. **2015**, 26, 432-42	226

1061	Photoactivatable CRISPR-Cas9 for optogenetic genome editing. **2015**, 33, 755-60	397
1060	A Single Kinase Generates the Majority of the Secreted Phosphoproteome. **2015**, 161, 1619-32	187
1059	Efficient generation of hiPSC neural lineage specific knockin reporters using the CRISPR/Cas9 and Cas9 double nickase system. **2015**, e52539	4
1058	Chemical pulldown reveals dynamic pseudouridylation of the mammalian transcriptome. **2015**, 11, 592-7	295
1057	CRISPR-ERA: a comprehensive design tool for CRISPR-mediated gene editing, repression and activation. **2015**, 31, 3676-8	124
1056	Efficient gene editing in with CRISPR technology. **2015**, 2, 4	129
1055	A detailed procedure for CRISPR/Cas9-mediated gene editing in Arabidopsis thaliana. **2015**, 60, 1332-1347	25
1054	Complete genome sequence of novel carbon monoxide oxidizing bacteria Citrobacter amalonaticus Y19, assembled de novo. **2015**, 211, 79-80	3
1053	A pre-screening FISH-based method to detect CRISPR/Cas9 off-targets in mouse embryonic stem cells. **2015**, 5, 12327	19
1052	A Call for Systematic Research on Solute Carriers. **2015**, 162, 478-87	312
1051	Gata6 potently initiates reprograming of pluripotent and differentiated cells to extraembryonic endoderm stem cells. **2015**, 29, 1239-55	59
1050	Simultaneous live imaging of the transcription and nuclear position of specific genes. **2015**, 43, e127	68
1049	Small molecules targeting microRNA for cancer therapy: Promises and obstacles. **2015**, 219, 237-247	66
1048	High Efficient Genome Modification by Designed Zinc Finger Nuclease. **2015**, 39-53	3
1047	The application of CRISPR-Cas9 genome editing in Caenorhabditis elegans. **2015**, 42, 413-21	10
1046	CRISPR-Cas9-Mediated Genome Editing in Leishmania donovani. **2015**, 6, e00861	113
1045	SOD2 targeted gene editing by CRISPR/Cas9 yields Human cells devoid of MnSOD. **2015**, 89, 379-86	22
1044	Post-Golgi anterograde transport requires GARP-dependent endosome-to-TGN retrograde transport. **2015**, 26, 3071-84	57

1043	Regulation of Glucose Homeostasis by Glucocorticoids. **2015**, 872, 99-126	246
1042	Flavonoid biosynthesis genes in wheat. **2015**, 5, 268-278	18
1041	Rapid Decoding of Sequence-Specific Nuclease-Induced Heterozygous and Biallelic Mutations by Direct Sequencing of PCR Products. **2015**, 8, 1285-7	84
1040	The EBNA3 family of Epstein-Barr virus nuclear proteins associates with the USP46/USP12 deubiquitination complexes to regulate lymphoblastoid cell line growth. **2015**, 11, e1004822	30
1039	Parameters affecting frequency of CRISPR/Cas9 mediated targeted mutagenesis in rice. **2015**, 34, 1807-15	64
1038	Hunting Viral Receptors Using Haploid Cells. **2015**, 2, 219-39	14
1037	Determinants of Receptor- and Tissue-Specific Actions in Androgen Signaling. **2015**, 36, 357-84	79
1036	High-throughput gene targeting and phenotyping in zebrafish using CRISPR/Cas9. **2015**, 25, 1030-42	309
1035	Enriching CRISPR-Cas9 targeted cells by co-targeting the HPRT gene. **2015**, 43, e134	28
1034	Application of CRISPR/Cas9 for biomedical discoveries. **2015**, 5, 33	41
1033	CRISPR-mediated genotypic and phenotypic correction of a chronic granulomatous disease mutation in human iPS cells. **2015**, 43, 838-848.e3	97
1032	Generation of muscular dystrophy model rats with a CRISPR/Cas system. **2014**, 4, 5635	90
1031	Passenger Mutations Confound Interpretation of All Genetically Modified Congenic Mice. **2015**, 43, 200-9	128
1030	CRISPR-Cas9-Mediated Genetic Screening in Mice with Haploid Embryonic Stem Cells Carrying a Guide RNA Library. **2015**, 17, 221-32	70
1029	Temporally coordinated signals progressively pattern the anteroposterior and dorsoventral body axes. **2015**, 42, 118-33	66
1028	Development of a Synthetic Malonyl-CoA Sensor in Saccharomyces cerevisiae for Intracellular Metabolite Monitoring and Genetic Screening. **2015**, 4, 1308-15	106
1027	Construction of a CRISPR-Cas9 System for Pig Genome Targeting. **2015**, 26, 279-88	9
1026	AMPK-HDAC5 pathway facilitates nuclear accumulation of HIF-1 and functional activation of HIF-1 by deacetylating Hsp70 in the cytosol. **2015**, 14, 2520-36	61

1025	The potential of the combination of CRISPR/Cas9 and pluripotent stem cells to provide human organs from chimaeric pigs. **2015**, 16, 6545-56	26
1024	CRISPR/Cas9-mediated endogenous protein tagging for RESOLFT super-resolution microscopy of living human cells. **2015**, 5, 9592	108
1023	Electroporation enables the efficient mRNA delivery into the mouse zygotes and facilitates CRISPR/Cas9-based genome editing. **2015**, 5, 11315	183
1022	A Rapid Embryonic Stem Cell-Based Mouse Model for B-cell Lymphomas Driven by Epstein-Barr Virus Protein LMP1. **2015**, 3, 641-9	3
1021	Precision cancer mouse models through genome editing with CRISPR-Cas9. **2015**, 7, 53	61
1020	Unraveling CRISPR-Cas9 genome engineering parameters via a library-on-library approach. **2015**, 12, 823-6	265
1019	Both TALENs and CRISPR/Cas9 directly target the HBB IVS2-654 (C > T) mutation in β-thalassemia-derived iPSCs. **2015**, 5, 12065	109
1018	A CRISPR/Cas-Mediated Selection-free Knockin Strategy in Human Embryonic Stem Cells. **2015**, 4, 1103-11	67
1017	Expression of CRISPR/Cas single guide RNAs using small tRNA promoters. **2015**, 21, 1683-9	42
1016	Archaeal ribonuclease P proteins have potential for biotechnological applications where precise hybridization of nucleic acids is needed. **2015**, 79, 2014-7	1
1015	The Hope for iPSC in Lung Stem Cell Therapy and Disease Modeling. **2015**, 113-143	0
1014	A CRISPR-Based Screen Identifies Genes Essential for West-Nile-Virus-Induced Cell Death. **2015**, 12, 673-83	150
1013	Systematic analysis of CRISPR-Cas9 mismatch tolerance reveals low levels of off-target activity. **2015**, 211, 56-65	99
1012	STARR-seq - principles and applications. **2015**, 106, 145-150	46
1011	Precision metabolic engineering: The design of responsive, selective, and controllable metabolic systems. **2015**, 31, 123-31	44
1010	Genetically Encoded Spy Peptide Fusion System to Detect Plasma Membrane-Localized Proteins In Vivo. **2015**, 22, 1108-21	45
1009	Enzymatically Generated CRISPR Libraries for Genome Labeling and Screening. **2015**, 34, 373-8	24
1008	Functional Correction of Large Factor VIII Gene Chromosomal Inversions in Hemophilia A Patient-Derived iPSCs Using CRISPR-Cas9. **2015**, 17, 213-20	214

1007	Site- and allele-specific polycomb dysregulation in T-cell leukaemia. **2015**, 6, 6094	35
1006	CRISPR-Cas: New Tools for Genetic Manipulations from Bacterial Immunity Systems. **2015**, 69, 209-28	125
1005	Comparison of CRISPR/Cas9 expression constructs for efficient targeted mutagenesis in rice. **2015**, 88, 561-72	161
1004	Highly efficient enrichment of porcine cells with deletions induced by CRISPR/Cas9 using dual fluorescence selection. **2015**, 214, 69-74	6
1003	Efficient CRISPR-mediated gene targeting and transgene replacement in the beetle Tribolium castaneum. **2015**, 142, 2832-9	112
1002	Recent developments and clinical studies utilizing engineered zinc finger nuclease technology. **2015**, 72, 3819-30	20
1001	Generation of a conditional analog-sensitive kinase in human cells using CRISPR/Cas9-mediated genome engineering. **2015**, 129, 19-36	17
1000	An inducible lentiviral guide RNA platform enables the identification of tumor-essential genes and tumor-promoting mutations in vivo. **2015**, 10, 1422-32	233
999	Genetic modification of the diarrhoeal pathogen Cryptosporidium parvum. **2015**, 523, 477-80	203
998	Generation of cell-type-specific gene mutations by expressing the sgRNA of the CRISPR system from the RNA polymerase II promoters. **2015**, 6, 689-692	7
997	Synthetic biology in cell-based cancer immunotherapy. **2015**, 33, 449-61	52
996	Somatic CRISPR/Cas9-mediated tumour suppressor disruption enables versatile brain tumour modelling. **2015**, 6, 7391	181
995	Generation of mutant mice via the CRISPR/Cas9 system using FokI-dCas9. **2015**, 5, 11221	32
994	Engineered CRISPR-Cas9 nucleases with altered PAM specificities. **2015**, 523, 481-5	1061
993	The Bacterial Origins of the CRISPR Genome-Editing Revolution. **2015**, 26, 413-24	56
992	Calcium release through P2X4 activates calmodulin to promote endolysosomal membrane fusion. **2015**, 209, 879-94	89
991	CRISPR/Cas9-Mediated Genome Editing of Epigenetic Factors for Cancer Therapy. **2015**, 26, 463-71	44
990	Delivery and Specificity of CRISPR-Cas9 Genome Editing Technologies for Human Gene Therapy. **2015**, 26, 443-51	130

989 Engineering Human Stem Cell Lines with Inducible Gene Knockout using CRISPR/Cas9. **2015**, 17, 233-44 116

988 Cas9-chromatin binding information enables more accurate CRISPR off-target prediction. **2015**, 43, e118 141

987 Optogenetic tools for modulating and probing the epileptic network. **2015**, 116, 15-26 25

986 Modeling of the human alveolar rhabdomyosarcoma Pax3-Foxo1 chromosome translocation in mouse myoblasts using CRISPR-Cas9 nuclease. **2015**, 11, e1004951 44

985 Redesigning photosynthesis to sustainably meet global food and bioenergy demand. **2015**, 112, 8529-36 515

984 A matter of scale: how emerging technologies are redefining our view of chromosome architecture. **2015**, 31, 454-64 17

983 STRUCTURAL BIOLOGY. A Cas9-guide RNA complex preorganized for target DNA recognition. *Science*, **2015**, 348, 1477-81 33.3 330

982 Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells. **2015**, 33, 985-989 626

981 Targeted gene editing by transfection of in vitro reconstituted Streptococcus thermophilus Cas9 nuclease complex. **2015**, 12, 1-4 18

980 Histone deacetylation promotes mouse neural induction by restricting Nodal-dependent mesendoderm fate. **2015**, 6, 6830 19

979 A Robust CRISPR/Cas9 System for Convenient, High-Efficiency Multiplex Genome Editing in Monocot and Dicot Plants. **2015**, 8, 1274-84 983

978 Identifying the biological basis of GWAS hits for endometriosis. **2015**, 92, 87 43

977 Transcription Factors Interpret cis-Regulatory Information. **2015**, 133-148

976 LRP8-Reelin-Regulated Neuronal Enhancer Signature Underlying Learning and Memory Formation. **2015**, 86, 696-710 87

975 The genomic and genetic toolbox of the teleost medaka (Oryzias latipes). **2015**, 199, 905-18 65

974 Spatiotemporal control of phosphatidylinositol 4-phosphate by Sac2 regulates endocytic recycling. **2015**, 209, 97-110 44

973 CRISPR-Cas9-mediated single-gene and gene family disruption in Trypanosoma cruzi. **2014**, 6, e02097-14 133

972 Efficient Genome Editing in Clostridium cellulolyticum via CRISPR-Cas9 Nickase. **2015**, 81, 4423-31 154

971	Transcription activator-like effector nucleases mediated metabolic engineering for enhanced fatty acids production in Saccharomyces cerevisiae. **2015**, 120, 364-71	21
970	What Is Next for Retinal Gene Therapy?. **2015**, 5,	10
969	Cas9-mediated targeting of viral RNA in eukaryotic cells. **2015**, 112, 6164-9	182
968	Lentiviral vectors in cancer immunotherapy. **2015**, 7, 271-84	24
967	Chromatin changes in response to drought, salinity, heat, and cold stresses in plants. **2015**, 6, 114	245
966	Sequential cancer mutations in cultured human intestinal stem cells. **2015**, 521, 43-7	624
965	Future translational applications from the contemporary genomics era: a scientific statement from the American Heart Association. **2015**, 131, 1715-36	32
964	Selective Distal Enhancer Control of the Mmp13 Gene Identified through Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR) Genomic Deletions. **2015**, 290, 11093-107	47
963	N6-methyladenine DNA modification in Drosophila. **2015**, 161, 893-906	401
962	Efficient Virus-Mediated Genome Editing in Plants Using the CRISPR/Cas9 System. **2015**, 8, 1288-91	178
961	Programmed cell death 4 protein (Pdcd4) and homeodomain-interacting protein kinase 2 (Hipk2) antagonistically control translation of Hipk2 mRNA. **2015**, 1853, 1564-73	8
960	New Transgenic Technologies. **2015**, 45-57	
959	CRISPR-Cas9 Based Genome Engineering: Opportunities in Agri-Food-Nutrition and Healthcare. **2015**, 19, 261-75	8
958	Advances in reprogramming-based study of neurologic disorders. **2015**, 24, 1265-83	16
957	A short splice form of Xin-actin binding repeat containing 2 (XIRP2) lacking the Xin repeats is required for maintenance of stereocilia morphology and hearing function. **2015**, 35, 1999-2014	32
956	Modeling cancer processes with CRISPR-Cas9. **2015**, 33, 317-9	7
955	Modularization of genetic elements promotes synthetic metabolic engineering. **2015**, 33, 1412-9	11
954	TP53 loss creates therapeutic vulnerability in´colorectal cancer. **2015**, 520, 697-701	154

953	CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes. **2015**, 6, 363-372	713
952	Centrin2 regulates CP110 removal in primary cilium formation. **2015**, 208, 693-701	47
951	CRISPR-Cas system enables fast and simple genome editing of industrial strains. **2015**, 2, 13-22	115
950	Methods for studying the zebrafish brain: past, present and future. **2015**, 42, 1746-63	39
949	Sensing, signaLling, and CONTROL of phosphate starvation in plants: molecular players and applications. **2015**, 23-63	7
948	Engineering T Cells to Functionally Cure HIV-1 Infection. **2015**, 23, 1149-1159	40
947	Fluorescence-based monitoring of ribosome assembly landscapes. **2015**, 16, 3	3
946	Targeted genome modifications in soybean with CRISPR/Cas9. **2015**, 15, 16	338
945	The CRISPR/Cas9 system inactivates latent HIV-1 proviral DNA. **2015**, 12, 22	156
944	RNA-guided CRISPR-Cas technologies for genome-scale investigation of disease processes. **2015**, 8, 31	7
943	"Off-Spotter": very fast and exhaustive enumeration of genomic lookalikes for designing CRISPR/Cas guide RNAs. **2015**, 10, 4	67
942	Psoriasis drug development and GWAS interpretation through in silico analysis of transcription factor binding sites. **2015**, 4, 13	31
941	TRAF Family Member-associated NF-Ƀ Activator (TANK) Inhibits Genotoxic Nuclear Factor Ƀ Activation by Facilitating Deubiquitinase USP10-dependent Deubiquitination of TRAF6 Ligase. **2015**, 290, 13372-85	53
940	Applications of Cas9 as an RNA-programmed RNA-binding protein. **2015**, 37, 732-9	27
939	Transcriptional regulation of GAD1 GABA synthesis gene in the prefrontal cortex of subjects with schizophrenia. **2015**, 167, 28-34	45
938	Establishment of Genetic Transformation in the Sexually Reproducing Diatoms Pseudo-nitzschia multistriata and Pseudo-nitzschia arenysensis and Inheritance of the Transgene. **2015**, 17, 452-62	28
937	An overview of microRNAs. **2015**, 87, 3-14	820
936	Strategies to increase genome editing frequencies and to facilitate the identification of edited cells. **2015**, 1239, 281-9	2

935	A chemical genetics approach for the functional assessment of novel cancer genes. **2015**, 75, 1949-58	66
934	CRISPR. **2015**,	9
933	Applications of CRISPR-Cas9 mediated genome engineering. **2015**, 2, 11	24
932	Genome Editing in Mice Using CRISPR/Cas. **2015**, 151-166	1
931	BORC, a multisubunit complex that regulates lysosome positioning. **2015**, 33, 176-88	201
930	Design of a functional cyclic HSV1-TK reporter and its application to PET imaging of apoptosis. **2015**, 10, 807-21	3
929	From marrow to matrix: novel gene and cell therapies for epidermolysis bullosa. **2015**, 23, 987-992	9
928	Temperate and lytic bacteriophages programmed to sensitize and kill antibiotic-resistant bacteria. **2015**, 112, 7267-72	267
927	Building a Cell Culture Process with Stable Foundations: Searching for Certainty in an Uncertain World. **2015**, 373-406	3
926	Increasing the efficiency of homology-directed repair for CRISPR-Cas9-induced precise gene editing in mammalian cells. **2015**, 33, 543-8	771
925	Targeted Germline Modifications in Rats Using CRISPR/Cas9 and Spermatogonial Stem Cells. **2015**, 10, 1828-35	78
924	Efficient human immunodeficiency virus (HIV-1) infection of cells lacking PDZD8. **2015**, 481, 73-8	18
923	Editing CCR5: a novel approach to HIV gene therapy. **2015**, 848, 117-30	20
922	Recent advances in use of gene therapy to treat hepatitis B virus infection. **2015**, 848, 31-49	3
921	Dramatic enhancement of genome editing by CRISPR/Cas9 through improved guide RNA design. **2015**, 199, 959-71	146
920	Generation of a Knockout Mouse Embryonic Stem Cell Line Using a Paired CRISPR/Cas9 Genome Engineering Tool. **2016**, 1341, 321-43	17
919	A Proteomic Strategy Identifies Lysine Methylation of Splicing Factor snRNP70 by the SETMAR Enzyme. **2015**, 290, 12040-7	24
918	Function of the N-terminal segment of the RecA-dependent nuclease Ref. **2015**, 43, 1795-803	5

917	First efficient CRISPR-Cas9-mediated genome editing in Leishmania parasites. **2015**, 17, 1405-12	83
916	DRAM-3 modulates autophagy and promotes cell survival in the absence of glucose. **2015**, 22, 1714-26	21
915	Utilization of TALEN and CRISPR/Cas9 technologies for gene targeting and modification. **2015**, 240, 1065-70	17
914	Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains. **2015**, 33, 661-7	464
913	CRISPR multitargeter: a web tool to find common and unique CRISPR single guide RNA targets in a set of similar sequences. **2015**, 10, e0119372	89
912	Genome Editing Using Zinc-Finger Nucleases (ZFNs) and Transcription Activator-Like Effector Nucleases (TALENs). **2015**, 3-24	2
911	Factor-induced Reprogramming and Zinc Finger Nuclease-aided Gene Targeting Cause Different Genome Instability in -Thalassemia Induced Pluripotent Stem Cells (iPSCs). **2015**, 290, 12079-89	27
910	CRISPR-Cas targeted plasmid integration into mammalian cells via non-homologous end joining. **2015**, 112, 2154-62	39
909	The expanding epigenetic landscape of non-model organisms. **2015**, 218, 114-22	41
908	Genome Editing in Zebrafish and Medaka. **2015**, 119-131	1
907	FTD and ALS--translating mouse studies into clinical trials. **2015**, 11, 360-6	55
906	The history and market impact of CRISPR RNA-guided nucleases. **2015**, 12, 85-90	26
905	Efficient CRISPR-Cas9-mediated generation of knockin human pluripotent stem cells lacking undesired mutations at the targeted locus. **2015**, 11, 875-883	111
904	Efficient CRISPR/Cas9-Mediated Genome Editing in Mice by Zygote Electroporation of Nuclease. **2015**, 200, 423-30	166
903	SoNar, a Highly Responsive NAD+/NADH Sensor, Allows High-Throughput Metabolic Screening of Anti-tumor Agents. **2015**, 21, 777-89	228
902	Cloning-free CRISPR/Cas system facilitates functional cassette knock-in in mice. **2015**, 16, 87	197
901	DNA Sequence-Specific Binding of CENP-B Enhances the Fidelity of Human Centromere Function. **2015**, 33, 314-27	143
900	EGFR-independent autophagy induction with gefitinib and enhancement of its cytotoxic effect by targeting autophagy with clarithromycin in non-small cell lung cancer cells. **2015**, 461, 28-34	38

899	Silica Microcapsules for Long-Term, Robust, and Reliable Room Temperature RNA Preservation. **2015**, 4, 1332-8	13
898	Liver-targeted gene therapy: Approaches and challenges. **2015**, 21, 718-37	21
897	Application of CRISPRi for prokaryotic metabolic engineering involving multiple genes, a case study: Controllable P(3HB-co-4HB) biosynthesis. **2015**, 29, 160-168	178
896	Application of gene-editing technologies to HIV-1. **2015**, 10, 123-7	14
895	An enhanced gene targeting toolkit for Drosophila: Golic+. **2015**, 199, 683-94	19
894	Targeted disruption of DNMT1, DNMT3A and DNMT3B in human embryonic stem cells. **2015**, 47, 469-78	288
893	Advances in CRISPR-Cas9 genome engineering: lessons learned from RNA interference. **2015**, 43, 3407-19	104
892	Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins. **2015**, 7, a016600	415
891	Application of CRISPR/Cas9 genome editing to the study and treatment of disease. **2015**, 89, 1023-34	38
890	Mammalian synthetic biology: emerging medical applications. **2015**, 12,	38
889	Hypothetical gene C18orf42 encodes a novel protein kinase A-binding protein. **2015**, 20, 267-80	1
888	Engineering biological systems toward a sustainable bioeconomy. **2015**, 42, 813-38	38
887	Determining the role of microRNAs in psychiatric disorders. **2015**, 16, 201-12	216
886	CRISPR-Cas9 Based Engineering of Actinomycetal Genomes. **2015**, 4, 1020-9	279
885	Gene Therapy for HIV and Chronic Infections. **2015**,	
884	Highly efficient Cas9-mediated transcriptional programming. **2015**, 12, 326-8	856
883	Engineering a bacterial tape recorder. **2015**, 16, 1027-9	2
882	In vivo genome editing using Staphylococcus aureus Cas9. **2015**, 520, 186-91	1700

881	Inhibition of HIV-1 infection of primary CD4+ T-cells by gene editing of CCR5 using adenovirus-delivered CRISPR/Cas9. **2015**, 96, 2381-2393	133
880	Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication. **2015**, 118, 110-7	166
879	Efficient Multiplexed Integration of Synergistic Alleles and Metabolic Pathways in Yeasts via CRISPR-Cas. **2015**, 1, 88-96	205
878	Efficient inversions and duplications of mammalian regulatory DNA elements and gene clusters by CRISPR/Cas9. **2015**, 7, 284-98	89
877	High-throughput functional genomics using CRISPR-Cas9. **2015**, 16, 299-311	748
876	Ppm1b negatively regulates necroptosis through dephosphorylating Rip3. **2015**, 17, 434-44	101
875	Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers. **2015**, 33, 510-7	1141
874	Phosphorylated ubiquitin chain is the genuine Parkin receptor. **2015**, 209, 111-28	171
873	Small molecule-triggered Cas9 protein with improved genome-editing specificity. **2015**, 11, 316-8	286
872	DNA-Mediated Cyclic GMP-AMP Synthase-Dependent and -Independent Regulation of Innate Immune Responses. **2015**, 194, 4914-23	36
871	The CRISPR-Cas immune system: biology, mechanisms and applications. **2015**, 117, 119-28	253
870	The therapeutic application of CRISPR/Cas9 technologies for HIV. **2015**, 15, 819-30	49
869	One-step generation of triple knockout CHO cell lines using CRISPR/Cas9 and fluorescent enrichment. **2015**, 10, 1446-56	95
868	Heterologous protein production using euchromatin-containing expression vectors in mammalian cells. **2015**, 43, e102	34
867	Enabling functional genomics with genome engineering. **2015**, 25, 1442-55	67
866	Egg cell-specific promoter-controlled CRISPR/Cas9 efficiently generates homozygous mutants for multiple target genes in Arabidopsis in a single generation. **2015**, 16, 144	452
865	Selection and Validation of Spacer Sequences for CRISPR-Cas9 Genome Editing and Transcription Regulation in Bacteria. **2015**, 1334, 233-44	
864	From Genomics to Gene Therapy: Induced Pluripotent Stem Cells Meet Genome Editing. **2015**, 49, 47-70	89

863	Genetic code flexibility in microorganisms: novel mechanisms and impact on physiology. **2015**, 13, 707-721		77
862	Human Induced Pluripotent Stem Cell NEUROG2 Dual Knockin Reporter Lines Generated by the CRISPR/Cas9 System. **2015**, 24, 2925-42		22
861	Modeling Disease In Vivo With CRISPR/Cas9. **2015**, 21, 609-621		77
860	Sperm calcineurin inhibition prevents mouse fertility with implications for male contraceptive. *Science*, **2015**, 350, 442-5	33.3	100
859	Generation of Hypertension-Associated STK39 Polymorphism Knockin Cell Lines With the Clustered Regularly Interspaced Short Palindromic Repeats/Cas9 System. **2015**, 66, 1199-206		9
858	Research of methods to detect genomic mutations induced by CRISPR/Cas systems. **2015**, 214, 128-32		16
857	ELABELA Is an Endogenous Growth Factor that Sustains hESC Self-Renewal via the PI3K/AKT Pathway. **2015**, 17, 435-47		104
856	Structure and specificity of the RNA-guided endonuclease Cas9 during DNA interrogation, target binding and cleavage. **2015**, 43, 8924-41		72
855	Using the CRISPR-Cas System to Positively Select Mutants in Genes Essential for Its Function. **2015**, 1311, 233-50		
854	Targeted Mutagenesis in Zebrafish Using CRISPR RNA-Guided Nucleases. **2015**, 1311, 317-34		16
853	DNA-Protein Interactions. **2015**,		
852	Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system. **2015**, 163, 759-71		2414
851	Tracking and transforming neocortical progenitors by CRISPR/Cas9 gene targeting and piggyBac transposase lineage labeling. **2015**, 142, 3601-11		40
850	CRISPR/Cas9-based tools for targeted genome editing and replication control of HBV. **2015**, 30, 317-25		15
849	Cloning-free CRISPR. **2015**, 5, 908-917		38
848	Broadening the targeting range of Staphylococcus aureus CRISPR-Cas9 by modifying PAM recognition. **2015**, 33, 1293-1298		381
847	The art of CHO cell engineering: A comprehensive retrospect and future perspectives. **2015**, 33, 1878-96		169
846	Strategies for precision modulation of gene expression by epigenome editing: an overview. **2015**, 8, 34		40

845	Putting RNA to work: Translating RNA fundamentals into biotechnological engineering practice. **2015**, 33, 1829-44	16
844	CRISPR/Cas9 somatic multiplex-mutagenesis for high-throughput functional cancer genomics in mice. **2015**, 112, 13982-7	135
843	Classification of EA1-box proteins and new insights into their role during reproduction in grasses. **2015**, 28, 183-97	7
842	CRISPR/Cas9-mediated mutagenesis in the sea lamprey Petromyzon marinus: a powerful tool for understanding ancestral gene functions in vertebrates. **2015**, 142, 4180-7	45
841	MITF and c-Jun antagonism interconnects melanoma dedifferentiation with pro-inflammatory cytokine responsiveness and myeloid cell recruitment. **2015**, 6, 8755	123
840	Combining CRISPR/Cas9 and rAAV Templates for Efficient Gene Editing. **2015**, 25, 287-96	19
839	CRISPR-Cas9 delivery to hard-to-transfect cells via membrane deformation. **2015**, 1, e1500454	154
838	Imbalanced PTEN and PI3K Signaling Impairs Class Switch Recombination. **2015**, 195, 5461-5471	13
837	Targeting hepatitis B virus cccDNA using CRISPR/Cas9. **2015**, 123, 188-92	66
836	The Fanconi Anemia Pathway Maintains Genome Stability by Coordinating Replication and Transcription. **2015**, 60, 351-61	212
835	Highly specific epigenome editing by CRISPR-Cas9 repressors for silencing of distal regulatory elements. **2015**, 12, 1143-9	554
834	Histone H1 couples initiation and amplification of ubiquitin signalling after DNA damage. **2015**, 527, 389-93	252
833	CRISPR/Cas mutagenesis of soybean and Medicago truncatula using a new web-tool and a modified Cas9 enzyme. **2015**, 6, 243-52	112
832	DNase H Activity of Neisseria meningitidis Cas9. **2015**, 60, 242-55	45
831	Discovery and Functional Characterization of Diverse Class 2 CRISPR-Cas Systems. **2015**, 60, 385-97	670
830	Efficient delivery of nuclease proteins for genome editing in human stem cells and primary cells. **2015**, 10, 1842-59	88
829	Promoter-distal RNA polymerase II binding discriminates active from inactive CCAAT/enhancer-binding protein beta binding sites. **2015**, 25, 1791-800	21
828	Targeted Chromosomal Translocations and Essential Gene Knockout Using CRISPR/Cas9 Technology in Caenorhabditis elegans. **2015**, 201, 1295-306	24

827	Chromatin extrusion explains key features of loop and domain formation in wild-type and engineered genomes. **2015**, 112, E6456-65	1008
826	Decoding Advances in Psychiatric Genetics: A Focus on Neural Circuits in Rodent Models. **2015**, 92, 75-106	1
825	Mitotic redistribution of the mitochondrial network by Miro and Cenp-F. **2015**, 6, 8015	64
824	Mechanisms of Enhancer-mediated Hormonal Control of Vitamin D Receptor Gene Expression in Target Cells. **2015**, 290, 30573-86	19
823	Functional Gene Correction for Cystic Fibrosis in Lung Epithelial Cells Generated from Patient iPSCs. **2015**, 12, 1385-90	219
822	CRISPR/Cas9: a powerful genetic engineering tool for establishing large animal models of neurodegenerative diseases. **2015**, 10, 35	77
821	Genomic analysis of mycosis fungoides and Sézary syndrome identifies recurrent alterations in TNFR2. **2015**, 47, 1056-60	186
820	Genomes by design. **2015**, 16, 501-16	39
819	Novel lentiviral vectors with mutated reverse transcriptase for mRNA delivery of TALE nucleases. **2014**, 4, 6409	42
818	Rapid generation of endogenously driven transcriptional reporters in cells through CRISPR/Cas9. **2015**, 5, 9811	31
817	Small-molecule enhancers of autophagy modulate cellular disease phenotypes suggested by human genetics. **2015**, 112, E4281-7	46
816	Desmocollin-2 alone forms functional desmosomal plaques, with the plaque formation requiring the juxtamembrane region and plakophilins. **2015**, 158, 339-53	16
815	CRISPR-STAT: an easy and reliable PCR-based method to evaluate target-specific sgRNA activity. **2015**, 43, e157	78
814	Non-viral therapeutic approaches to ocular diseases: An overview and future directions. **2015**, 219, 471-487	34
813	Using the GEMM-ESC strategy to study gene function in mouse models. **2015**, 10, 1755-85	32
812	Mammalian designer cells: Engineering principles and biomedical applications. **2015**, 10, 1005-18	15
811	Medical case reports in the age of genomic medicine. **2015**, 4, e45	3
810	Transcriptional implications of intragenic DNA methylation in the oestrogen receptor alpha gene in breast cancer cells and tissues. **2015**, 15, 337	14

809	Reversion of FMR1 Methylation and Silencing by Editing the Triplet Repeats in Fragile X iPSC-Derived Neurons. **2015**, 13, 234-41		132
808	Mutation of the ER retention receptor KDELR1 leads to cell-intrinsic lymphopenia and a failure to control chronic viral infection. **2015**, 112, E5706-14		9
807	Wiskott-Aldrich Syndrome Interacting Protein Deficiency Uncovers the Role of the Co-receptor CD19 as a Generic Hub for PI3 Kinase Signaling in B Cells. **2015**, 43, 660-73		42
806	Targeted Large-Scale Deletion of Bacterial Genomes Using CRISPR-Nickases. **2015**, 4, 1217-25		66
805	CRISPR/Cas9-Mediated Genome Editing in Human Pluripotent Stem Cells. **2015**, 103-116		1
804	Efficient gene-targeting in rat embryonic stem cells by CRISPR/Cas and generation of human kynurenine aminotransferase II (KAT II) knock-in rat. **2015**, 24, 991-1001		11
803	Autophagy protects intestinal epithelial cells against deoxynivalenol toxicity by alleviating oxidative stress via IKK signaling pathway. **2015**, 89, 944-51		68
802	A Safeguard System for Induced Pluripotent Stem Cell-Derived Rejuvenated T Cell Therapy. **2015**, 5, 597-608		49
801	Interactome analysis identifies a new paralogue of XRCC4 in non-homologous end joining DNA repair pathway. **2015**, 6, 6233		118
800	Inhibition of β-catenin-TCF1 interaction delays differentiation of mouse embryonic stem cells. **2015**, 211, 39-51		21
799	ScreenBEAM: a novel meta-analysis algorithm for functional genomics screens via Bayesian hierarchical modeling. **2016**, 32, 260-7		23
798	Identification and characterization of essential genes in the human genome. *Science*, **2015**, 350, 1096-1101	33.3	977
797	Gene essentiality and synthetic lethality in haploid human cells. *Science*, **2015**, 350, 1092-6	33.3	513
796	Generation of gene-target dogs using CRISPR/Cas9 system. **2015**, 7, 580-3		76
795	MAP4K family kinases act in parallel to MST1/2 to activate LATS1/2 in the Hippo pathway. **2015**, 6, 8357		273
794	Identification of potential drug targets for tuberous sclerosis complex by synthetic screens combining CRISPR-based knockouts with RNAi. **2015**, 8, rs9		86
793	Genome scale engineering techniques for metabolic engineering. **2015**, 32, 143-154		38
792	BiOutils: an interface to connect university laboratories with microbiology classes in schools. **2015**, 362,		1

791	Genome-wide inactivation of porcine endogenous retroviruses (PERVs). *Science*, **2015**, 350, 1101-4	33.3	394
790	Targeted Porcine Genome Engineering with TALENs. **2015**, 17-33		
789	Jarid2 Coordinates Nanog Expression and PCP/Wnt Signaling Required for Efficient ESC Differentiation and Early Embryo Development. **2015**, 12, 573-86		32
788	The DEK Oncoprotein Is a Critical Component of the EKLF/KLF1 Enhancer in Erythroid Cells. **2015**, 35, 3726-38		8
787	TALEN-mediated functional correction of X-linked chronic granulomatous disease in patient-derived induced pluripotent stem cells. **2015**, 69, 191-200		62
786	Transgenic DNA modules with pre-programmed self-destruction: Universal molecular devices to escape 'genetic litter' in gene and cell therapy. **2015**, 85, 686-9		3
785	The Intrinsically Disordered Protein BKI1 Is Essential for Inhibiting BRI1 Signaling in Plants. **2015**, 8, 1675-8		29
784	Reinvigorating natural product combinatorial biosynthesis with synthetic biology. **2015**, 11, 649-59		151
783	Targeted Mutagenesis, Precise Gene Editing, and Site-Specific Gene Insertion in Maize Using Cas9 and Guide RNA. **2015**, 169, 931-45		464
782	Overview of guide RNA design tools for CRISPR-Cas9 genome editing technology. **2015**, 10, 289-296		20
781	Globin gene regulation for treating □-thalassemias: progress, obstacles and future. **2015**, 3, 1047-1062		
780	Knockout of cGAS and STING Rescues Virus Infection of Plasmid DNA-Transfected Cells. **2015**, 89, 11169-73		32
779	Hematopoietic Differentiation of Human Pluripotent Stem Cells. **2015**,		1
778	Proteomic mapping of ER-PM junctions identifies STIMATE as a regulator of Ca□+ influx. **2015**, 17, 1339-47		138
777	CRISPRscan: designing highly efficient sgRNAs for CRISPR-Cas9 targeting in vivo. **2015**, 12, 982-8		664
776	Highly efficient editing of the actinorhodin polyketide chain length factor gene in Streptomyces coelicolor M145 using CRISPR/Cas9-CodA(sm) combined system. **2015**, 99, 10575-85		92
775	A CRISPR/Cas9 Toolbox for Multiplexed Plant Genome Editing and Transcriptional Regulation. **2015**, 169, 971-85		408
774	Nanopatterned Human iPSC-based Model of a Dystrophin-Null Cardiomyopathic Phenotype. **2015**, 8, 320-332		48

773	Rapid and efficient one-step generation of paired gRNA CRISPR-Cas9 libraries. **2015**, 6, 8083	79
772	CRISPR/Cas9 Genome Editing in Caenorhabditis elegans: Evaluation of Templates for Homology-Mediated Repair and Knock-Ins by Homology-Independent DNA Repair. **2015**, 5, 1649-56	39
771	Orientation-specific joining of AID-initiated DNA breaks promotes antibody class switching. **2015**, 525, 134-139	76
770	Crystal Structure of Staphylococcus aureus Cas9. **2015**, 162, 1113-26	257
769	Cas9-Guide RNA Directed Genome Editing in Soybean. **2015**, 169, 960-70	316
768	Prospect and progress of gene therapy in treating atherosclerosis. **2015**, 15, 1699-712	7
767	RORRegulates Multiple Aspects of Dendrite Development in Cerebellar Purkinje Cells In Vivo. **2015**, 35, 12518-34	35
766	Conditionally Stabilized dCas9 Activator for Controlling Gene Expression in Human Cell Reprogramming and Differentiation. **2015**, 5, 448-59	119
765	CETCh-seq: CRISPR epitope tagging ChIP-seq of DNA-binding proteins. **2015**, 25, 1581-9	84
764	Procedures for Generating CRISPR Mutants with Novel Spacers Acquired from Viruses or Plasmids. **2015**, 1311, 195-222	1
763	A modular open platform for systematic functional studies under physiological conditions. **2015**, 43, e112	30
762	Lentivirus technologies for modulation of the immune system. **2015**, 24, 119-27	11
761	Outbred genome sequencing and CRISPR/Cas9 gene editing in butterflies. **2015**, 6, 8212	111
760	Engineered cellular gene-replacement platform for selective and inducible proteolytic profiling. **2015**, 112, 8344-9	6
759	Prosaposin facilitates sortilin-independent lysosomal trafficking of progranulin. **2015**, 210, 991-1002	112
758	Magnetogenetics: remote non-invasive magnetic activation of neuronal activity with a magnetoreceptor. **2015**, 60, 2107-2119	61
757	BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis. **2015**, 527, 192-7	528
756	The New State of the Art: Cas9 for Gene Activation and Repression. **2015**, 35, 3800-9	150

755	Live imaging of Tribolium castaneum embryonic development using light-sheet-based fluorescence microscopy. **2015**, 10, 1486-507	17
754	Generation of Targeted Mutations in Zebrafish Using the CRISPR/Cas System. **2015**, 1332, 205-17	25
753	PRC2 Is Required to Maintain Expression of the Maternal Gtl2-Rian-Mirg Locus by Preventing De Novo DNA Methylation in Mouse Embryonic Stem Cells. **2015**, 12, 1456-70	46
752	Modeling Human Severe Combined Immunodeficiency and Correction by CRISPR/Cas9-Enhanced Gene Targeting. **2015**, 12, 1668-77	71
751	Lack of mitochondrial topoisomerase I (TOP1mt) impairs liver regeneration. **2015**, 112, 11282-7	37
750	ERManI (Endoplasmic Reticulum Class I -Mannosidase) Is Required for HIV-1 Envelope Glycoprotein Degradation via Endoplasmic Reticulum-associated Protein Degradation Pathway. **2015**, 290, 22184-92	17
749	Proven and novel strategies for efficient editing of the human genome. **2015**, 24, 105-12	17
748	Skeletal muscle perfusion and stem cell delivery in muscle disorders using intra-femoral artery canulation in mice. **2015**, 339, 103-11	5
747	Electroporation Knows No Boundaries: The Use of Electrostimulation for siRNA Delivery in Cells and Tissues. **2015**, 20, 932-42	30
746	Development of the CRISPR/Cas9 System for Targeted Gene Disruption in Aspergillus fumigatus. **2015**, 14, 1073-80	138
745	Double-Strand Break Repair and Its Application to Genome Engineering in Plants. **2015**, 1-20	4
744	Regulatory RNA-assisted genome engineering in microorganisms. **2015**, 36, 85-90	16
743	The Daxx/Atrx Complex Protects Tandem Repetitive Elements during DNA Hypomethylation by Promoting H3K9 Trimethylation. **2015**, 17, 273-86	79
742	Cas-Designer: a web-based tool for choice of CRISPR-Cas9 target sites. **2015**, 31, 4014-6	149
741	Drosophila melanogaster Oogenesis: An Overview. **2015**, 1328, 1-20	48
740	Targeted Transcriptional Repression in Bacteria Using CRISPR Interference (CRISPRi). **2015**, 1311, 349-62	37
739	Efficient CRISPR/Cas9-mediated multiplex genome editing in CHO cells via high-level sgRNA-Cas9 complex. **2015**, 20, 825-833	12
738	Identification of intergenic long noncoding RNA by deep sequencing. **2015**, 223-235	

737	Diversity of CRISPR-Cas immune systems and molecular machines. **2015**, 16, 247	61
736	Off-target Effects in CRISPR/Cas9-mediated Genome Engineering. **2015**, 4, e264	549
735	Characterization of Staphylococcus aureus Cas9: a smaller Cas9 for all-in-one adeno-associated virus delivery and paired nickase applications. **2015**, 16, 257	179
734	Human stem cell-based disease modeling: prospects and challenges. **2015**, 37, 84-90	26
733	Microfluidic assessment of functional culture-derived platelets in human thrombi under flow. **2015**, 43, 891-900.e4	5
732	CRISPR/Cas9-mediated viral interference in plants. **2015**, 16, 238	299
731	Efficient Gene Editing in Pluripotent Stem Cells by Bacterial Injection of Transcription Activator-Like Effector Nuclease Proteins. **2015**, 4, 913-26	13
730	Identification of a Non-Gatekeeper Hot Spot for Drug-Resistant Mutations in mTOR Kinase. **2015**, 11, 446-59	16
729	Marine metagenomics as a source for bioprospecting. **2015**, 24 Pt 1, 21-30	36
728	High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities. **2015**, 163, 1515-26	863
727	Functional genomics to uncover drug mechanism of action. **2015**, 11, 942-8	58
726	Highly efficient Cas9-mediated gene drive for population modification of the malaria vector mosquito Anopheles stephensi. **2015**, 112, E6736-43	656
725	Gmnc Is a Master Regulator of the Multiciliated Cell Differentiation Program. **2015**, 25, 3267-73	56
724	MET gene exon 14 deletion created using the CRISPR/Cas9 system enhances cellular growth and sensitivity to a MET inhibitor. **2015**, 90, 590-7	26
723	Synthetic CRISPR RNA-Cas9-guided genome editing in human cells. **2015**, 112, E7110-7	120
722	Biological Networks Governing the Acquisition, Maintenance, and Dissolution of Pluripotency: Insights from Functional Genomics Approaches. **2015**, 80, 189-98	2
721	Versatile Viral Vector Strategies for Postscreening Target Validation and RNAi ON-Target Control. **2015**, 20, 976-84	2
720	Low-Dose Irradiation Enhances Gene Targeting in Human Pluripotent Stem Cells. **2015**, 4, 998-1010	15

719	Preferable sites and orientations of transgene inserted in the adenovirus vector genome: The E3 site may be unfavorable for transgene position. **2015**, 22, 421-9	14
718	R loops regulate promoter-proximal chromatin architecture and cellular differentiation. **2015**, 22, 999-1007	96
717	Functional genomics identifies negative regulatory nodes controlling phagocyte oxidative burst. **2015**, 6, 7838	19
716	Functional screen reveals essential roles of miR-27a/24 in differentiation of embryonic stem cells. **2015**, 34, 361-78	44
715	SOX17 is a critical specifier of human primordial germ cell fate. **2015**, 160, 253-68	490
714	PK11195 effect on steroidogenesis is not mediated through the translocator protein (TSPO). **2015**, 156, 1033-9	63
713	Efficient generation of knock-in transgenic zebrafish carrying reporter/driver genes by CRISPR/Cas9-mediated genome engineering. **2014**, 4, 6545	191
712	Editing plant genomes with CRISPR/Cas9. **2015**, 32, 76-84	364
711	The CRISPR/Cas9 system for plant genome editing and beyond. **2015**, 33, 41-52	772
710	A mouse geneticist's practical guide to CRISPR applications. **2015**, 199, 1-15	248
709	Methods to locate and track ion channels and receptors expressed in live neurons. **2015**, 6, 189-98	3
708	Rabbit models for the study of human atherosclerosis: from pathophysiological mechanisms to translational medicine. **2015**, 146, 104-19	194
707	Single-cell and multivariate approaches in genetic perturbation screens. **2015**, 16, 18-32	65
706	BREX is a novel phage resistance system widespread in microbial genomes. **2015**, 34, 169-83	230
705	Genome-wide detection of DNA double-stranded breaks induced by engineered nucleases. **2015**, 33, 179-86	467
704	Stimuli-responsive nanomaterials for biomedical applications. **2015**, 137, 2140-54	373
703	The Addgene repository: an international nonprofit plasmid and data resource. **2015**, 43, D1152-7	48
702	Multigene knockout utilizing off-target mutations of the CRISPR/Cas9 system in rice. **2015**, 56, 41-7	155

701	CRISPRdirect: software for designing CRISPR/Cas guide RNA with reduced off-target sites. **2015**, 31, 1120-3	593
700	Enabling plant synthetic biology through genome engineering. **2015**, 33, 120-31	161
699	Creation of targeted genomic deletions using TALEN or CRISPR/Cas nuclease pairs in one-cell mouse embryos. **2015**, 5, 26-35	36
698	Efficient production of a gene mutant cell line through integrating TALENs and high-throughput cell cloning. **2015**, 20, 46-50	3
697	Improved hematopoietic differentiation efficiency of gene-corrected beta-thalassemia induced pluripotent stem cells by CRISPR/Cas9 system. **2015**, 24, 1053-65	119
696	CRISPR-based self-cleaving mechanism for controllable gene delivery in human cells. **2015**, 43, 1297-303	36
695	Competition between target sites of regulators shapes post-transcriptional gene regulation. **2015**, 16, 113-26	182
694	Efficient and reversible Cas13d-mediated knockdown with an all-in-one lentivirus-vector. 10,	0
693	Advances in CRISPR/Cas9. **2022**, 2022, 1-13	2
692	A programmable system to methylate and demethylate N6-Methyladenosine (m6A) on specific RNA transcripts in mammalian cells. **2022**, 102525	0
691	Ectopic expression of meiotic cohesin generates chromosome instability in cancer cell line. **2022**, 119,	2
690	Lipid-based nucleic acid therapeutics with in vivo efficacy.	1
689	Guide RNA engineering enables efficient CRISPR editing with a miniature Syntrophomonas palmitatica Cas12f1 nuclease. **2022**, 40, 111418	1
688	Robust genome editing via modRNA-based Cas9 or base editor in human pluripotent stem cells. **2022**, 2, 100290	0
687	Delivering gene therapy for mucopolysaccharide diseases. 9,	0
686	Applications of CRISPR/Cas technology against drug-resistant lung cancers: an update.	0
685	Current AAV-mediated gene therapy in sensorineural hearing loss. **2022**,	0
684	Identification of orphan ligand-receptor relationships using a cell-based CRISPRa enrichment screening platform. 11,	2

683	Genome-Scale CRISPR screen identifies LAPTM5 driving lenvatinib resistance in hepatocellular carcinoma. 1-15	0
682	CRISPR-Based Genome Editing and Its Applications in Woody Plants. **2022**, 23, 10175	1
681	Combining CRISPR-Cas9 and brain imaging to study the link from genes to molecules to networks. **2022**, 119,	0
680	CRISPR-Based Therapeutic Gene Editing for Duchenne Muscular Dystrophy: Advances, Challenges and Perspectives. **2022**, 11, 2964	0
679	Engineering plant immune circuit: walking to the bright future with a novel toolbox.	0
678	Mitochondrial E3 ubiquitin ligase MARCHF5 controls BAK apoptotic activity independently of BH3-only proteins.	0
677	Reversibility and Therapeutic Development for Neurodevelopmental Disorders, Insights from Genetic Animal Models. **2022**, 114562	1
676	Comprehensive assessment of miniature CRISPR-Cas12f nucleases for gene disruption. **2022**, 13,	1
675	Heterozygous LRP1 deficiency causes developmental dysplasia of the hip by impairing triradiate chondrocytes differentiation due to inhibition of autophagy. **2022**, 119,	1
674	LINE-1 activation in the cerebellum drives ataxia. **2022**,	0
673	Phytoremediation and sequestration of soil metals using the CRISPR/Cas9 technology to modify plants: a review.	3
672	Gene therapy using genome-edited iPS cells for targeting malignant glioma.	0
671	Research progress of CRISPR-based biosensors and bioassays for molecular diagnosis. 10,	3
670	CRISPR-Analytics (CRISPR-A): a platform for precise analytics and simulations for gene editing.	0
669	Genomic Mutations of the STAT5 Transcription Factor Are Associated with Human Cancer and Immune Diseases. **2022**, 23, 11297	0
668	Coronary artery disease and cancer: a significant resemblance. **2022**, 39,	0
667	Recent Progress and Future Prospect of CRISPR/Cas-Derived Transcription Activation (CRISPRa) System in Plants. **2022**, 11, 3045	1
666	Smart breeding approaches in post-genomics era for developing climate-resilient food crops. 13,	0

665	Establishment of MDR1-knockout human enteroids for pharmaceutical application. **2022**, 100476	0
664	Modeling Brain Tumors Using Genetically Edited Brain Organoids. **2023**, 159-171	0
663	Recent developments in multi-omics and breeding strategies for abiotic stress tolerance in maize (Zea mays L.). 13,	1
662	Two types of type IV P-type ATPases independently re-establish the asymmetrical distribution of phosphatidylserine in plasma membranes. **2022**, 102527	0
661	SynMADE: synthetic microbiota across diverse ecosystems. **2022**,	0
660	Role for N -glycans and calnexin-calreticulin chaperones in SARS-CoV-2 Spike maturation and viral infectivity. **2022**, 8,	0
659	Research Progress on Nanoparticles-Based CRISPR/Cas9 System for Targeted Therapy of Tumors. **2022**, 12, 1239	0
658	Fluorescence Signal-Readout of CRISPR/Cas Biosensors for Nucleic Acid Detection. **2022**, 12, 779	3
657	Rice grain yield and quality improvement via CRISPR/Cas9 system: an updated review. **2022**, 50, 12388	0
656	CRISPR/Cas12a-based biosensing platform for the on-site detection of single-base mutants in gene-edited rice. 13,	1
655	CRISPR Spherical Nucleic Acids.	1
654	Biomimetic Mineralization of Iron-Fumarate Nanoparticles for Protective Encapsulation and Intracellular Delivery of Proteins.	0
653	Cilia regeneration requires an RNA splicing factor from the ciliary base. **2022**, 11,	0
652	Recent Progress of Smart Nano-Based Biosensors and their Applications in Biomedicine.	0
651	Detection of target DNA with a visual CRISPR-associated hyperbranched rolling circle amplification technique. **2022**, 114940	0
650	Programmable RNA sensing for cell monitoring and manipulation.	0
649	RNA-Responsive gRNAs for Controlling CRISPR Activity: Current Advances, Future Directions, and Potential Applications.	0
648	Simultaneous ultrasensitive ADP and ATP quantification based on CRISPR/Cas12a integrated ZIF-90@Ag3AuS2@Fe3O4 nanocomposites. **2022**, 114784	0

647	Marker-free co-selection for successive rounds of prime editing in human cells. **2022**, 13,	0
646	Early reduction to practice of the CRISPR Cas9 invention in eukaryotic cells. 13,	0
645	Lymphopenic condition enhanced the antitumor immunity of PD-1-knockout T cells mediated by CRISPR/Cas9 system in malignant melanoma. **2022**, 250, 15-22	0
644	Emerin prevents BAF-mediated aggregation of Lamin A on chromosomes in telophase to allow nuclear membrane expansion and nuclear lamina formation..	0
643	Distinct effects of disease-associated TREM2 R47H/+ and T66M mutations on iPSC-derived microglia..	0
642	Recent advances on CRISPR/Cas system-enabled portable detection devices for on-site agri-food safety assay. **2022**,	0
641	CRISPR for accelerating genetic gains in under-utilized crops of the drylands: Progress and prospects. 13,	0
640	In silico optimization of RNA protein interactions for CRISPR-Cas13-based antimicrobials. **2022**, 17,	0
639	Latent HIV-1 provirus in vitro suppression using combinatorial CRISPR/Cas9 strategy. **2022**, 29, 101686	0
638	Challenges and hopes in CRISPR CAS technology in future. 5-12	0
637	CRISPR-Cas: A continuously evolving technology. **2021**, 91,	0
636	CRISPR: En metode til anvendelse i næste generations genterapier. **2021**, 132,	0
635	Microfluidic-assisted biomineralization of CRISPR/Cas9 in near-infrared responsive metal organic frameworks for programmable gene-editing. **2022**, 14, 15832-15844	0
634	Engineering the Plant Microbiome for Biotic Stress Tolerance: Biotechnological Advances. **2022**, 133-151	0
633	Polymer-Mediated Delivery of CRISPR-Cas9 Genome-Editing Therapeutics for CNS Disease. **2022**, 229-258	0
632	Amyloid precursor protein in Alzheimer's disease. **2022**,	0
631	Low density lipoprotein receptor endocytosis in cardiovascular disease and the factors affecting LDL levels. **2022**,	0
630	The expanding CRISPR toolbox for natural product discovery and engineering in filamentous fungi.	0

629	Genome Editing advances in Soybean Improvement against Biotic and Abiotic Stresses. **2022**, 241-274	0
628	The Role of Transcription Factors in Response to Biotic Stresses in Maize. **2022**, 175-194	0
627	Technologies Enabling Single-Molecule Super-Resolution Imaging of mRNA. **2022**, 11, 3079	0
626	Molecular basis of cyclic tetra-oligoadenylate processing by small standalone CRISPR-Cas ring nucleases.	2
625	GiRAFR improves gRNA detection and annotation in single cell CRISPR screens.	0
624	Wildtype heterogeneity contributes to clonal variability in genome edited cells. **2022**, 12,	1
623	Identification of CRISPR-Induced Mutations in Plants: with a Focus on the Next-Generation Sequencing Assay.	0
622	Construction and Transcriptomic Study of Chicken IFNAR1-Knockout Cell Line Reveals the Essential Roles of Cell Growth- and Apoptosis-Related Pathways in Duck Tembusu Virus Infection. **2022**, 14, 2225	0
621	Non-uniform dystrophin re-expression after CRISPR-mediated exon excision in the dystrophin/utrophin double-knockout mouse model of DMD. **2022**,	0
620	Application of advanced technology in traditional Chinese medicine for cancer therapy. 13,	0
619	Adapting Crops to Climate Change. **2022**, 53-77	0
618	CasPlay provides a gRNA-barcoded CRISPR-based display platform for antibody repertoire profiling. **2022**, 2, 100318	0
617	Transient inhibition of p53 enhances prime editing and cytosine base-editing efficiencies in human pluripotent stem cells. **2022**, 13,	1
616	Genome editing in mice and its application to the study of spermatogenesis. **2022**, 100014	0
615	Selecting for CRISPR-Edited Knock-In Cells. **2022**, 23, 11919	1
614	BoostMEC: predicting CRISPR-Cas9 cleavage efficiency through boosting models. **2022**, 23,	0
613	Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia. **2022**, 14,	2
612	CRISPR/Cas9-mediated AtGATA25 mutant represents a novel model for regulating hypocotyl elongation in Arabidopsis thaliana.	0

611	Application of CRISPR/Cas Systems in the Nucleic Acid Detection of Infectious Diseases. **2022**, 12, 2455	0
610	Point-of-care CRISPR/Cas biosensing technology: A promising tool for preventing the possible COVID-19 resurgence caused by contaminated cold-chain food and packaging.	0
609	Molecular Biology, Genetics, and Translational Models of Human Cancer. 1-34	0
608	Application of the CRISPR/Cas System in Pathogen Detection: A Review. **2022**, 27, 6999	0
607	Governing Agricultural Biotechnologies in the United States, the United Kingdom, and Germany: A Trans-decadal Study of Regulatory Cultures. 016224392211225	0
606	G-quadruplex-guided RNA engineering to modulate CRISPR-based genomic regulation.	0
605	A fast blind zero-shot denoiser.	0
604	CRISPR-Cas systems mediated biosensing and applications in food safety detection. 1-26	0
603	Frankenstein Cas9: engineering improved gene editing systems. **2022**, 50, 1505-1516	0
602	A Novel CRISPR Interference Effector Enabling Functional Gene Characterization with Synthetic Guide RNAs.	0
601	A synthetic transcription platform for programmable gene expression in mammalian cells. **2022**, 13,	0
600	Perturbation of Gene Regulation by Genome Editing. **2023**, 59-68	0
599	Application of CRISPR for In Vivo Mouse Cancer Studies. **2022**, 14, 5014	0
598	Human Cytomegalovirus Utilizes Multiple Viral Proteins to Regulate the Basement Membrane Protein Nidogen 1. **2022**, 96,	0
597	RM2Target: a comprehensive database for targets of writers, erasers´and readers of RNA modifications.	0
596	Chicken genome editing for investigating poultry pathogens. 1-11	0
595	Solving the MCM paradox by visualizing the scaffold of CMG helicase at active replisomes. **2022**, 13,	0
594	Discovering DNA Methylation, the History and Future of the Writing on DNA.	0

593	CEDA: integrating gene expression data with CRISPR-pooled screen data identifies essential genes with higher expression.	0
592	En masse organoid phenotyping informs metabolic-associated genetic susceptibility to NASH. **2022**, 185, 4216-4232.e16	0
591	Fire Burn and Cauldron Bubble: What Is in Your Genome Editing Brew?.	0
590	Combinatorial gene targeting in primary human hematopoietic stem and progenitor cells. **2022**, 12,	0
589	Comparison of DNA targeting CRISPR editors in human cells.	0
588	Exosome Secretion and Epithelial-Mesenchymal Transition in Ovarian Cancer Are Regulated by Phospholipase D. **2022**, 23, 13286	0
587	Construction and Evaluation of a Novel Organic Anion Transporter 1/3 CRISPR/Cas9 Double-Knockout Rat Model. **2022**, 14, 2307	0
586	A Short Promoter Region Containing Conserved Regulatory Motifs Is Required for Steroidogenic Acute Regulatory Protein (Star) Gene Expression in the Mouse Testis. **2022**, 23, 12009	0
585	Current updates of CRISPR/Cas9-mediated genome editing and targeting within tumor cells: an innovative strategy of cancer management.	1
584	Hepatocyte or macrophage-specific SREBP-1a deficiency in mice exacerbates methionine- and choline-deficient diet-induced NAFLD.	0
583	Development of an in vivo cleavable donor plasmid for targeted transgene integration by CRISPR-Cas9 and CRISPR-Cas12a. **2022**, 12,	0
582	CRISPR/Cas9-mediated excision of ALS/FTD-causing hexanucleotide repeat expansion in C9ORF72 rescues major disease mechanisms in vivo and in vitro. **2022**, 13,	1
581	Biotechnological Advances to Improve Abiotic Stress Tolerance in Crops. **2022**, 23, 12053	1
580	Application of the transgenic pig model in biomedical research: A review. 10,	0
579	FBXO34 promotes latent HIV-1 activation by post-transcriptional modulation. 1-101	0
578	Quantitative profiling of pseudouridylation landscape in the human transcriptome.	0
577	CRISPR /Cas9-mediated deletion of Fam83h induces defective tooth mineralization and hair development in rabbits.	0
576	Genome-Wide CRISPR/Cas9 Library Screening Revealed Dietary Restriction of Glutamine in Combination with Inhibition of Pyruvate Metabolism as Effective Liver Cancer Treatment. 2202104	0

575	Genome editing technologies, mechanisms´and improved production of therapeutic phytochemicals: Opportunities and prospects.	1
574	Bioengineering Human Pluripotent Stem Cell-Derived Retinal Organoids and Optic Vesicle-Containing Brain Organoids for Ocular Diseases. **2022**, 11, 3429	0
573	CRISPR Gene Editing of Hematopoietic Stem and Progenitor Cells. **2023**, 39-62	0
572	EZ Clear for simple, rapid, and robust mouse whole organ clearing. 11,	0
571	PARP10 Mediates Mono-ADP-Ribosylation of Aurora-A Regulating G2/M Transition of the Cell Cycle. **2022**, 14, 5210	1
570	CRISPR/Cas systems usher in a new era of disease treatment and diagnosis. **2022**, 3,	1
569	AUTS2 Controls Neuronal Lineage Choice Through a Novel PRC1-Independent Complex and BMP Inhibition.	0
568	Contribution of CRISPRable DNA to human complex traits. **2022**, 5,	0
567	Halomonas spp., as chassis for low-cost production of chemicals. **2022**, 106, 6977-6992	0
566	lncRNA Malat1 and miR-26 cooperate in the regulation of neuronal progenitor cell proliferation and differentiation. rna.079436.122	0
565	Design of SaCas9-HF for In Vivo Gene Therapy. **2023**, 261-268	0
564	A new family of CRISPR -type V nucleases with C-rich PAM recognition.	0
563	Therapeutic modulation of gene expression in the disease state: Treatment strategies and approaches for the development of next-generation of the epigenetic drugs. 10,	0
562	Advances in CRISPR therapeutics.	0
561	Trait Improvement of Solanaceae Fruit Crops for Vertical Farming by Genome Editing.	0
560	The race to develop oral SERDs and other novel estrogen receptor inhibitors: recent clinical trial results and impact on treatment options.	0
559	License to cut: Smart RNA guides for conditional control of CRISPR-Cas9.	0
558	Applying a Knock-In Strategy to Create Reporter-Tagged Knockout Alleles in Axolotls. **2023**, 351-368	0

557	Modeling the efficacy of CRISPR gene drive for snail immunity on schistosomiasis control. **2022**, 16, e0010894	0
556	PEGG: A computational pipeline for rapid design of prime editing guide RNAs and sensor libraries.	0
555	Genome-wide CRISPR Screen Reveal Targets of Chiral Gold(I) Anticancer Compound in Mammalian Cells. **2022**, 7, 39197-39205	0
554	A Genome-Wide CRISPR-Cas9 Loss-of-Function Screening to Identify Host Restriction Factors Modulating Oncolytic Virotherapy. **2023**, 379-399	0
553	Clustered Regularly Interspaced short palindromic repeats-Based Microfluidic System in Infectious Diseases Diagnosis: Current Status, Challenges, and Perspectives. 2204172	0
552	Gold Nanoparticle-Mediated Gene Therapy. **2022**, 14, 5366	0
551	Receptor-Mediated Ovary Transduction of Cargo ReMOT Control: a Comprehensive Review and Detailed Protocol for Implementation. **2022**, 125-148	0
550	Site-Directed DNA Sequence Modification Using CRISPR/Cas 9. **2022**, 149-173	0
549	Site-Specific Recombination for Gene Locus-Directed Transgene Integration and Modification. **2022**, 100-124	0
548	Loss of CD99L2 contributed to temozolomide resistance and glioblastoma tumorigenesis based on Genome-scale CRISPR/Cas9 screening.	0
547	Circadian expression and specific localization of synaptotagmin17 in the suprachiasmatic nucleus, the master circadian oscillator in mammals. **2022**, 148129	0
546	Retinitis pigmentosa associated mutations in mouse Prpf8 cause misexpression of circRNAs and degeneration of cerebellar granule neurons.	0
545	Risk Analysis of Transgenic Insects. **2022**, 552-578	0
544	Reconstitution of human adrenocortical specification and steroidogenesis using induced pluripotent stem cells.	0
543	Identification of the EH CRISPR-Cas9 system on a metagenome and its application to genome engineering.	0
542	Structural insights into target DNA recognition and cleavage by the CRISPR-Cas12c1 system.	0
541	Cell-cell contacts via N-cadherin induce a regulatory renin secretory phenotype in As4.1 cells. **2022**, 26, 479-499	0
540	An Introduction to the Molecular Genetics of Gene Drives and Thoughts on Their Gradual Transition to Field Use. **2022**, 1-21	0

539	Simultaneous editing of three homoeologs of TaCIPK14 confers broad-spectrum resistance to stripe rust in wheat.	1
538	Human Hereditary Cardiomyopathy Shares a Genetic Substrate With Bicuspid Aortic Valve.	0
537	The economics and policy of genome editing in crop improvement.	0
536	Dual-gene detection in a single-tube system based on CRISPR-Cas12a/Cas13a for severe fever thrombocytopenia syndrome virus. 13,	1
535	Application of CRISPR/Cas system in cereal improvement for biotic and abiotic stress tolerance. **2022**, 256,	0
534	The Crispr Revolution in Genome Engineering: Perspectives from Religious Ethics.	0
533	Erratic and blood vessel-guided migration of astrocyte progenitors in the cerebral cortex. **2022**, 13,	0
532	Characterization based on genotype–biochemical phenotype association in fructose-1,6-bisphosphatase deficiency.	0
531	Epigenome editing in mice: The dawn of the reverse epigenetics era. **2022**, 3-4, 100012	0
530	Activation of the cGAS-STING pathway combined with CRISPR-Cas9 gene editing triggering long-term immunotherapy. **2022**, 291, 121871	1
529	In vivo delivery of CRISPR-Cas9 genome editing components for therapeutic applications. **2022**, 291, 121876	1
528	Modeling leukemia with zebrafish (Danio rerio): Towards precision medicine. **2022**, 421, 113401	0
527	Human models as new tools for drug development and precision medicine. **2023**, 155-171	0
526	Gene editing hPSCs for modeling neurological disorders. **2023**, 289-311	0
525	Murine fertility and spermatogenesis are independent of the testis-specific Spdye4a gene. **2023**, 330, 114148	0
524	Improvement of Resistance in Plants Against Insect-Pests Using Genome Editing Tools. **2022**, 237-249	0
523	CRISPR/Cas9-Mediated Targeted Mutagenesis in Medicinal Plants. **2022**, 55-70	0
522	Genome Engineering as a Tool for Enhancing Crop Traits: Lessons from CRISPR/Cas9. **2022**, 3-25	0

521	Multiplexed Genome Editing in Plants Using CRISPR/Cas-Based Endonuclease Systems. **2022**, 143-169	1
520	Genome Editing: A Review of the Challenges and Approaches. **2022**, 71-101	0
519	Biosensor-assisted titratable CRISPRi high-throughput (BATCH) screening for over-production phenotypes. **2023**, 75, 58-67	0
518	Applications of CRISPR/Cas9 in agriculture, nutrition, health and disease. **2019**, 17, 30-35	0
517	Imaging the unimaginable: leveraging signal generation of CRISPR-Cas for sensitive genome imaging. **2022**,	1
516	Identification and Analysis of Small Molecule Inhibitors of CRISPR-Cas9 in Human Cells. **2022**, 11, 3574	0
515	NDRG1 is induced by antigen-receptor signaling but dispensable for B and T cell self-tolerance. **2022**, 5,	0
514	The landscape of genome sequencing and assembling in plants.	0
513	CRISPR-based DNA methylation editing of NNT rescues the cisplatin resistance of lung cancer cells by reducing autophagy.	0
512	RNA-binding proteins of KHDRBS and IGF2BP families control the oncogenic activity of MLL-AF4. **2022**, 13,	0
511	Arc controls alcohol cue relapse by a central amygdala mechanism.	1
510	Studying Virus-Host Interactions with CRISPR Technology. **2023**, 105-117	0
509	CRISPR/Cas9 Genome-Editing Technology and Potential Clinical Application in Gastric Cancer. **2022**, 13, 2029	0
508	Genome-Wide Identification of the Aconitase Gene Family in Tomato (Solanum lycopersicum) and CRISPR-Based Functional Characterization of SlACO2 on Male-Sterility. **2022**, 23, 13963	0
507	A neurodevelopmental disorder associated with an activating de novo missense variant in ARF1.	0
506	Engineering the native methylotrophs for the bioconversion of methanol to value-added chemicals: Current status and future perspectives. **2022**,	0
505	Engineering Abiotic Stress Tolerance in Crop Plants through CRISPR Genome Editing. **2022**, 11, 3590	1
504	Orthogonal Chemical Activation of Enzyme-Inducible CRISPR/Cas9 for Cell-Selective Genome Editing.	2

503	Novel methods for the generation of genetically engineered animal models. **2022**, 116612	0
502	GPR56 S4 variant is required for microglia-mediated synaptic pruning.	0
501	A gap-free genome assembly of Chlamydomonas reinhardtii and detection of translocations induced by CRISPR-mediated mutagenesis. **2022**, 100493	1
500	Studies on the Genetic Characteristics of the Brewing Yeasts Saccharomyces: A Review. 1-12	0
499	Efficient Gene Knockout in Salivary Gland Epithelial Explant Cultures. 002203452211282	0
498	Improvement of Rice Agronomic Traits by Editing Type-B Response Regulators. **2022**, 23, 14165	0
497	Site-specific genome editing in treatment of inherited diseases: possibility, progress, and perspectives. **2022**,	0
496	Indel-free prime editing with bona fide Cas9 nickases.	0
495	CRISPR-Cas9 Technology for the Creation of Biological Avatars Capable of Modeling and Treating Pathologies: From Discovery to the Latest Improvements. **2022**, 11, 3615	0
494	Genome Editing Is Induced in a Binary Manner in Single Human Cells. **2022**, 105619	0
493	Immune Editing: Overcoming Immune Barriers in Stem Cell Transplantation. **2022**, 8, 206-218	0
492	Application of Machine Learning in Spatial Proteomics.	0
491	Multiplexed biosensor for point-of-care COVID-19 monitoring: CRISPR-powered unamplified RNA diagnostics and protein-based therapeutic drug management. **2022**,	0
490	Multiplex CRISPR/Cas9-mediated raffinose synthase gene editing reduces raffinose family oligosaccharides in soybean. 13,	1
489	A nematode model to evaluate microdeletion phenotype expression.	0
488	Site-specific CRISPR-based mitochondrial DNA manipulation is limited by gRNA import. **2022**, 12,	2
487	Shifted PAMs generate DNA overhangs and enhance SpCas9 post-catalytic complex dissociation.	0
486	P-body dynamics revealed by DDX6 protein knockdown via the auxin inducible degron system.	0

485	Gene editing strategies to treat lysosomal disorders: The example of mucopolysaccharidoses. **2022**, 191, 114616	0
484	Constructing next-generation CRISPR/Cas tools from structural blueprints. **2022**, 78, 102839	0
483	Intraosseous injection of SMNP vectors enables CRISPR/Cas9-mediated knock-in of HBB gene into hematopoietic stem and progenitor cells. **2022**, 47, 101659	0
482	Biofabrication of synthetic human liver tissue with advanced programmable functions. **2022**, 25, 105503	0
481	Genome editing and bioinformatics. **2022**, 3-4, 100018	0
480	Progresses of CRISPR/Cas9 genome editing in forage crops. **2022**, 279, 153860	1
479	Lipids and lipid derivatives for delivery of the CRISPR/Cas9 system. **2022**, 78, 103948	0
478	A general approach to identify cell-permeable and synthetic anti-CRISPR small molecules.	0
477	CRISPR-Cas9 Correction of Duchenne Muscular Dystrophy in Mice by a Self-Complementary AAV Delivery System. **2023**, 411-425	0
476	RYR-1-Related Diseases International Research Workshop: From Mechanisms to Treatments Pittsburgh, PA, U.S.A., 21-22 July 2022. **2022**, 1-20	0
475	Integration of CRISPR/Cas9 with artificial intelligence for improved cancer therapeutics. **2022**, 20,	1
474	Folate Receptor-Mediated Delivery of Cas9 RNP for Enhanced Immune Checkpoint Disruption in Cancer Cells. 2205318	0
473	Towards elucidating disease-relevant states of neurons and glia by CRISPR-based functional genomics. **2022**, 14,	0
472	Rab32/38-Dependent and -Independent Transport of Tyrosinase to Melanosomes in B16-F1 Melanoma Cells. **2022**, 23, 14144	0
471	CRISPR-induced miRNA156-recognition element mutations in TaSPL13 improve multiple agronomic traits in wheat.	0
470	Quantitative measurement of PROTAC intracellular accumulation. **2022**,	0
469	Knockout of the odorant receptor co-receptor, orco, impairs feeding, mating and egg-laying behavior in the fall armyworm Spodoptera frugiperda. **2023**, 152, 103889	1
468	Mycobacterial mycolic acids trigger inhibitory receptor Clec12A to suppress host immune responses. **2023**, 138, 102294	1

467	Dynamics of endogenous PARP1 and PARP2 during DNA damage revealed by live-cell single-molecule imaging. **2023**, 26, 105779	2
466	Improvements in the genetic editing technologies: CRISPR-Cas and beyond. **2023**, 852, 147064	0
465	Nanotechnology-based diagnostic methods for coronavirus: From nucleic acid extraction to amplification. **2023**, 13, 100289	0
464	First report on CRISPR/Cas9 mediated editing of the eye colour gene, Tryptophan 2, 3-dioxygenase in egg plant shoot and fruit borer Leucinodes orbonalis Guenᅠ (Lepidoptera: Crambidae). **2023**, 26, 102031	0
463	Generating a New sgRNA Vector, pGL3-U6-sgRNA-PGK-mRFP-T2A-PuroR, to Improve Base Editing. **2022**, 2, 1-6	0
462	Multiplexing with CRISPR-Cas Arrays. **2022**,	0
461	Genome editing. **2022**, 12,	0
460	Versatile and efficient genome editing with Neisseria cinerea Cas9. **2022**, 5,	0
459	CRISPR/Cas systems: Delivery and application in gene therapy. 10,	0
458	Engineering of efficiency-enhanced Cas9 and base editors with improved gene therapy efficacies. **2022**,	1
457	PEAR1 is a potential regulator of early hematopoiesis of human pluripotent stem cells.	0
456	Immortalization of primary marmoset skin fibroblasts by CRISPR-Cas9-mediated gene targeting. 1-9	1
455	Comparison of CRISPR-Cas9-mediated megabase-scale genome deletion methods in mouse embryonic stem cells.	0
454	Novel Production Methods of Polyhydroxyalkanoates and Their Innovative Uses in Biomedicine and Industry. **2022**, 27, 8351	1
453	Evaluation of genome and base editing tools in maize protoplasts. 13,	0
452	Thermodynamic Parameters Contributions of Single Internal Mismatches In RNA/DNA Hybrid Duplexes.	0
451	CRISPR-Cas12a induced DNA double-strand breaks are repaired by multiple pathways with different mutation profiles in Magnaporthe oryzae. **2022**, 13,	2
450	Necessity of integrated genomic analysis to establish a designed knock-in mouse from CRISPR-Cas9-induced mutants. **2022**, 12,	0

449	Cytokinetic diversity in mammalian cells is revealed by the characterization of endogenous anillin, Ect2 and RhoA. **2022**, 12,	1
448	High-content CRISPR screening in tumor immunology. 13,	0
447	TEMPO enables sequential genetic labeling and manipulation of vertebrate cell lineages. **2022**,	0
446	A method for generating user-defined circular single-stranded DNA from plasmid DNA using Golden Gate intramolecular ligation.	0
445	Drag-and-drop genome insertion of large sequences without double-strand DNA cleavage using CRISPR-directed integrases.	2
444	A review on bioinformatics advances in CRISPR-Cas technology.	0
443	Low-dose AAV-CRISPR-mediated liver-specific knock-in restored hemostasis in neonatal hemophilia B mice with subtle antibody response. **2022**, 13,	0
442	Improving Wheat Salt Tolerance for Saline Agriculture. **2022**, 70, 14989-15006	0
441	Displacement and dissociation of oligonucleotides during DNA hairpin closure under strain. **2022**, 50, 12082-12093	0
440	Identification of SaCas9 orthologs containing a conserved serine residue that determines simple NNGG PAM recognition. **2022**, 20, e3001897	0
439	Multiplexed engineering and precision gene editing in cellular immunotherapy. 13,	0
438	Genetic Enhancement: a New Avenue to Combat Aging-related Diseases.	0
437	Long noncoding RNA study: Genome-wide approaches. **2022**,	0
436	Wikipedia as a tool for contemporary history of science: A case study on CRISPR.	0
435	Rapid Single-Pot Assembly of Modular Chromatin Proteins for Epigenetic Engineering. **2023**, 191-214	0
434	Pig macrophages with site-specific edited CD163 decrease the susceptibility to infection with porcine reproductive and respiratory syndrome virus. **2022**,	0
433	CRISPR/Cas9-Based Knock-Out of the PMR4 Gene Reduces Susceptibility to Late Blight in Two Tomato Cultivars. **2022**, 23, 14542	0
432	Reconstitution of human adrenocortical specification and steroidogenesis using induced pluripotent stem cells. **2022**, 57, 2566-2583.e8	1

431	The compact Cas (Cas12l) Bracelet provides a unique structural platform for DNA manipulation.	0
430	CRISPR/SaCas9 mutagenesis of stromal interaction molecule 1 in proopiomelanocortin neurons increases glutamatergic excitability and protects against diet-induced obesity. **2022**, 66, 101645	0
429	Genome Editing and Fatty Liver. **2023**, 191-206	0
428	CRISPR screens for functional interrogation of immunity.	0
427	CRISPR-Based Diagnostics: Challenges and Potential Solutions toward Point-of-Care Applications.	1
426	Potential therapeutic strategies for photoreceptor degeneration: the path to restore vision. **2022**, 20,	1
425	Research Advances in Improving Disease Resistance and Abiotic Stress Tolerance Using CRISPR/Cas9 Gene Editing in Rice. **2022**, 54, 331-344	0
424	Candidate Genes Associated with Abiotic Stress Response in Plants as Tools to Engineer Tolerance to Drought, Salinity and Extreme Temperatures in Wheat: An Overview. **2022**, 11, 3358	1
423	Genome editing in plants. **2022**, 3-4, 100020	0
422	Gene editing of the ABC Transporter/White locus using CRISPR/Cas9-mediated mutagenesis in the Indian Meal Moth. **2022**, 104471	0
421	Chapter 29: Perspectives on the genetic manipulation of mosquitoes: advancements in studying sensory biology in vector insects. **2022**, 743-771	1
420	Ectopic activation of the polar body extrusion pathway triggers cell fragmentation in preimplantation embryos.	0
419	Targeting TPO-independent strategy in the discovery of a novel megakaryocytopoiesis inducer DMAG for treatment of thrombocytopenia.	0
418	Construction and Evaluation of gRNA Arrays for Multiplex CRISPR-Cas9.	0
417	Three linked opposing regulatory variants under selection associate withIVD.	0
416	Kinome-wide Screening Uncovers A Role for Bromodomain Protein 3 in DNA Double-stranded Break Repair. **2022**, 103445	0
415	The Golgi-resident protein ACBD3 concentrates STING at ER-Golgi contact sites to drive export from the ER. **2022**, 41, 111868	0
414	Novel compound heterozygous mutations in UHRF1 are associated with atypical immunodeficiency, centromeric instability, and facial anomalies (ICF) syndrome with distinctive genome-wide DNA hypomethylation.	0

413	Copper-inducible expression system for metabolic engineering of Escherichia coli.	0
412	Challenges in Gene Therapy for Somatic Reverted Mosaicism in X-Linked Combined Immunodeficiency by CRISPR/Cas9 and Prime Editing. **2022**, 13, 2348	0
411	Circular single-stranded DNA is a superior homology-directed repair donor template for efficient genome engineering.	0
410	Frame Editors for Precise, Template-Free Frameshifting.	0
409	Enabling Precision Medicine with CRISPR-Cas Genome Editing Technology: A Translational Perspective. **2023**, 315-339	0
408	In vivo genome editing using novel AAV-PHP variants rescues motor function deficits and extends survival in a SOD1-ALS mouse model.	0
407	Umifenovir Epigenetically Targets the IL-10 Pathway in Therapy against Coxsackievirus B4 Infection.	0
406	Balance Cell Apoptosis and Pyroptosis of Caspase-3-Activating Chemotherapy for Better Antitumor Therapy. **2023**, 15, 26	0
405	Introducing the CRISPR/Cas9 cytosine base editor toolbox □eishBASEedit□□Gene editing and high-throughput screening in□eishmaniawithout requiring DNA double-strand breaks, homologous recombination or donor DNA.	1
404	CRISPR: a tool with potential for genomic reprogramming in neurological disorders.	0
403	CRISPR-Mediated Genome Engineering in Cell Lines. **2023**, 267-278	0
402	CRISPR Manipulations in Stem Cell Lines. **2023**, 249-256	0
401	Circular Guide RNA for Improved Stability and CRISPR-Cas9 Editing Efficiency in Vitro and in Bacteria.	0
400	CRISPR-Cas9-mediated gene therapy in lung cancer.	0
399	Adenovirus vector system: construction, history and therapeutic applications. **2022**, 73, 297-305	1
398	DNA SYNTHESIS AND SYNTHETIC GENOME. **2023**, 157-181	0
397	SAFB associates with nascent RNAs to promote gene expression in mouse embryonic stem cells.	0
396	A novel TAPP-DHTA COF cathodic photoelectrochemical immunosensor based on CRISPR/Cas12a-induced nanozyme catalytic generation of heterojunction. **2022**, 141771	0

395	Polarity of the CRISPR roadblock to transcription. **2022**, 29, 1217-1227	0
394	Genome Editing and Pathological Cardiac Hypertrophy. **2023**, 87-101	0
393	Prospective Advances in Genome Editing Investigation. **2023**, 301-313	0
392	Evaluation of a Novel Oncolytic Adenovirus Silencing SYVN1. **2022**, 23, 15430	0
391	Simultaneous loading of PCR-based multiple fragments on mouse artificial chromosome vectors in DT40 cell for gene delivery. **2022**, 12,	0
390	An Overview of Genome Editing in Cardiovascular and Metabolic Diseases. **2023**, 3-16	0
389	Genome Editing and Diabetic Cardiomyopathy. **2023**, 103-114	0
388	Online Databases of Genome Editing in Cardiovascular and Metabolic Diseases. **2023**, 19-33	0
387	Modeling long QT syndrome type 2 on-a-chip via in-depth assessment of isogenic gene-edited 3D cardiac tissues. **2022**, 8,	1
386	Background: Genome Editing with Programmable Nucleases. **2023**, 17-50	0
385	Blastocyst complementation and interspecies chimeras in gene edited pigs. 10,	0
384	sgRNA structural constraints and genetic limitations for efficient Cas9 genome editing to generate knock-outs.	0
383	Multiparametric and accurate functional analysis of genetic sequence variants using CRISPR-Select. **2022**, 54, 1983-1993	1
382	CRISPR-Cas9 Genome Editing and Rapid Selection of Cell Pools. **2022**, 2,	0
381	A Review on Advanced CRISPR-Based Genome-Editing Tools: Base Editing and Prime Editing.	1
380	An insulin hypersecretion phenotype precedes pancreatic □cell failure in MODY3 patient-specific cells. **2022**,	0
379	From DNA-protein interactions to the genetic circuit design using CRISPR-dCas systems. 9,	0
378	Workflow for Performing Genetic Manipulation in Human Trophoblast Stem Cells Using CRISPR/Cas9 Technology. **2023**,	0

377	Modular UBE2H-CTLH E2-E3 complexes regulate erythroid maturation. 11,	0
376	A quantitative model for the dynamics of target recognition and off-target rejection by the CRISPR-Cas Cascade complex. **2022**, 13,	0
375	-arrestin 2 negatively regulates lung cancer progression by inhibiting the TRAF6 signaling axis for NF-B activation and autophagy induced by TLR3 and TLR4.	0
374	Comprehensive computational analysis of epigenetic descriptors affecting CRISPR-Cas9 off-target activity. **2022**, 23,	0
373	Development and application of brain region-specific organoids for investigating psychiatric disorders. **2022**,	0
372	IFT-A structure reveals carriages for membrane protein transport into cilia. **2022**, 185, 4971-4985.e16	1
371	MATE transporter GFD1 cooperates with sugar transporters, mediates carbohydrate partitioning, and controls grain filling duration, grain size and number in rice.	0
370	Inhibiting POLQ-mediated alternative NHEJ enhances CRISPR/Cas9 mediated precise genome editing in CHO cells.	0
369	Prime Editing in Mammals: The Next Generation of Precision Genome Editing. **2022**, 5, 746-768	0
368	CRISPR activation and interference as investigative tools in the cardiovascular system. **2022**, 106348	0
367	Design of a self-driven probiotic-CRISPR/Cas9 nanosystem for sono-immunometabolic cancer therapy. **2022**, 13,	0
366	Scheduled simple production method of pseudopregnant female mice for embryo transfer using the luteinizing hormone-releasing hormone agonist. **2022**, 12,	0
365	Acceleration of genome replication uncovered by single-cell nascent DNA sequencing.	0
364	Structural variants drive context-dependent oncogene activation in cancer. **2022**, 612, 564-572	2
363	Impaired migration and premature differentiation underlie the neurological phenotype associated with PCDH12 loss of function.	0
362	Doxycycline-dependent Cas9-expressing pig resources for conditional in vivo gene nullification and activation. **2023**, 24,	0
361	Assessing and advancing the safety of CRISPR-Cas tools: from DNA to RNA editing. **2023**, 14,	2
360	Hematopoietic stem and progenitors cells gene editing: Beyond blood disorders. 4,	0

359	PTBP1-activated co-transcriptional splicing controls epigenetic status of pluripotent stem cells. **2023**,	1
358	Full-Length Model of SaCas9-sgRNA-DNA Complex in Cleavage State. **2023**, 24, 1204	0
357	Correlative light and volume electron microscopy to study brain development.	0
356	Biotechnologies and Strategies for Grapevine Improvement. **2023**, 9, 62	0
355	STRA6 is essential for induction of vascular smooth muscle lineages in human embryonic cardiac outflow tract development.	0
354	Phage DNA polymerase prevents on-target damage and enhances precision of CRISPR editing.	0
353	Gene-editing techniques and their applications in livestock and beyond.	0
352	Induciblein vivogenome editing in the sea starPatiria miniata.	0
351	CRISPR-Cas-Docker: Web-basedin silicodocking and machine learning-based classification of crRNAs with Cas proteins.	0
350	Efficient CRISPR-Cas9 based cytosine base editors for phytopathogenic bacteria. **2023**, 6,	0
349	CRISPR-Cas9 recognition of enzymatically synthesized base-modified nucleic acids.	0
348	Remodeling of maternal mRNA through poly(A) tail orchestrates human oocyte-to-embryo transition.	0
347	Engineering CRISPR/Cas-based nanosystems for therapeutics, diagnosis and bioimaging. **2023**, 108134	0
346	A homozygous frameshift mutation in ADAD2 cause male infertility with spermatogenic impairments. **2023**,	0
345	Delivering Base Editors In Vivo by Adeno-Associated Virus Vectors. **2023**, 135-158	0
344	Nutritional Enhancement in Horticultural Crops by CRISPR/Cas9: Status and Future Prospects. **2023**, 399-430	0
343	Engineered Adipose-Derived Stem Cells Overexpressing RXFP1 via CRISPR Activation Ameliorate Erectile Dysfunction in Diabetic Rats. **2023**, 12, 171	0
342	Multiplex CRISPR/Cas9 gene-editing platform in oil palm targeting mutations in EgFAD2 and EgPAT genes. **2023**, 21,	0

341	Clustered regularly interspaced short palindromic repeats/Cas9-mediated gene editing. A promising strategy in hematological disorders. **2023**,	0
340	Uncovering the Dynamics of Precise Repair at CRISPR/Cas9-induced Double-Strand Breaks.	0
339	Targeted gene deletion withSpCas9 and multiple guide RNAs inArabidopsis thaliana: four are better than two.	0
338	Recent Advances in Genome-Engineering Strategies. **2023**, 14, 129	1
337	Two RNA-binding proteins mediate the sorting of miR223 from mitochondria into exosomes.	0
336	CRISPR interference for sequence-specific regulation of fibroblast growth factor receptor A in Schistosoma mansoni. 13,	0
335	Precise and heritable gene targeting in rice using a sequential transformation strategy. **2023**, 100389	0
334	Smart Plant Breeding for Potato in the Post-genomics Era. **2023**, 337-356	0
333	MDM2 antagonists promote CRISPR/Cas9-mediated precise genome editing in sheep primary cells. **2023**,	0
332	An interactive web application for processing, correcting, and visualizing genome-wide pooled CRISPR-Cas9 screens. **2023**, 100373	0
331	Comparison of DNA targeting CRISPR editors in human cells. **2023**, 13,	0
330	CRISPR/Cas9 therapeutics: progress and prospects. **2023**, 8,	0
329	CRISPR-interceded CHO cell line development approaches.	0
328	The compact Cas□(Cas12l) □bracelet□provides a unique structural platform for DNA manipulation.	1
327	Forced expression of □2,3-sialyltransferase IV rescues impaired heart development in □2,6-sialyltransferase I-deficient medaka. **2023**,	0
326	A genetic variant of the Wnt receptor LRP6 accelerates synapse degeneration during aging and in Alzheimer□s disease. **2023**, 9,	0
325	Identification of novel regulators involved in AD pathogenesis using the CRISPR-Cas9 system. **2023**, 158, 21-25	0
324	CRISPR-Cas9 editing of a TNPO3 mutation in a muscle cell model of Limb-Girdle Muscular Dystrophy type D2. **2023**,	0

323	Facioscapulohumeral muscular dystrophy: the road to targeted therapies.	0
322	Pigs with an INS point mutation derived from zygotes electroporated with CRISPR/Cas9 and ssODN. 11,	0
321	The SPOC domain is a phosphoserine binding module that bridges transcription machinery with co- and post-transcriptional regulators. **2023**, 14,	0
320	Loss of RREB1 in pancreatic beta cells reduces cellular insulin content and affects endocrine cell gene expression.	0
319	Conditional, tissue-specific CRISPR/Cas9 vector system in zebrafish reveal the role of neuropilin-1b in heart regeneration.	0
318	Enhanced production of d-pantothenic acid in Corynebacterium glutamicum using an efficient CRISPR□pf1 genome editing method. **2023**, 22,	0
317	Decoding CRISPR□as9 PAM recognition with UniDesign.	0
316	Precise cut-and-paste DNA insertion using engineered type V-K CRISPR-associated transposases.	0
315	CAS12e (CASX2) CLEAVAGE OF CCR5: IMPACT OF GUIDE RNA LENGTH AND PAM SEQUENCE ON CLEAVAGE ACTIVITY.	0
314	Two target gene activation pathways for orphan ERR nuclear receptors.	1
313	The CRISPR Patent Ruling and Implications for Medicine.	0
312	CRISPR/Cas9-based genome editing for multimodal synergistic cancer nanotherapy. **2023**, 48, 101734	0
311	AcrPred: A hybrid optimization with enumerated machine learning algorithm to predict Anti-CRISPR proteins. **2023**, 228, 706-714	0
310	Extracellular transportation of □synuclein by HLA class II molecules. **2023**, 644, 25-33	0
309	ERAP2 supports TCR recognition of three immunotherapy targeted tumor epitopes. **2023**, 154, 61-68	0
308	Secreted PGK1 and IGFBP2 contribute to the bystander effect of miR-10b gene editing in glioma. **2023**, 31, 265-275	0
307	Advances of CRISPR-Cas13 system in COVID-19 diagnosis and treatment. **2022**,	0
306	Role of Adenylyl Cyclase Type 7 in Functions of BV-2 Microglia. **2023**, 24, 347	0

305	KW-2449 and VPA exert therapeutic effects on human neurons and cerebral organoids derived from MECP2-null hESCs. **2022**, 13,	0
304	Plant genome editing: CRISPR, base editing, prime editing, and beyond.	0
303	Potent ClpP agonists with anticancer properties bind with improved structural complementarity and alter the mitochondrial N-terminome. **2022**,	1
302	ISG15-modification of the Arp2/3 complex restricts pathogen spread.	0
301	Insights into the Mechanism of CRISPR/Cas9-Based Genome Editing from Molecular Dynamics Simulations. **2023**, 8, 1817-1837	0
300	Nucleic acid nanostructure for delivery of CRISPR/Cas9-based gene editing system.	0
299	sgRNA-2wPSM: Identify sgRNAs on-target activity by combining two-window-based position specific mismatch and synthetic minority oversampling technique. **2022**, 106489	0
298	Delivery of CRISPR/Cas9 Plasmid DNA by Hyperbranched Polymeric Nanoparticles Enables Efficient Gene Editing. **2023**, 12, 156	0
297	Building Blocks of Artificial CRISPR-Based Systems beyond Nucleases. **2023**, 24, 397	0
296	Characterization and acceleration of genome shuffling and ploidy reduction in synthetic allopolyploids by genome sequencing and editing. **2023**, 51, 198-217	0
295	Chromatin organization drives the exploration strategy of nuclear factors.	0
294	Genome Editing Using Cas9 Ribonucleoprotein Is Effective for Introducing PDGFRA Variant in Cultured Human Glioblastoma Cell Lines. **2023**, 24, 500	0
293	Advances in CRISPR-Cas9 for the Baculovirus Vector System: A Systematic Review. **2023**, 15, 54	0
292	RNA-guided multiplex genome engineering using cas9 nucleases for crop improvement: A review. **2018**, 88, 1811-1817	0
291	CRISPR engineering in organoids for gene repair and disease modelling. **2023**, 1, 32-45	0
290	Microbes and wastewater treatment. **2023**, 239-255	1
289	Construction of a Set of Novel Transposon Vectors for Efficient Silencing of Protein and lncRNA Genes via CRISPR Interference.	0
288	Nuclear modifier YARS2 allele correction restored retinal ganglion cells-specific deficiencies in Leber hereditary optic neuropathy.	0

287	T-REX17 is a transiently expressed non-coding RNA essential for human endoderm formation. 12,	0
286	The Glucocorticoid Receptor is Required for Efficient Aldosterone-Induced Transcription by the Mineralocorticoid Receptor.	0
285	Genome Editing of Pig. **2023**, 269-292	0
284	Enzyme-Assisted Nucleic Acid Amplification in Molecular Diagnosis: A Review. **2023**, 13, 160	0
283	SNPD-CRISPR: Single Nucleotide Polymorphism-Distinguishable Repression or Enhancement of a Target Gene Expression by CRISPR System. **2023**, 49-62	0
282	Genome Editing in the Synthetic Biology for Sustainable Production of Biomolecules. **2023**, 315-329	0
281	An Efficient CRISPR-Cas9 Method to Knock Out MiRNA Expression in Xenopus Tropicalis. **2023**, 231-241	0
280	Role of Wnt signaling in the maintenance and regeneration of the intestinal epithelium. **2023**,	0
279	Editing genomes to modify plant response to abiotic stress. **2023**, 403-414	0
278	Updates and Applications of CRISPR/Cas Technology in Plants.	0
277	TGF-/IFN-Antagonism in Subversion and Self-Defense of Phase II Coxiella burnetii - Infected Dendritic Cells.	0
276	DNA synthesis technologies to close the gene writing gap.	0
275	The genome editing revolution. **2023**,	0
274	Yeast Cell Factory for Production of Biomolecules. **2023**, 211-251	0
273	Review of CRISPR/Cas Systems on Detection of Nucleotide Sequences. **2023**, 12, 477	1
272	Implications of CRISPR-Cas9 genome editing methods in atherosclerotic cardiovascular diseases. **2023**, 101603	0
271	Cell culture: in vitro model system and a promising path to in vivo applications. 1-4	0
270	Acoustically Targeted Noninvasive Gene Therapy in Large Brain Regions.	0

269	Tet-Regulated Expression and Optical Clearing for In Vivo Visualization of Genetically Encoded Chimeric dCas9/Fluorescent Protein Probes. **2023**, 16, 940	0
268	Genetic manipulation and tools in myxobacteria for the exploitation of secondary metabolism. **2023**, 100075	0
267	CRISPR-Cas Biochemistry and CRISPR-Based Molecular Diagnostics.	0
266	Efficient Detection of Flox Mice Using In Vitro Cre Recombination. **2023**, 149-159	0
265	PASTE: The Way Forward for Large DNA Insertions.	1
264	Recent progress in nucleic acid detection with CRISPR.	1
263	Clinical progress in genome-editing technology and in vivo delivery techniques. **2023**,	0
262	Precise transcript targeting by CRISPR-Csm complexes.	2
261	CRISPR-Cas Biochemistry and CRISPR-Based Molecular Diagnostics.	0
260	ArpC5 isoforms regulate Arp2/3 complex□dependent protrusion through differential Ena/VASP positioning. **2023**, 9,	0
259	Advances in CRISPR/Cas technologies and their application in plants. **2023**, 1-10	0
258	An affinity-directed phosphatase, AdPhosphatase, system for targeted protein dephosphorylation. **2023**,	0
257	Epigenetic resetting in the human germ line entails histone modification remodeling. **2023**, 9,	0
256	Agricultural biotechnology in Bangladesh: The way forward. **2023**, 143-166	0
255	Plexin-A2 enables the proliferation and the development of tumors from glioblastoma derived cells. **2023**, 14,	0
254	Elevated expression of exogenous RAD51 enhances the CRISPR/Cas9-mediated genome editing efficiency. **2023**,	0
253	Gene Modulation with CRISPR-based Tools in Human iPSC-Cardiomyocytes.	0
252	Recent Advances in CRISPR-Cas Technologies for Synthetic Biology. **2023**, 61, 13-36	0

251	Construction of the genetic switches in response to mannitol based on artificial MtlR box. **2023**, 10,	0
250	CRISPR-Cas system as a promising player against bacterial infection and antibiotic resistance. **2023**, 68, 100948	0
249	Automating the design-build-test-learn cycle towards next-generation bacterial cell factories. **2023**, 74, 1-15	0
248	Roles of innovative genome editing technologies in stem cell engineering, rheumatic diseases and other joint/bone diseases. **2023**, 53-77	0
247	Emerging Nano-/Biotechnology Drives Oncolytic Virus-Activated and Combined Cancer Immunotherapy. **2023**, 6,	0
246	Improved Genome Editing via Oviductal Nucleic Acids Delivery (i-GONAD): Protocol Steps and Additional Notes. **2023**, 325-340	0
245	Type I-D CRISPR System-Mediated Genome Editing in Plants. **2023**, 21-38	0
244	A high-content flow cytometry and dual CRISPR-Cas9 based platform to quantify genetic interactions. **2023**,	0
243	Precise genome editing with base editors. **2023**, 3, 75-84	0
242	Biosynthesis of 2-Acetyl-1-pyrroline in Fragrant Rice: Recent Insights into Agro-management, Environmental Factors, and Functional Genomics. **2023**, 71, 4201-4215	0
241	Genome editing in cotton: challenges and opportunities. **2023**, 6,	0
240	CRISPR-detector: fast and accurate detection, visualization, and annotation of genome-wide mutations induced by genome editing events. **2023**,	0
239	Retinitis pigmentosa□associated mutations in mouse Prpf8 cause misexpression of circRNAs and degeneration of cerebellar granule cells. **2023**, 6, e202201855	0
238	Genome-scale CRISPR-Cas9 knockout screening in nasopharyngeal carcinoma for radiosensitive and radioresistant genes. **2023**, 30, 101625	0
237	Controlling protein stability with SULI, a highly sensitive tag for stabilization upon light induction. **2023**, 14,	0
236	Targeting epigenetic aberrations of sarcoma in CRISPR era.	0
235	MOZ/ENL complex is a recruiting factor of leukemic AF10 fusion proteins. **2023**, 14,	0
234	Recent advances in therapeutic CRISPR-Cas9 genome editing: mechanisms and applications. **2023**, 4,	0

233	CRISPR-Cas effector specificity and cleavage site determine phage escape outcomes. **2023**, 21, e3002065	0
232	Use of CRISPR-based screens to identify mechanisms of chemotherapy resistance.	0
231	Recent Advances in Genome-Editing Technology with CRISPR/Cas9 Variants and Stimuli-Responsive Targeting Approaches within Tumor Cells: A Future Perspective of Cancer Management. **2023**, 24, 7052	0
230	The development of a fluorescence/colorimetric biosensor based on the cleavage activity of CRISPR-Cas12a for the detection of non-nucleic acid targets. **2023**, 449, 131044	0
229	CRISPR-Cas for genome editing: Classification, mechanism, designing and applications. **2023**, 238, 124054	1
228	Strain breeding and gene complementation strategies for filamentous fungi. **2023**, 128, 181-189	0
227	Polysaccharides from marine resources exhibit great potential in the treatment of tumor: A review. **2023**, 5, 100308	0
226	GOLGA8 increases bulk antisense oligonucleotide uptake and activity in mammalian cells. **2023**, 32, 289-301	0
225	Advances in chimeric antigen receptor T cells therapy in the treatment of breast cancer. **2023**, 162, 114609	0
224	Precise homology-directed installation of large genomic edits in human cells with cleaving and nicking high-specificity Cas9 variants.	0
223	Generating minimum set of gRNA to cover multiple targets in multiple genomes with MINORg.	0
222	Sensitive and automated detection of bacteria by CRISPR/Cas12a-assisted amplification with digital microfluidics. **2023**, 381, 133409	0
221	Applications of Genome Editing Techniques for the Improvement of Medicinal Plants. **2022**, 545-569	0
220	The Current Status of Antisense Gene Therapies for Bacteria-caused Diseases Challenges and Opportunities. **2023**, 29, 272-282	0
219	CRISPR technology: A decade of genome editing is only the beginning. **2023**, 379,	4
218	Gene Nanovector for Genome Therapy. **2022**, 1-36	0
217	Genetic Engineering. **2022**, 613-618	0
216	Modulating mutational outcomes and improving precise gene editing at CRISPR-Cas9-induced breaks by chemical inhibition of end-joining pathways. **2023**, 42, 112019	0

215	A universal platform for one-pot detection of circulating non-coding RNA combining CRISPR-Cas12a and branched rolling circle amplification. **2023**, 1246, 340896	0
214	Intellectual Property and Biotechnology Patents. **2021**, 489-498	0
213	Screening of Lymphoma Radiotherapy-Resistant Genes with CRISPR Activation Library. Volume 16, 67-80	0
212	Efficient bi-allelic tagging in human induced pluripotent stem cells using CRISPR. **2023**, 4, 102084	0
211	Genome editing with natural and engineered CjCas9 orthologs. **2023**, 31, 1177-1187	0
210	E3 ubiquitin ligase ASB8 promotes selinexor-induced proteasomal degradation of XPO1. **2023**, 160, 114305	0
209	A genome-wide CRISPR functional survey of the human phagocytosis molecular machinery. **2023**, 6, e202201715	5
208	Tail-Engineered Phage P2 Enables Delivery of Antimicrobials into Multiple Gut Pathogens. **2023**, 12, 596-607	1
207	Chemical and Biological Approaches to Interrogate off-Target Effects of Genome Editing Tools. **2023**, 18, 205-217	0
206	Increased On-Target Rate and Risk of Concatemerization after CRISPR-Enhanced Targeting in ES Cells. **2023**, 14, 401	0
205	CRISPR/Cas9 mediated gene editing in non-model nematode Panagrolaimus sp. PS1159. 5,	0
204	Cas, a novel class of miniature type-V Cas12f nucleases with diverse PAM.	0
203	Non-canonical inhibition strategies and structural basis of anti-CRISPR proteins targeting type I CRISPR-Cas systems. **2023**, 435, 167996	0
202	Exploring the potential of CRISPR/Cas genome editing for vegetable crop improvement: An overview of challenges and approaches. **2023**, 120, 1215-1228	0
201	The distribution of neuroligin4, an autism-related postsynaptic molecule, in the human brain. **2023**, 16,	0
200	Profiling the impact of the promoters on CRISPR-Cas12a system in human cells.	0
199	CriSNPr, a single interface for the curated and de novo design of gRNAs for CRISPR diagnostics using diverse Cas systems. 12,	0
198	Enabling technology and core theory of synthetic biology.	0

197	miRNA-27a is essential for bone remodeling by modulating p62-mediated osteoclast signaling. 12,	0
196	Dual-targeting therapy against HER3 / MET in human colorectal cancers.	0
195	Transition from Animal-Based to Human Induced Pluripotent Stem Cells (iPSCs)-Based Models of Neurodevelopmental Disorders: Opportunities and Challenges. **2023**, 12, 538	0
194	Systematically attenuating DNA targeting enables CRISPR-driven editing in bacteria. **2023**, 14,	0
193	Transient and DNA-free in vivo CRISPR/Cas9 genome editing for flexible modeling of endometrial carcinogenesis.	0
192	Structural insights into pathogenic mechanism of hypohidrotic ectodermal dysplasia caused by ectodysplasin A variants. **2023**, 14,	0
191	CRISPR-based nucleic acid diagnostics for pathogens. **2023**, 160, 116980	0
190	Gene Drive: Past, Present and Future Roads to Vertebrate Biocontrol. **2023**, 2, 52-70	0
189	Current Metabolic Engineering Strategies for Photosynthetic Bioproduction in Cyanobacteria. **2023**, 11, 455	1
188	CRISPR/Cas genome editing system and its application in potato. 14,	0
187	A Novel miRNA in Rice Associated with the Low Seed Setting Rate Symptom of Rice Stripe Virus. **2023**, 24, 3675	0
186	Recent advances in nanocomposite-based delivery systems for targeted CRISPR/Cas delivery and therapeutic genetic manipulation.	0
185	A luciferase reporter mouse model to optimize in´vivo gene editing validated by lipid nanoparticle delivery of adenine base editors. **2023**, 31, 1159-1166	0
184	Genome-Editing Approaches for Biofortification of Cereal Crops. **2023**, 93-126	0
183	Microbiota□liver Diseases Interactions. **2023**, 24, 3883	0
182	Progress in and Prospects of Genome Editing Tools for Human Disease Model Development and Therapeutic Applications. **2023**, 14, 483	0
181	Phase separation of an actin nucleator by junctional microtubules regulates epithelial function. **2023**, 9,	0
180	Recent advances and applications of CRISPR-Cas9 in cancer immunotherapy. **2023**, 22,	0

179	Cauliflower mosaic virus: Virus-host interactions and its uses in biotechnology and medicine. **2023**, 580, 112-119	0
178	Research and Therapeutic Approaches in Stem Cell Genome Editing by CRISPR Toolkit. **2023**, 28, 1982	0
177	Treatment of Fabry Disease: Established and Emerging Therapies. **2023**, 16, 320	0
176	A non-genetic switch triggers alternative telomere lengthening and cellular immortalization in ATRX deficient cells. **2023**, 14,	0
175	Impaired neurogenesis and neural progenitor fate choice in a human stem cell model of SETBP1 disorder. **2023**, 14,	0
174	Editing the Melanocortin-4 Receptor Gene in Channel Catfish Using the CRISPR-Cas9 System. **2023**, 8, 116	0
173	The Experimental Animal Models in Psoriasis Research: A Comprehensive Review. **2023**, 117, 109897	0
172	Editorial: Genetic engineering in farm animals. 14,	0
171	Determination of oligomeric organization of membrane proteins from native membranes at nanoscale-spatial and single-molecule resolution.	0
170	Establishment of an Integrated CRISPR/Cas9 Plasmid System for Simple and Efficient Genome Editing in Medaka In Vitro and In Vivo. **2023**, 12, 336	0
169	CRISPR-Fortschritte Schnitt für Schnitt zu neuen Möglichkeiten. **2023**, 29, 25-28	0
168	Delivery challenges for CRISPR Cas9 genome editing for Duchenne muscular dystrophy. **2023**, 4, 011307	0
167	A New Method for Programmable RNA Editing Using CRISPR Effector Cas13X.1. **2023**,	0
166	High-capacity adenovector delivery of forced CRISPR-Cas9 heterodimers fosters precise chromosomal deletions in human cells. **2023**, 31, 746-762	0
165	Application of Nicotinamide to Culture Medium Improves the Efficiency of Genome Editing in Hexaploid Wheat. **2023**, 24, 4416	0
164	Hacking hematopoiesis emerging tools for examining variant effects. **2023**, 16,	0
163	BAP18 facilitates CTCF-mediated chromatin accessible to regulate enhancer activity in breast cancer.	0
162	Genome editing for improving nutritional quality, post-harvest shelf life and stress tolerance of fruits, vegetables, and ornamentals. 5,	0

161	Shotgun knockdown of RNA by CRISPR-Cas13d in fission yeast. **2023**, 136,	0
160	CRISPR-gene-engineeredCYBBknock-out PLB-985 cells, a useful model to study functional impact of X-linked chronic granulomatous disease mutations: application to the G412E X91+-CGD mutation.	0
159	APTX acts in DNA double-strand break repair in a manner distinct from XRCC4.	1
158	G-quadruplex-based CRISPR photoswitch for spatiotemporal control of genomic modulation.	0
157	Gold Nanomaterials-Implemented CRISPR-Cas Systems for Biosensing. 2300057	0
156	Production of chickens with GFP-knockin in the Z chromosome and detection of GFP-positive chicks in the embryonic stage.	0
155	Gene Therapy and Gene Editing. **2023**, 269-334	0
154	Germline Gene Editing: The Gender Issues. **2023**, 32, 186-192	0
153	New advances in CRISPR/Cas-mediated precise gene-editing techniques. **2023**, 16,	0
152	Applying the CRISPR/Cas9 for treating human and animal diseases: a comprehensive review. **2023**,	0
151	Genetic modification of plants to increase the saccharification of lignocellulose. **2023**, 39-53	0
150	DEVELOPMENT OF THE CRISPR/CAS9 SYSTEM FOR THE GENOME
EDITING OF THE NtPDS GENE OF TOBACCO (NICOTIANA TABACUM). **2022**, 33, 47-57	0
149	CRISPR-Cas9-Edited <i>SNCA</i> Knockout Human Induced Pluripotent Stem Cell-Derived Dopaminergic Neurons and Their Vulnerability to Neurotoxicity. **2023**, 46, 517-522	0
148	Characterization of POLE c.1373A > T p.(Tyr458Phe), causing high cancer risk.	0
147	Viral vectors and extracellular vesicles: innate delivery systems utilized in CRISPR/Cas-mediated cancer therapy.	0
146	Transcription of MERVL retrotransposons is required for preimplantation embryo development. **2023**, 55, 484-495	0
145	A simple, rapid, and efficient method for generating multigene-knockout culture cells by the CRISPR/Cas9 system.	0
144	CRISPR techniques and potential for the detection and discrimination of SARS-CoV-2 variants of concern. **2023**, 161, 117000	0

143	Improving the Editing Efficiency of CRISPR-Cas9 by Reducing the Generation of Escapers Based on the Surviving Mechanism. **2023**, 12, 672-680	0
142	HAP1, a new revolutionary cell model for gene editing using CRISPR-Cas9. 11,	0
141	NUDT22 promotes cancer growth through pyrimidine salvage. **2023**, 42, 1282-1293	0
140	Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) in Cardiovascular Disease: A Comprehensive Clinical Review on Dilated Cardiomyopathy. **2023**,	0
139	The history, use, and challenges of therapeutic somatic cell and germline gene editing. **2023**,	0
138	Genotype-phenotype mapping of a patient-derived lung cancer organoid biobank identifies NKX2-1-defined Wnt dependency in lung adenocarcinoma. **2023**, 42, 112212	0
137	oFlowSeq: a quantitative approach to identify protein coding mutations affecting cell type enrichment using mosaic CRISPR-Cas9 edited cerebral organoids.	0
136	One-step generation of mice with gene editing by Tol2 transposon-dependent gRNA delivery. **2023**, 597, 975-984	0
135	A chemically controlled Cas9 switch enables temporal modulation of diverse effectors.	0
134	Mechanisms regulating the CRISPR-Cas systems. 14,	0
133	CRISPR/Cas9-mediated homology donor repair base editing confers glyphosate resistance to rice (Oryza sativa L.). 14,	0
132	Investigations into the FLG Null Phenotype: Showcasing the Methodology for CRISPR/Cas9 Editing of Human Keratinocytes. **2023**,	0
131	Long-read sequence analysis of MMEJ-mediated CRISPR genome editing reveals complex on-target vector insertions that may escape standard PCR-based quality control.	0
130	Packaging and Uncoating of CRISPR/Cas Ribonucleoproteins for Efficient Gene Editing with Viral and Non-Viral Extracellular Nanoparticles. **2023**, 15, 690	0
129	Reprogramming an RNA-guided archaeal TnpB endonuclease for genome editing.	0
128	The MYO1B and MYO5B motor proteins and the SNX27 sorting nexin regulate membrane mucin MUC17 trafficking in enterocytes.	0
127	Immunomodulation: general review of the current state-of-the-art and new therapeutic strategies for targeting the immune system. 14,	0
126	Off-target effects in CRISPR/Cas9 gene editing. 11,	0

125	Long-Term Evaluation of Retinal Morphology and Function in Rosa26-Cas9 Knock-In Mice. **2023**, 24, 5186	0
124	Glycolytic System in Axons Supplement Decreased ATP Levels after Axotomy of the Peripheral Nerve. **2023**, 10, ENEURO.0353-22.2023	0
123	Recent advances in CRISPR-based genome editing technology and its applications in cardiovascular research. **2023**, 10,	0
122	Genetic improvement in Musa through modern biotechnological methods. **2023**, 8, 1-13	0
121	Prime editing in hematopoietic stem cells: from ex vivo to in vivo CRISPR-based treatment of blood disorders. 5,	0
120	Inducible expression of the restriction enzyme uncovered genome-wide distribution and dynamic behavior of histones H4K16ac and H2A.Z at DNA double-strand breaks inArabidopsis.	0
119	Nonspecific interactions between Cas12a and dsDNA located downstream of the PAM mediate target search and assist AsCas12a for DNA cleavage. **2023**, 14, 3839-3851	0
118	An optimized SpCas9 high-fidelity variant for direct protein delivery. **2023**,	0
117	Remodeling Tumor Immunogenicity with Dual-Activatable Binary CRISPR Nanomedicine for Cancer Immunotherapy. **2023**, 17, 5713-5726	0
116	Optimized Nonviral Gene Disruption in Primary Murine and Human Myeloid Cells. **2023**, 201-217	0
115	Variability in genome-engineering source materials: consider your starting point. **2023**, 8,	0
114	Higenamine Promotes Osteogenesis Via IQGAP1 / SMAD4 Signaling Pathway and Prevents Age- and Estrogen-Dependent Bone Loss in Mice.	0
113	New CRISPR Technology for Creating Cell Models of Lipoprotein Assembly and Secretion.	0
112	Symmetric control of sister chromatid cohesion establishment.	0
111	Danger Analysis: Risk-Averse on/off-Target Assessment for CRISPR Editing Without a Reference Genome.	0
110	Massively parallel characterization of CRISPR activator efficacy in human induced pluripotent stem cells and neurons. **2023**, 83, 1125-1139.e8	0
109	Enhancing the quality of staple food crops through CRISPR/Cas-mediated site-directed mutagenesis. **2023**, 257,	0
108	RTF2 controls replication repriming and ribonucleotide excision at the replisome.	0

107	Split-tracrRNA as an efficient tracrRNA system with an improved potential of scalability.	0
106	GenoPipe: identifying the genotype of origin within (epi)genomic datasets.	0
105	Induction of fetal meiotic oocytes from embryonic stem cells in cynomolgus monkeys.	0
104	Excision of Integrated Human Herpesvirus 6A Genomes Using CRISPR/Cas9 Technology. **2023**, 11,	0
103	Bioengineering of fungal endophytes through the CRISPR/Cas9 system. 14,	0
102	Motif elucidation in ChIP-seq datasets with a knockout control. **2023**, 3,	0
101	The APC/C E3 ligase subunit ANAPC11 mediates FOXO3 protein degradation to promote cell proliferation and lymph node metastasis of urothelial bladder cancer.	0
100	Drug discovery: Chaos can be your friend or your enemy. **2023**, 417-511	0
99	The Potential Revolution of Cancer Treatment with CRISPR Technology. **2023**, 15, 1813	0
98	Guide-specific loss of efficiency and off-target reduction with Cas9 variants.	0
97	Multiplex epigenome editing of ion channel expression in nociceptive neurons abolished degenerative IVD -conditioned media-induced mechanical sensitivity.	0
96	Ultra-high throughput mapping of genetic design space.	0
95	Application of CRISPR-Cas9 gene editing technology in basic research, diagnosis and treatment of colon cancer. 14,	0
94	Mitochondrial Base Editing: Recent Advances towards Therapeutic Opportunities. **2023**, 24, 5798	0
93	CRISPR/Cas systems for the detection of nucleic acid and non-nucleic acid targets.	0
92	Editing the Genome. **2023**, 715-718	0
91	Current Approaches to and the Application of Intracytoplasmic Sperm Injection (ICSI) for Avian Genome Editing. **2023**, 14, 757	0
90	Design of Four Small-Molecule-Inducible Systems in the Yeast Chromosome, Applied to Optimize Terpene Biosynthesis. **2023**, 12, 1119-1132	0

89	CRISPR-mediated technology for seed oil improvement in rapeseed: Challenges and future perspectives. 14,	0
88	Self-delivering CRISPR RNAs for AAV Co-delivery and Genome Editingin vivo.	0
87	Establishment, optimization, and application of genetic technology in Aspergillus spp.. 14,	0
86	Emerging Therapies for Transthyretin Amyloidosis.	0
85	Bacterial genome engineering using CRISPR RNA-guided transposases.	0
84	Perceptions of plant breeding methods from phenotypic selection to genetic modification and new breeding technologies 1-49	0
83	Multiplexed genome engineering for porcine fetal fibroblasts with gRNA RNA arrays based on CRISPR/Cas9. 1-10	0
82	In vivo models of pancreatic ductal adenocarcinoma. **2023**,	0
81	CRISPR-Cas-mediated transcriptional modulation: The therapeutic promises of CRISPRa and CRISPRi. **2023**,	0
80	CRISPR/Cas9 establishment-mediated targeted mutagenesis in Macrobrachium nipponense. 14,	0
79	Endogenous bioluminescent reporters reveal a sustained increase in utrophin gene expression upon EZH2 and ERK1/2 inhibition. **2023**, 6,	0
78	Mapping cellular responses to DNA double-strand breaks using CRISPR technologies. **2023**,	0
77	CRISPR-Cas9 editing of TLR4 to improve the outcome of cardiac cell therapy. **2023**, 13,	0
76	Advances in CRISPR/Cas gene therapy for inborn errors of immunity. 14,	0
75	Nanotechnology and CRISPR/Cas9 system for sustainable agriculture.	0
74	Recent progress and challenges in CRISPR-Cas9 engineered algae and cyanobacteria. **2023**, 71, 103068	0
73	CRISPR/Cas9 Gene Editing System Can Alter Gene Expression and Induce DNA Damage Accumulation. **2023**, 14, 806	0
72	Targeted gene deletion with SpCas9 and multiple guide RNAs in Arabidopsis thaliana: four are better than two. **2023**, 19,	0

71	Recent progress in polymeric gene vectors: Delivery mechanisms, molecular designs, and applications. **2023**, 4, 011313	0
70	Strategies and Methods for Improving the Efficiency of CRISPR/Cas9 Gene Editing in Plant Molecular Breeding. **2023**, 12, 1478	0
69	Massively Parallel Profiling of RNA-targeting CRISPR-Cas13d.	0
68	Improved cotton yield: Can we achieve this goal by regulating the coordination of source and sink?. 14,	0
67	Massively Parallel Reporter Assays for High-Throughput In Vivo Analysis of Cis-Regulatory Elements. **2023**, 10, 144	0
66	Recent Advances in Engineering of In Vivo Haploid Induction Systems. **2023**, 365-383	0
65	Prime editing with genuine Cas9 nickases minimizes unwanted indels. **2023**, 14,	0
64	Direct Virus Gene Detection: A CRISPR/dCas9-Mediated Surface-Enhanced Raman Scattering Strategy with Enzyme-Catalyzed Signal Amplification. **2023**, 95, 5927-5936	0
63	Transgenesis and Genome Engineering: A Historical Review. **2023**, 1-32	0
62	A genome-wide CRISPR screen maps endogenous regulators of PPARG gene expression in bladder cancer. **2023**, 26, 106525	0
61	Gene Editing in Mouse Zygotes Using the CRISPR/Cas9 System. **2023**, 207-230	0
60	Delivery of CRISPR-Cas12a Ribonucleoprotein Complex for Genome Editing in an Embryogenic Citrus Cell Line. **2023**, 153-171	0
59	CRISPR/Cas9-Mediated Genome Editing in Zebrafish. **2023**, 371-380	0
58	In Vivo Modeling of Skeletal Muscle Diseases Using the CRISPR/Cas9 System in Rats. **2023**, 277-285	0
57	CRISMERE Chromosome Engineering in Mouse and Rat. **2023**, 277-297	0
56	Extracellular Vesicle-Mediated CRISPR/Cas Delivery: Their Applications in Molecular Imaging and Precision Biomedicine. **2022**, 1-22	0
55	Myeloid-associated differentiation marker is an essential host factor for human parechovirus PeV-A3 entry. **2023**, 14,	0
54	ERCC6L2 mitigates replication stress and promotes centromere stability. **2023**, 42, 112329	0

53	A monoclonal antibody raised against human EZH2 cross-reacts with the RNA-binding protein SAFB.	0
52	Induced Mutations for Development of New Cultivars and Molecular Analysis of Genes in Japan. **2023**, 301-354	0
51	Quantitative profiling of pseudouridylation landscape in the human transcriptome.	0
50	Plant Mutagenesis Tools for Precision Breeding: Conventional CRISPR/Cas9 Tools and Beyond. **2023**, 269-291	0
49	Review: Recent Applications of Gene Editing in Fish Species and Aquatic Medicine. **2023**, 13, 1250	0
48	A Dual-Function IRE-Lox System for Genetic Deletion or Reversible, Titratable, and Near-Complete Downregulation of Cathepsin D. **2023**, 24, 6745	0
47	A Cas12a ortholog with distinct TTNA PAM enables sensitive detection of HPV16/18. **2023**, 100444	0
46	An overview of genome engineering in plants, including its scope, technologies, progress and grand challenges. **2023**, 23,	0
45	A Rapid, Functional sgRNA Screening Method for Generating Murine RET and NTRK1 Fusion Oncogenes.	0
44	Therapeutic strategy for spinal muscular atrophy by combining gene supplementation and genome editing.	0
43	Neuroprotective effects of genome-edited human iPS cell-derived neural stem/progenitor cells on traumatic brain injury.	0
42	Screening Method for the Identification and Characterization of Transcription Factors Regulating Flesh Fruit Development and Ripening. **2023**, 17-61	0
41	Mitigating a TDP-43 proteinopathy using RNA-targeting CRISPR effector proteins.	0
40	Ewing sarcoma treatment: a gene therapy approach.	0
39	Optimization of Cas9 activity through the addition of cytosine extensions to single-guide RNAs.	0
38	The APE2 nuclease is essential for DNA double-strand break repair by microhomology-mediated end joining. **2023**,	0
37	Biomaterial-Based Delivery Systems for Chemotherapeutics. **2023**, 105-178	0
36	Animal Transgenesis and Cloning: Combined Development and Future Perspectives. **2023**, 121-149	0

35	CRISPR-Cas12-Based Diagnostic Applications in Infectious and Zoonotic Diseases. **2023**, 267-278	0
34	Engineered CRISPR-OsCas12f1 and RhCas12f1 with robust activities and expanded target range for genome editing. **2023**, 14,	0
33	A Review of CRISPR-Based Advances in Dermatological Diseases.	0
32	Computationally Engineered CRISPR-SpyCas9 High-Fidelity Variants with Improved Specificity and Reduced Non-specific DNA Damage.	0
31	CRISPR-cas technology: A key approach for SARS-CoV-2 detection. 11,	0
30	The biology and type I/III hybrid nature of type I-D CRISPR□as systems. **2023**, 480, 471-488	0
29	CRISPR-EDITING THERAPY FOR DUCHENNE MUSCULAR DYSTROPHY.	0
28	Somatic protospacer adjacent motifs are numerous and selectively targetable in cancers.	0
27	Large-scale F0 CRISPR screens in vivo using MIC-Drop.	0
26	Overcoming the Limitations of CRISPR-Cas9 Systems in Saccharomyces cerevisiae: Off-Target Effects, Epigenome, and Mitochondrial Editing. **2023**, 11, 1040	0
25	Chromatin structure and context-dependent sequence features control prime editing efficiency.	0
24	Atoh1 is required for the formation of lateral line electroreceptors and hair cells, whereas Foxg1 represses an electrosensory fate.	0
23	All-in-one AAV-delivered epigenome-editing platform:proof-of-conceptand therapeutic implications for neurodegenerative disorders.	0
22	Genetically Encoded DNA Origami for Gene Therapy In Vivo.	0
21	KaryoCreate: A CRISPR-based technology to study chromosome-specific aneuploidy by targeting human centromeres. **2023**,	0
20	Application of CRISPR/Cas9-mediated gene editing for abiotic stress management in crop plants. 14,	0
19	Programmable mammalian translational modulators by CRISPR-associated proteins. **2023**, 14,	0
18	PAM-flexible Cas9-mediated base editing of a hemophilia B mutation in induced pluripotent stem cells. **2023**, 3,	0

17	Decoding CRISPR□as PAM recognition with UniDesign.	0
16	Oncogenic CDK13 mutations impede nuclear RNA surveillance. **2023**, 380,	0
15	Sensitive CRISPR-Cas12a-Assisted Immunoassay for Small Molecule Detection in Homogeneous Solution.	0
14	Genome-edited crops. **2023**, 73-99	0
13	How has CRISPR transformed therapeutic drug discovery?. **2023**, 74, 119-121	0
12	The New Way to Define Key Oncogenic Drivers of Small Cell Lung Cancer. **2023**, 27, 1-7	0
11	CRISPR-Combo□mediated orthogonal genome editing and transcriptional activation for plant breeding.	0
10	Using traditional machine learning and deep learning methods for on- and off-target prediction in CRISPR/Cas9: a review.	0
9	Application of new technologies in embryos: From gene editing to synthetic embryos. **2023**, 853-886	0
8	Necessity of HuR/ELAVL1 for activation-induced cytidine deaminase-dependent decrease in topoisomerase 1 in antibody diversification.	0
7	Applicability of Smart Tools in Vegetable Disease Diagnostics. **2023**, 13, 1211	0
6	Reversal of hepatic fibrosis by the co-delivery of drug and ribonucleoprotein-based genome editor. **2023**, 298, 122133	0
5	Alternative CDC20 translational isoforms tune mitotic arrest duration. **2023**, 617, 154-161	0
4	Harnessing CRISPR-Cas for oomycete genome editing. **2023**,	0
3	Discovery of Diverse CRISPR-Cas Systems and Expansion of the Genome Engineering Toolbox.	0
2	Deep sampling of gRNA in the human genome and deep-learning-informed prediction of gRNA activities. **2023**, 9,	0
1	Insight into the molecular mechanism of the transposon-encoded type I-F CRISPR-Cas system. **2023**, 21,	0